<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Protein Cell</journal-id><journal-id journal-id-type="iso-abbrev">Protein Cell</journal-id><journal-id journal-id-type="publisher-id">proteincell</journal-id><journal-title-group><journal-title>Protein &#x00026; Cell</journal-title></journal-title-group><issn pub-type="ppub">1674-800X</issn><issn pub-type="epub">1674-8018</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38733347</article-id><article-id pub-id-type="pmc">PMC11786724</article-id>
<article-id pub-id-type="doi">10.1093/procel/pwae026</article-id><article-id pub-id-type="publisher-id">pwae026</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/SCI00960</subject></subj-group></article-categories><title-group><article-title>Alzheimer&#x02019;s disease: insights into pathology, molecular mechanisms, and therapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7843-3365</contrib-id><name><surname>Zheng</surname><given-names>Qiuyang</given-names></name><aff>
<institution>Shenzhen Research Institute of Xiamen University</institution>, <addr-line>Shenzhen 518057</addr-line>, <country country="CN">China</country></aff><aff>
<institution>State Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Department of Neurology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University</institution>, <addr-line>Xiamen 361005</addr-line>, <country country="CN">China</country></aff><xref rid="c2" ref-type="corresp"/><!--qyzheng@xmu.edu.cn--></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2421-4639</contrib-id><name><surname>Wang</surname><given-names>Xin</given-names></name><aff>
<institution>Shenzhen Research Institute of Xiamen University</institution>, <addr-line>Shenzhen 518057</addr-line>, <country country="CN">China</country></aff><aff>
<institution>State Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Department of Neurology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University</institution>, <addr-line>Xiamen 361005</addr-line>, <country country="CN">China</country></aff><xref rid="c1" ref-type="corresp"/><!--wangx@xmu.edu.cn--></contrib></contrib-group><author-notes><corresp id="c1">Correspondence: <email>wangx@xmu.edu.cn</email></corresp><corresp id="c2">Correspondence: <email>qyzheng@xmu.edu.cn</email></corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-05-11"><day>11</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>5</month><year>2024</year></pub-date><volume>16</volume><issue>2</issue><fpage>83</fpage><lpage>120</lpage><history><date date-type="received"><day>04</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2024</year></date><date date-type="corrected-typeset"><day>07</day><month>6</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="pwae026.pdf"/><abstract><title>Abstract</title><p>Alzheimer&#x02019;s disease (AD), the leading cause of dementia, is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. This condition casts a significant shadow on global health due to its complex and multifactorial nature. In addition to genetic predispositions, the development of AD is influenced by a myriad of risk factors, including aging, systemic inflammation, chronic health conditions, lifestyle, and environmental exposures. Recent advancements in understanding the complex pathophysiology of AD are paving the way for enhanced diagnostic techniques, improved risk assessment, and potentially effective prevention strategies. These discoveries are crucial in the quest to unravel the complexities of AD, offering a beacon of hope for improved management and treatment options for the millions affected by this debilitating disease.</p></abstract><kwd-group><kwd>Alzheimer&#x02019;s disease</kwd><kwd>pathophysiology</kwd><kwd>risk factors</kwd><kwd>biomarkers</kwd><kwd>prevention</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>National Key R&#x00026;D Program of China</institution><institution-id institution-id-type="DOI">10.13039/501100012166</institution-id></institution-wrap>
</funding-source><award-id>2021ZD0202402</award-id><award-id>2021YFA1101401</award-id></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="DOI">10.13039/501100001809</institution-id></institution-wrap>
</funding-source><award-id>82325018</award-id><award-id>U21A20358</award-id><award-id>82271451</award-id></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Natural Science Foundation of Fujian Province of China</institution></institution-wrap>
</funding-source><award-id>2021J02004</award-id></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Guangdong Basic and Applied Basic Research Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100021171</institution-id></institution-wrap>
</funding-source><award-id>2021B1515120081</award-id></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Fundamental Research Funds for the Chinese Central Universities</institution></institution-wrap>
</funding-source><award-id>20720230070</award-id><award-id>20720220052</award-id></award-group></funding-group><counts><page-count count="38"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD), the predominant type of neurodegenerative disorder, is characterized by the extracellular buildup of &#x003b2;-amyloid (A&#x003b2;) plaques and the intracellular aggregation of neurofibrillary tangles (NFTs), which are composed of hyperphosphorylated tau. Additionally, AD is characterized by the loss of synapses and neurons, as well as gliosis (<xref rid="CIT0278" ref-type="bibr">Long and Holtzman, 2019</xref>). Since its initial identification by Alois Alzheimer in the early 20th century, AD has emerged as a significant healthcare challenge, and no cure is currently available (<xref rid="CIT0005" ref-type="bibr">Alzheimer et al., 1995</xref>).</p></sec><sec id="s2"><title>Clinical signs and symptoms</title><p>AD presents a spectrum of clinical symptoms, initially manifesting as early amnestic cognitive impairment and difficulties with short-term memory. As AD progresses, affected individuals may experience impairments in complex attention, expressive speech, visuospatial processing, and executive functions (<xref rid="CIT0307" ref-type="bibr">McKhann et al., 2011</xref>; <xref rid="CIT0449" ref-type="bibr">Tarawneh and Holtzman, 2012</xref>). Neuropsychiatric symptoms frequently accompany cognitive deficits in AD, particularly in earlier stages, when anxiety, depression, and apathy are prevalent. With disease progression, patients may develop additional symptoms, including delusions, hallucinations, agitation/aggression, and irritability/lability (<xref rid="CIT0087" ref-type="bibr">D&#x02019;Onofrio et al., 2012</xref>).</p><p>Historically, AD diagnosis was limited to the dementia stage, characterized by significant, progressive cognitive impairment across various domains or neurobehavioral symptoms severe enough to markedly impair daily functioning (<xref rid="CIT0403" ref-type="bibr">Scheltens et al., 2021</xref>). With advancements in biomarker research, Clifford Jack and colleagues redefined AD diagnosis from a purely clinical syndrome to a biological framework based on biomarkers. These biomarkers are categorized into A&#x003b2; deposition (A), pathological tau (T), and neurodegeneration (N) biomarkers. The diagnosis of AD, according to this research framework, depends on the presence of A&#x003b2; and phosphorylated tau (<xref rid="CIT0205" ref-type="bibr">Jack et al., 2018</xref>). The ATN framework underscores the critical roles of A&#x003b2; and tau in diagnosing AD, distinctly identifying AD as a unique neurodegenerative disease among various dementia-causing disorders.</p><p>In 2010, Clifford Jack et al. introduced a hypothetical model of dynamic biomarkers for AD, spanning the cognitive continuum from health to dementia (<xref rid="CIT0204" ref-type="bibr">Jack et al., 2010</xref>). They segmented the clinical disease stages of AD into three phases: the presymptomatic phase, the prodromal phase (often referred to as mild cognitive impairment (MCI)), and the dementia phase. AD pathology may initially be asymptomatic, manifesting through a stage of MCI before progressing to overt dementia. The onset of A&#x003b2; pathology in individuals predisposed to AD occurs approximately 15&#x02013;20 years before the anticipated onset of progressive cognitive decline (<xref rid="CIT0126" ref-type="bibr">Fleisher et al., 2012</xref>; <xref rid="CIT0374" ref-type="bibr">Reiman et al., 2012</xref>). Elevated cerebrospinal fluid (CSF) tau levels indicate neuronal injury and correlate with disease severity. <sup>18</sup>fluorodeoxyglucose (<sup>18</sup>FDG)-positron emission tomography (PET) is a reliable marker of synaptic dysfunction associated with neurodegeneration in AD patients. Structural magnetic resonance imaging (MRI) quantifies cerebral atrophy as synapses and neurons deteriorate, which is closely correlated with the severity of clinical impairment, even in the disease&#x02019;s advanced stages, and aligns with Braak staging and tau tangle pathology observed postmortem (<xref rid="CIT0204" ref-type="bibr">Jack et al., 2010</xref>).</p></sec><sec id="s3"><title>Epidemiology</title><p>AD represents 60%&#x02013;80% of dementia cases (<xref rid="CIT0016" ref-type="bibr">Alzheimer's Association., 2023</xref>). In 2019, the global number of individuals with dementia was approximately 57.4 million. From 2000 to 2019, the number of deaths attributable to AD increased by more than 145%, indicating that AD is the sixth leading cause of death in the United States (<xref rid="CIT0016" ref-type="bibr">Alzheimer's Association., 2023</xref>).</p><p>Approximately 1% of AD cases fall under the category of early-onset autosomal dominant AD, with the remaining 99% being late-onset sporadic AD. Autosomal dominant AD typically manifests before age 65, with many individuals experiencing symptoms in their 40s and 50s (<xref rid="CIT0029" ref-type="bibr">Bateman et al., 2011</xref>; <xref rid="CIT0388" ref-type="bibr">Ryman et al., 2014</xref>).</p><p>Genetic predispositions significantly influence the pathophysiological mechanisms of AD, accounting for an estimated 58%&#x02013;79% of cases (<xref rid="CIT0141" ref-type="bibr">Gatz et al., 2006</xref>). Rare mutations in <italic toggle="yes">APP</italic>, <italic toggle="yes">PSEN1,</italic> and <italic toggle="yes">PSEN2</italic> are linked to autosomal dominant AD (<xref rid="CIT0037" ref-type="bibr">Bertram et al., 2010</xref>). The apolipoprotein E (APOE) gene is a major genetic risk factor for sporadic AD (<xref rid="CIT0080" ref-type="bibr">Corder et al., 1993</xref>; <xref rid="CIT0355" ref-type="bibr">Peacock et al., 1993</xref>). The prevalence of <italic toggle="yes">APOE&#x003b5;4</italic> was 66% among patients with AD-type dementia and 64% among those with MCI (<xref rid="CIT0301" ref-type="bibr">Mattsson et al., 2018</xref>). Possession of one <italic toggle="yes">APOE&#x003b5;4</italic> allele amplifies the risk 3&#x02013;4 times, whereas two alleles heighten the risk by 9&#x02013;15 times (<xref rid="CIT0120" ref-type="bibr">Farrer et al., 1997</xref>; <xref rid="CIT0144" ref-type="bibr">Genin et al., 2011</xref>; <xref rid="CIT0336" ref-type="bibr">Neu et al., 2017</xref>). Whole-genome sequencing (WGS) and genome-wide association studies (GWAS) have revealed additional genetic loci associated with late-onset AD risk, including <italic toggle="yes">TREM2</italic>, <italic toggle="yes">BIN1</italic>, <italic toggle="yes">CLU</italic>, <italic toggle="yes">ABCA7</italic>, <italic toggle="yes">CR1</italic>, <italic toggle="yes">PICALM</italic>, <italic toggle="yes">MS4A6A</italic>, <italic toggle="yes">CD33</italic>, <italic toggle="yes">MS4A4E</italic>, <italic toggle="yes">CD2AP</italic>, <italic toggle="yes">EPHA1</italic>, and <italic toggle="yes">EXOC3L2</italic>/<italic toggle="yes">BLOC1S3</italic>/<italic toggle="yes">MARK4</italic>, among others (<xref rid="CIT0167" ref-type="bibr">Guerreiro et al., 2013</xref>; <xref rid="CIT0179" ref-type="bibr">Harold et al., 2009</xref>; <xref rid="CIT0187" ref-type="bibr">Hollingworth et al., 2011</xref>; <xref rid="CIT0217" ref-type="bibr">Jonsson et al., 2013</xref>; <xref rid="CIT0249" ref-type="bibr">Lambert et al., 2009</xref>; <xref rid="CIT0330" ref-type="bibr">Naj et al., 2011</xref>; <xref rid="CIT0411" ref-type="bibr">Seshadri et al., 2010</xref>). A meta-analysis further identified several susceptibility loci for late-onset AD, including <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB5</italic>-<italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1</italic>, <italic toggle="yes">PTK2B</italic>, <italic toggle="yes">SORL1</italic>, <italic toggle="yes">SLC24A4</italic>-<italic toggle="yes">RIN3</italic>, <italic toggle="yes">DSG2</italic>, <italic toggle="yes">INPP5D</italic>, <italic toggle="yes">MEF2C</italic>, <italic toggle="yes">NME8</italic>, <italic toggle="yes">ZCWPW1</italic>, <italic toggle="yes">CELF1</italic>, <italic toggle="yes">FERMT2</italic>, and <italic toggle="yes">CASS4</italic> (<xref rid="CIT0250" ref-type="bibr">Lambert et al., 2013</xref>).</p><p>Age remains the most significant risk factor for developing AD. Approximately 18.1% of individuals aged &#x02265;&#x02005;65 years are affected by AD, a figure that rises to 33.2% among those aged &#x02265;&#x02005;85 years (<xref rid="CIT0016" ref-type="bibr">Alzheimer&#x02019;s Association., 2023</xref>). Additionally, in the United States, 21.1% of women and 11.6% of men over 65 years old are affected by AD (<xref rid="CIT0016" ref-type="bibr">Alzheimer's Association., 2023</xref>).</p><p>The Lancet Commission on Dementia Prevention has identified 12 modifiable risk factors that collectively account for approximately 40% of dementia worldwide. These factors include lower education levels, hypertension, hearing impairment, smoking, obesity, depression, physical inactivity, diabetes, and limited social interaction (<xref rid="CIT0276" ref-type="bibr">Livingston et al., 2020</xref>).</p></sec><sec id="s4"><title>Pathophysiology</title><sec id="s5"><title>A&#x003b2;</title><p>The accumulation of A&#x003b2; aggregates in the brain is a fundamental cause of AD (<xref rid="CIT0278" ref-type="bibr">Long and Holtzman, 2019</xref>). A&#x003b2; was initially identified as the main component of cerebrovascular amyloid (<xref rid="CIT0152" ref-type="bibr">Glenner and Wong, 1984</xref>) and was later identified as the central component of cerebral amyloid plaques in both AD patients and aged individuals with Down syndrome (DS) (<xref rid="CIT0296" ref-type="bibr">Masters et al., 1985</xref>).</p><sec id="s6"><title>
&#x003b2;-Amyloid precursor protein (APP) processing</title><p>The gene encoding APP is located on human chromosome 21. APP is a type-I transmembrane protein with an extracellular amino (N)-terminus and an intracellular carboxyl (C)-terminus oriented intracellularly (<xref rid="CIT0105" ref-type="bibr">Dyrks et al., 1988</xref>; <xref rid="CIT0225" ref-type="bibr">Kang et al., 1987</xref>). It exists in three primary isoforms due to alternative splicing: APP695, APP751, and APP770. The APP695 isoform, comprising 695 amino acids, is primarily found in neurons. In contrast, the APP751 and APP770 isoforms, containing 751 and 770 amino acids, respectively, are ubiquitously expressed across various tissues (<xref rid="CIT0383" ref-type="bibr">Rohan de Silva et al., 1997</xref>). According to the AlzForum Mutations database, researchers have identified 20 pathogenic mutations within the <italic toggle="yes">APP</italic> gene in individuals diagnosed with AD. The APP-A673T variant (Icelandic mutation) is the sole variant known to confer protection against A&#x003b2; generation (<xref rid="CIT0355" ref-type="bibr">Peacock et al., 1993</xref>).</p><p>APP undergoes two main processing pathways: the amyloidogenic pathway, which leads to the production of neurotoxic A&#x003b2;, and the anti-amyloidogenic pathway, which inhibits A&#x003b2; generation (<xref rid="F1" ref-type="fig">Fig. 1</xref>).</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Illustration of APP processing pathways. In the amyloidogenic pathway, APP undergoes cleavage by &#x003b2;- and &#x003b3;-secretase, leading to the production of A&#x003b2;. Alternatively, the anti-amyloidogenic pathway results in the generation of neuroprotective sAPP&#x003b1; instead of A&#x003b2;. The processing of APP is also influenced by the action of &#x003b7;-secretase and caspases.</p></caption><graphic xlink:href="pwae026_fig1" position="float"/></fig><p>In the amyloidogenic pathway, APP is sequentially proteolytically cleaved by &#x003b2;- and &#x003b3;-secretase, resulting in the formation of A&#x003b2; peptides (<xref rid="CIT0522" ref-type="bibr">Zhang et al., 2011</xref>). The initial cleavage by &#x003b2;-secretase occurs at the N-terminus of A&#x003b2;, releasing the soluble ectodomain of APP (sAPP&#x003b2;) and the membrane-bound APP carboxyl-terminal fragment (&#x003b2;CTF or C99). BACE1 has been identified as the primary &#x003b2;-secretase, functioning optimally in acidic conditions found in the Golgi and endosomal organelles (<xref rid="CIT0193" ref-type="bibr">Huse et al., 2000</xref>, <xref rid="CIT0194" ref-type="bibr">2002</xref>; <xref rid="CIT0195" ref-type="bibr">Hussain et al., 2000</xref>; <xref rid="CIT0265" ref-type="bibr">Lin et al., 2000</xref>; <xref rid="CIT0424" ref-type="bibr">Sinha et al., 1999</xref>; <xref rid="CIT0469" ref-type="bibr">Vassar et al., 1999</xref>; <xref rid="CIT0476" ref-type="bibr">Walter et al., 2001</xref>; <xref rid="CIT0511" ref-type="bibr">Yan et al., 1999</xref>). The &#x003b3;-secretase complex further cleaves C99, releasing various A&#x003b2; peptides and the APP intracellular domain (AICD) (<xref rid="CIT0039" ref-type="bibr">Bibl et al., 2006</xref>). Among these peptides, A&#x003b2;<sub>40</sub> and A&#x003b2;<sub>42</sub> are predominant in the AD brain, with A&#x003b2;<sub>42</sub> being prone to aggregation and becoming more neurotoxic due to its hydrophobic C-terminus (<xref rid="CIT0384" ref-type="bibr">Roher et al., 1993</xref>). The &#x003b3;-secretase complex consists of four protein subunits, namely, presenilin (PS1 or PS2), presenilin enhancer 2 (PEN2), APH2, and nicastrin (<xref rid="CIT0235" ref-type="bibr">Kimberly et al., 2003</xref>; <xref rid="CIT0445" ref-type="bibr">Takasugi et al., 2003</xref>), with mutations in <italic toggle="yes">PSEN1</italic> or <italic toggle="yes">PSEN2</italic> implicated in most cases of autosomal dominant AD (<xref rid="CIT0258" ref-type="bibr">Levy-Lahad et al., 1995</xref>; <xref rid="CIT0416" ref-type="bibr">Sherrington et al., 1995</xref>).</p><p>In the anti-amyloidogenic pathway, APP undergoes sequential cleavage by &#x003b1;- and &#x003b3;-secretase. &#x003b1;-Secretase cuts APP within the A&#x003b2; domain, producing a truncated APP CTF (&#x003b1;CTF or C83) and a soluble ectodomain (sAPP&#x003b1;) (<xref rid="CIT0112" ref-type="bibr">Esch et al., 1990</xref>; <xref rid="CIT0425" ref-type="bibr">Sisodia et al., 1990</xref>). sAPP&#x003b1; is crucial for neuronal plasticity and survival, offering protection to hippocampal neurons from excitotoxicity (<xref rid="CIT0134" ref-type="bibr">Furukawa et al., 1996</xref>). Moreover, sAPP&#x003b1; alone has been demonstrated to mitigate behavioral abnormalities and synaptic deficits in APP-knockout mice (<xref rid="CIT0377" ref-type="bibr">Ring et al., 2007</xref>). &#x003b1;-Secretase activity is attributed to three members of the ADAM (a disintegrin and metalloproteinase) family: ADAM9, ADAM10, and ADAM17, also known as tumor necrosis factor-&#x003b1; converting enzymes (TACE) (<xref rid="CIT0522" ref-type="bibr">Zhang et al., 2011</xref>). Subsequently, &#x003b3;-secretase further cleaves C83, releasing the truncated A&#x003b2; peptides P3 and AICD (<xref rid="CIT0172" ref-type="bibr">Haass et al., 1993</xref>; <xref rid="CIT0400" ref-type="bibr">Sastre et al., 2001</xref>).</p><p>Beyond the classical APP processing pathway, APP can be cleaved by the membrane-bound matrix metalloproteinase &#x003b7;-secretase, such as MT5-MMP. This cleavage generates soluble truncated ectodomains of APP (sAPP&#x003b7;) and &#x003b7;CTF. Subsequently, &#x003b7;CTF undergoes cleavage by ADAM10 and BACE1, yielding the peptides A&#x003b7;-&#x003b1; and A&#x003b7;-&#x003b2; (<xref rid="F1" ref-type="fig">Fig. 1</xref>), and &#x003b7;CTF is enriched in dystrophic neurites. Like A&#x003b2;, A&#x003b7;-&#x003b1; exhibits neurotoxic effects (<xref rid="CIT0494" ref-type="bibr">Willem et al., 2015</xref>).</p><p>Additionally, APP is subject to cleavage by caspases, predominantly caspase-3, at the D664 residue within its C-terminus (based on APP695 numbering), resulting in a C-terminal 31-amino acid peptide (C31). &#x003b3;-Secretase cleavage also produces the Jcasp fragment, which spans the region between the &#x003b3;- and caspase-cleavage sites (amino acids 649&#x02013;664; <xref rid="F1" ref-type="fig">Fig. 1</xref>) (<xref rid="CIT0147" ref-type="bibr">Gervais et al., 1999</xref>; <xref rid="CIT0351" ref-type="bibr">Park et al., 2009</xref>). Both C31 and Jcasp are associated with neurotoxicity (<xref rid="CIT0283" ref-type="bibr">Lu et al., 2003</xref>). Importantly, blocking caspase cleavage in a human APP transgenic mouse model with the D664A mutation led to reduced synaptic loss, astrogliosis, and cognitive deficits despite the presence of abundant A&#x003b2; plaques in the brain (<xref rid="CIT0137" ref-type="bibr">Galvan et al., 2006</xref>).</p></sec><sec id="s7"><title>A&#x003b2; seeding and spreading</title><p>Due to their hydrophobic amino acids, A&#x003b2; monomers tend to aggregate and form oligomers. These oligomers range from low-molecular-weight species such as dimers and trimers to intermediate-sized nonamers, dodecamers, and high-molecular-weight oligomers (protofibrils). The interaction between the hydrophobic amino acids in protofibrils or oligomers within amyloid plaques leads to the formation of fibrils. These fibrils then stack together, resulting in plaque formation (<xref rid="CIT0515" ref-type="bibr">Yang et al., 2017</xref>).</p><p>Recent advancements in cryo-electron microscopy (cryo-EM) have unveiled the structures of A&#x003b2;<sub>42</sub> filaments in the human brain, identifying two distinct filament types characterized by their S-shaped protofilament folds. Type I filaments, which are mainly found in sporadic AD patients, consist of two identical S-shaped intertwined protofilaments. Their structure includes five &#x003b2;-strands and two hydrophobic clusters. Type II filaments, observed in familial AD patients, have smaller protofilament interfaces stabilized by electrostatic interactions. Both filament types exhibit left-handed twists, differing from the A&#x003b2; structure in cerebral amyloid angiopathy (CAA) in AD patients. Notably, A&#x003b2;<sub>42</sub> deposits in <italic toggle="yes">App</italic><sup><italic toggle="yes">NL-G-F</italic></sup>-knock-in mice predominantly consist of Type II fibrils (<xref rid="CIT0516" ref-type="bibr">Yang et al., 2022</xref>).</p><p>A&#x003b2; fibrillization can be initiated in a prion-like manner through the formation of misfolded &#x003b2;-sheet-containing A&#x003b2; seeds, which act as templates for larger amyloid aggregates (<xref rid="CIT0475" ref-type="bibr">Walker and Jucker, 2015</xref>). Experiments involving the intracerebral injection of AD patient-derived brain extracts into marmosets have led to amyloid plaque formation, dystrophic neurites, and cerebral amyloid angiopathy without NFTs (<xref rid="CIT0021" ref-type="bibr">Baker et al., 1993</xref>). Similarly, injections of A&#x003b2;-containing brain extracts into human APP transgenic mice have been shown to induce cerebral &#x003b2;-amyloidosis and associated pathologies (<xref rid="CIT0108" ref-type="bibr">Eisele et al., 2009</xref>, <xref rid="CIT0109" ref-type="bibr">2010</xref>; <xref rid="CIT0130" ref-type="bibr">Fritschi et al., 2014</xref>; <xref rid="CIT0309" ref-type="bibr">Meyer-Luehmann et al., 2006</xref>). There have also been reports of human-to-human transmission of iatrogenic A&#x003b2; in young adults treated with cadaver-derived pituitary growth hormone contaminated with both Creutzfeldt&#x02013;Jakob disease (CJD) prions and A&#x003b2; seeds (<xref rid="CIT0368" ref-type="bibr">Purro et al., 2018</xref>).</p><p>Several cofactors, including metal ions (<xref rid="CIT0001" ref-type="bibr">Abelein, 2023</xref>), glycosaminoglycans (<xref rid="CIT0198" ref-type="bibr">Iannuzzi et al., 2015</xref>), APOE (<xref rid="CIT0140" ref-type="bibr">Garai et al., 2014</xref>; <xref rid="CIT0180" ref-type="bibr">Hashimoto et al., 2012</xref>), &#x003b1;-synuclein (<xref rid="CIT0063" ref-type="bibr">Chia et al., 2017</xref>), and &#x003b2;2-microglobulin (B2M) (<xref rid="CIT0531" ref-type="bibr">Zhao et al., 2023</xref>), have been implicated in facilitating A&#x003b2; aggregation. Notably, B2M, a component of the major histocompatibility complex class I (MHC-I), plays a crucial role in antigen presentation to cytotoxic T lymphocytes and is vital for adaptive immune responses (<xref rid="CIT0082" ref-type="bibr">Cresswell et al., 2005</xref>). Recent studies have characterized novel amyloid-like protein aggregates composed of B2M and A&#x003b2; in the AD brain. Elevated levels of B2M in the brains of individuals with AD are crucial for A&#x003b2; aggregation and neurotoxicity, whereas depletion of B2M reduces amyloid spreading and completely neutralizes the neurotoxicity of A&#x003b2;. In contrast to A&#x003b2;, peripheral B2M can cross the blood&#x02012;brain barrier (BBB) and enter the brain parenchyma (<xref rid="CIT0531" ref-type="bibr">Zhao et al., 2023</xref>). Antibody-mediated depletion of peripheral B2M effectively eliminates cognitive deficits in AD and DS mouse models (<xref rid="CIT0139" ref-type="bibr">Gao et al., 2023</xref>; <xref rid="CIT0531" ref-type="bibr">Zhao et al., 2023</xref>). This research suggests targeting peripheral B2M as a potential strategy for treating cognitive impairment in individuals with AD and DS, potentially overcoming the challenge of drug delivery across the BBB that is commonly encountered in the treatment of central nervous system (CNS) diseases.</p><p>The spread of A&#x003b2; in AD shares similarities with prion spreading, potentially propagating through neuron-to-neuron transmission (<xref rid="CIT0102" ref-type="bibr">Domert et al., 2014</xref>; <xref rid="CIT0332" ref-type="bibr">Nath et al., 2012</xref>; <xref rid="CIT0430" ref-type="bibr">Song et al., 2014</xref>). Furthermore, the propagation of A&#x003b2; pathology, triggered by seeding, may follow neuroanatomical routes aligned with the limbic connectome (<xref rid="CIT0518" ref-type="bibr">Ye et al., 2015</xref>). Analysis of florbetapir (<sup>18</sup>F-AV45) PET data revealed the distribution pattern of A&#x003b2; pathology. Typically, the deposition of A&#x003b2; plaques begins in the temporobasal and frontomedial areas and then gradually extends to encompass the broader associative neocortex, primary sensory-motor regions, and the medial temporal lobe, ultimately reaching the striatum (<xref rid="CIT0164" ref-type="bibr">Grothe et al., 2017a</xref>).</p></sec><sec id="s8"><title>Amyloid cascade hypothesis</title><p>Building on multiple sources of evidence, Hardy and Higgins introduced the amyloid cascade hypothesis in 1992 (<xref rid="CIT0178" ref-type="bibr">Hardy and Higgins, 1992</xref>). This hypothesis posits that the increase in the generation and aggregation of A&#x003b2; in the brain is the initial step in AD pathogenesis, leading to NFT formation, neuronal loss, and ultimately, cognitive decline.</p><p>Individuals with DS who have a third copy of chromosome 21 carry an extra copy of the <italic toggle="yes">APP</italic> gene. This genetic duplication results in increased A&#x003b2; deposition and AD-like neuropathology. Additionally, missense mutations in the <italic toggle="yes">APP</italic> gene, identified in patients with autosomal dominant AD, further contribute to AD pathology. Notably, the APP-A673T variant has been linked to a decreased risk of developing AD, providing strong support for the amyloid cascade hypothesis (<xref rid="CIT0450" ref-type="bibr">Tcw and Goate, 2017</xref>). Recent clinical trials of monoclonal antibodies targeting A&#x003b2;, including lecanemab, donanemab and aducanumab, have shown promising results in slowing the progression of early-stage AD (<xref rid="CIT0049" ref-type="bibr">Budd Haeberlein et al., 2022</xref>; <xref rid="CIT0423" ref-type="bibr">Sims et al., 2023</xref>; <xref rid="CIT0468" ref-type="bibr">van Dyck et al., 2023</xref>). These results offer significant clinical evidence for the crucial role of A&#x003b2; in AD pathogenesis and further validate the amyloid cascade hypothesis.</p><p>However, the simplicity of this neuron-centric, linear model has been questioned based on clinical observations, challenging the direct causal relationship between A&#x003b2; and dementia (<xref rid="CIT0097" ref-type="bibr">De Strooper and Karran, 2016</xref>). The severity of cognitive decline has been shown to correlate more closely with the presence of NFTs than with the presence of A&#x003b2; plaques (<xref rid="CIT0333" ref-type="bibr">Nelson et al., 2012</xref>). Furthermore, regional brain hypometabolism appears to be unrelated to the burden of regional A&#x003b2; plaques (<xref rid="CIT0004" ref-type="bibr">Altmann et al., 2015</xref>). These insights suggest that while A&#x003b2; accumulation may initiate AD progression, other downstream processes, such as neuroinflammation and tau pathology, might be the main drivers of neurodegeneration (<xref rid="CIT0278" ref-type="bibr">Long and Holtzman, 2019</xref>).</p><p>The ongoing debate surrounding the relative importance of A&#x003b2; and tau in AD pathogenesis reflects the complexity of AD and the need for a deeper understanding of the interplay between A&#x003b2; and tau in the disease process. It is possible that A&#x003b2; and tau each play critical, yet distinct, roles in AD pathogenesis, with A&#x003b2; initiating the cascade and tau driving subsequent neurodegeneration. However, the specific mechanisms through which A&#x003b2; and tau interact and contribute to the development and progression of AD remain unclear. Further research is required to clarify the exact roles of A&#x003b2; and tau in AD pathogenesis. This may include developing new imaging techniques and biomarkers to better monitor disease progression, as well as identifying novel therapeutic targets that address both A&#x003b2; and tau pathology.</p></sec></sec><sec id="s9"><title>Tau</title><p>Tau, the primary component of NFTs, plays a crucial role in regulating microtubule stability and intracellular trafficking under normal conditions as a microtubule-associated protein (<xref rid="CIT0471" ref-type="bibr">Vershinin et al., 2007</xref>). However, impaired tau function can lead to various neurological issues. For instance, tau deficiency has been shown to disrupt the trafficking of APP, also an iron export protein, to the neuronal surface, resulting in toxic iron retention, cognitive deficits, and parkinsonism-like symptoms in mice (<xref rid="CIT0253" ref-type="bibr">Lei et al., 2012</xref>). Tau deficiency protects young mice from ischemic stroke by preventing ferroptosis, and this effect diminishes in older tau knockout mice due to accelerated age-dependent brain iron accumulation (<xref rid="CIT0462" ref-type="bibr">Tuo et al., 2017</xref>). Furthermore, additional research indicates that tau may also affect axonal elongation and maturation, synaptic plasticity, and neuronal excitability (<xref rid="CIT0477" ref-type="bibr">Wang and Mandelkow, 2016</xref>). The diverse roles of tau highlight its multifaceted nature and its significance in maintaining neuronal homeostasis and overall brain function. Given the involvement of tau in a variety of cellular functions, from microtubule dynamics to synaptic activity, further research into its impact on neuronal processes is crucial.</p><p>The regional progression of brain atrophy in AD strongly correlates with tau accumulation, more so than with A&#x003b2; deposition (<xref rid="CIT0148" ref-type="bibr">Giannakopoulos et al., 2003</xref>). In addition to AD, NFTs are also found in the brains of older individuals who may show no cognitive impairment or only amnestic changes, even in the absence of amyloid plaques. These instances are classified as &#x0201c;primary age-related tauopathy&#x0201d; (PART) (<xref rid="CIT0081" ref-type="bibr">Crary et al., 2014</xref>). Moreover, tau pathology appears in other tauopathies, traumatic brain injury (TBI), and stroke (<xref rid="CIT0076" ref-type="bibr">Congdon and Sigurdsson, 2018</xref>). Mutations in the tau gene <italic toggle="yes">MAPT</italic>, located on chromosome 17, are linked to several tauopathies, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick disease (PiD), and frontotemporal dementia (FTD) (<xref rid="CIT0077" ref-type="bibr">Congdon et al., 2023</xref>).</p><p>Alternative splicing of the <italic toggle="yes">MAPT</italic> gene, particularly involving exons 2 and 3 at the N-terminus (N) and exon 10 within the microtubule-binding repeat domain (MBRD), leads to six distinct isoforms in the adult human brain: 0N3R, 0N4R, 1N3R, 1N4R, 2N3R, and 2N4R (<xref rid="CIT0153" ref-type="bibr">Goedert et al., 1989</xref>). Normally, the brain maintains equal levels of 4R- and 3R-tau isoforms, AD typically presents with a combination of both 4R- and 3R-tau, CBD and PSP show aggregates of 4R-tau only, and PiD features 3R-tau aggregates. In cases of FTD associated with tau pathology, patients often exhibit aggregates of either exclusively 4R- or 3R-tau (<xref rid="CIT0247" ref-type="bibr">Kyalu Ngoie Zola et al., 2023</xref>; <xref rid="CIT0436" ref-type="bibr">Spillantini and Goedert, 1998</xref>).</p><p>In AD patients, the levels of soluble tau are lower, yet there are approximately 100 times more insoluble tau than in controls. Soluble tau tends to be full-length, incorporating both its N-terminal domain and all four MBRDs (2N4Rs). Conversely, the insoluble fraction often lacks N-terminal domains and is predominantly composed of the 0N4R isoform (<xref rid="CIT0492" ref-type="bibr">Wesseling et al., 2020</xref>).</p><sec id="s10"><title>Posttranslational modification of Tau</title><p>Prior to forming NFTs, the tau protein undergoes an intricate array of posttranslational modifications (PTMs), including phosphorylation (P), ubiquitination (Ub), SUMOylation, acetylation (Ac), methylation, glycosylation and truncation (<xref rid="F2" ref-type="fig">Fig. 2</xref>). Through comprehensive qualitative and quantitative analysis of tau proteoforms from postmortem human brains involving 49 AD patients and 42 controls, researchers identified 95 unique PTMs across 88 amino acid residues, encompassing 55 phosphorylation, 17 ubiquitination, 19 acetylation, and four methylation sites. Additionally, clusters with higher Braak stages displayed increased levels of tau and A&#x003b2; as well as elevated tau PTMs. Phosphorylation was most common in the proline-rich region (PRR) and the C-terminus, while ubiquitination and acetylation were mainly localized to the MBRD, with certain residues exhibiting both modifications. In AD patients at Braak stages V-VI, significant PTMs, such as phosphorylation at S262 and S263; acetylation at K311, K353, and K369; and ubiquitination at K259, K267, K311, and K317, are associated with increased tau and amyloid burdens (<xref rid="CIT0492" ref-type="bibr">Wesseling et al., 2020</xref>). Furthermore, specific PTMs in soluble tau&#x02014;Ub-K369 and Ub-K343 for 4R-tau and Ac-K311 and P-S184&#x02005;+&#x02005;P-S185 for 3R-tau&#x02014;were identified as key discriminators between 4R- and 3R-tauopathies (<xref rid="CIT0247" ref-type="bibr">Kyalu Ngoie Zola et al., 2023</xref>). Additionally, the levels of free UFM1, a type I ubiquitin-like protein, were found to be reduced in the brains of patients with AD or PSP. Knockdown of genes associated with the UFMylation process, including <italic toggle="yes">UBA5</italic> and <italic toggle="yes">UFM1</italic>, reduces tau inclusion formation in human neurons derived from induced pluripotent stem cells (iPSCs) harboring the Tau-P301S mutation. Furthermore, depletion of the UFM1-activating enzyme UBA5 has been shown to ameliorate tau propagation in the PS19 mouse model of tauopathy (<xref rid="CIT0353" ref-type="bibr">Parra Bravo et al., 2024</xref>). These findings suggest that the UFMylation pathway plays a role in the pathogenesis of both AD and PSP. Therefore, targeting the UFMylation process could represent a potential therapeutic strategy for these neurodegenerative disorders.</p><fig position="float" id="F2"><label>Figure 2.</label><caption><p>Tau protein and the formation of neurofibrillary tangles. The diagram illustrates the structural features of the 2N4R tau protein. In the adult human brain, six isoforms of tau are produced through alternative splicing of the <italic toggle="yes">MAPT</italic> gene, with variations in the inclusion of exons at the N-terminus and exon 10 in the MBRD. In addition to genetic mutations, PTMs such as phosphorylation, ubiquitination, acetylation, and C-terminal truncation initiate the accumulation of tau into oligomers and filaments, including paired helical filaments (PHFs) and straight filaments (SFs). This accumulation culminates in the formation of NFTs, which are toxic and play a crucial role in the pathogenesis of tauopathies, thereby contributing to their detrimental impacts.</p></caption><graphic xlink:href="pwae026_fig2" position="float"/></fig><sec id="s11"><title>Phosphorylation</title><p>Tau hyperphosphorylation is a key pathological event in the development of tauopathies. Researchers have identified 86 phosphorylation events on tau, 55 of which are specifically linked to pathologically insoluble tau formation (<xref rid="CIT0492" ref-type="bibr">Wesseling et al., 2020</xref>). Hyperphosphorylation of tau, an early pathological marker, impairs its microtubule-stabilizing function, leading to its mislocalization to the somatodendritic compartment (<xref rid="CIT0077" ref-type="bibr">Congdon et al., 2023</xref>). Certain phosphorylation sites, such as S199, S202, S205, T231, and S262, are pivotal during the pre-tangle phase of the disease (<xref rid="CIT0018" ref-type="bibr">Augustinack et al., 2002</xref>; <xref rid="CIT0287" ref-type="bibr">Luna-Munoz et al., 2007</xref>). The emergence of S422 phosphorylation, which correlates with an increase in somatic tau protein (<xref rid="CIT0177" ref-type="bibr">Hanger and Wray, 2010</xref>), appears to prevent cleavage at D421, a process occurring before this phosphorylation event. Moreover, phosphorylation at S396 becomes increasingly prominent as AD progresses (<xref rid="CIT0236" ref-type="bibr">Kimura et al., 1996</xref>).</p><p>Phosphorylation at residues T217, T231, S262, and S396 is known to promote tau aggregation (<xref rid="CIT0169" ref-type="bibr">Guo et al., 2006</xref>; <xref rid="CIT0183" ref-type="bibr">Helboe et al., 2022</xref>; <xref rid="CIT0223" ref-type="bibr">Kadavath et al., 2018</xref>; <xref rid="CIT0401" ref-type="bibr">Savastano et al., 2021</xref>). In contrast, phosphorylation at residues T212, S237, and S404 is associated with a reduction in tau aggregation (<xref rid="CIT0365" ref-type="bibr">Povellato et al., 2014</xref>). Interestingly, while no unique phosphorylation site on soluble tau has been identified as exclusively indicative of AD, the presence of phosphorylation at T217, T231, and S396 within the soluble tau fraction serves as a potential biomarker to distinguish AD patients from non-AD individuals (<xref rid="CIT0247" ref-type="bibr">Kyalu Ngoie Zola et al., 2023</xref>).</p><p>Tau phosphorylation is modulated by three main groups of kinases: proline-directed serine-threonine protein kinases, non-proline-directed serine-threonine protein kinases, and tyrosine protein kinases (<xref rid="CIT0170" ref-type="bibr">Guo et al., 2017</xref>). Key kinases, such as glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;), c-JUN N-terminal kinase (JNK), and cyclin-dependent kinase 5 (CDK5), are upregulated in the AD brain (<xref rid="CIT0422" ref-type="bibr">Shukla et al., 2012</xref>; <xref rid="CIT0451" ref-type="bibr">Tell and Hilgeroth, 2013</xref>; <xref rid="CIT0517" ref-type="bibr">Yarza et al., 2015</xref>). In contrast, the activity of protein phosphatase 1 (PP1) and PP2A, which are responsible for dephosphorylating tau, is reduced in postmortem AD brains (<xref rid="CIT0156" ref-type="bibr">Gong et al., 1993</xref>; <xref rid="CIT0433" ref-type="bibr">Sontag et al., 2004</xref>; <xref rid="CIT0473" ref-type="bibr">Vogelsberg-Ragaglia et al., 2001</xref>).</p></sec><sec id="s12"><title>Ubiquitination</title><p>The accumulation of ubiquitinated proteins within NFTs and amyloid plaques is a hallmark of AD pathology, highlighting the critical role of ubiquitination in the disease process (<xref rid="CIT0317" ref-type="bibr">Mori et al., 1987</xref>; <xref rid="CIT0359" ref-type="bibr">Perry et al., 1987</xref>). Seventeen out of 40 lysine residues have been pinpointed as ubiquitination sites in the human tau protein (<xref rid="CIT0492" ref-type="bibr">Wesseling et al., 2020</xref>). Ubiquitination at residues K311, K317, K321, or K369 reduces kinetic barriers, promoting the formation of tau filaments (<xref rid="CIT0492" ref-type="bibr">Wesseling et al., 2020</xref>). The PTMs (Ub-K311, Ub-K317, and Ub-K267&#x02005;+&#x02005;P-S262) in soluble tau from postmortem human brains have been identified as AD-specific, distinguishing them from other tauopathies, such as CBD, FTD, and PiD (<xref rid="CIT0247" ref-type="bibr">Kyalu Ngoie Zola et al., 2023</xref>).</p><p>Ubiquitination of tau, facilitated by E3 ligases such as the C-terminus of Hsc70-interacting protein (CHIP), TNF receptor-associated factor 6 (TRAF6) and axotrophin/MARCH7, plays a critical role in tau dynamics (<xref rid="CIT0019" ref-type="bibr">Babu et al., 2005</xref>; <xref rid="CIT0125" ref-type="bibr">Flach et al., 2014</xref>; <xref rid="CIT0361" ref-type="bibr">Petrucelli et al., 2004</xref>). CHIP targets the MBRD of tau, promoting K48- and K63-linked ubiquitination, which leads to increased tau aggregation. Moreover, Hsp70 enhances tau turnover, reducing the levels of both insoluble and hyperphosphorylated tau (<xref rid="CIT0361" ref-type="bibr">Petrucelli et al., 2004</xref>), indicating the crucial role of the Hsp70/CHIP chaperone system in managing tau pathology. The role of TRAF6 in mediating K63 polyubiquitination points toward its involvement in the ubiquitin&#x02012;proteasome system&#x02019;s tau degradation pathway (<xref rid="CIT0019" ref-type="bibr">Babu et al., 2005</xref>). On the other hand, the effect of axotrophin/MARCH7 on tau monoubiquitylation reduces the microtubule-binding capacity of tau (<xref rid="CIT0125" ref-type="bibr">Flach et al., 2014</xref>).</p><p>Further research into the role of ubiquitin-specific peptidases, such as X-linked ubiquitin-specific peptidase 11 (USP11), revealed its increase in the AD brain. The ability of USP11 to deubiquitinate tau at K281 leads to enhanced tau acetylation and subsequent pathological aggregation in PS19 mice (<xref rid="CIT0513" ref-type="bibr">Yan et al., 2022</xref>). Conversely, the ubiquitin thioesterase Otub1 has been identified as a tau deubiquitinating enzyme that disrupts K48-linked tau deubiquitylation, impairing tau degradation and promoting aggregation (<xref rid="CIT0480" ref-type="bibr">Wang et al., 2017a</xref>).</p></sec><sec id="s13"><title>SUMOylation</title><p>SUMOylation, the covalent attachment of small ubiquitin-related modifier (SUMO) proteins, is another reversible PTM that influences tau function and pathology (<xref rid="CIT0143" ref-type="bibr">Geiss-Friedlander and Melchior, 2007</xref>). Tripartite motif 11 (TRIM11), a SUMO E3 ligase for tau, is downregulated in the AD brain. TRIM11 facilitates SUMOylation and proteasomal degradation of mutant tau. Moreover, TRIM11 enhances tau solubility by acting both as a chaperone to prevent its misfolding and as a disaggregated to break down existing tau fibrils (<xref rid="CIT0527" ref-type="bibr">Zhang et al., 2023</xref>). Additionally, SUMOylation at the K340 residue of tau facilitates its phosphorylation while simultaneously blocking ubiquitination-mediated tau degradation (<xref rid="CIT0288" ref-type="bibr">Luo et al., 2014</xref>).</p></sec><sec id="s14"><title>Acetylation</title><p>Acetylation is another critical PTM affecting tau, with 23 lysines and two cysteines identified as potential acetylation sites across the tau sequence (<xref rid="CIT0315" ref-type="bibr">Min et al., 2010</xref>; <xref rid="CIT0366" ref-type="bibr">Prifti et al., 2021</xref>). Acetylation at K274, K280, and K281 disrupts the physiological functions of tau, impairing its interaction with microtubules and leading to its mislocalization and pathological aggregation, which contributes to synaptic deficits in tauopathies (<xref rid="CIT0073" ref-type="bibr">Cohen et al., 2011</xref>; <xref rid="CIT0428" ref-type="bibr">Sohn et al., 2016</xref>; <xref rid="CIT0461" ref-type="bibr">Tracy et al., 2016</xref>). Moreover, acetylation at K163, K174, and K180 has been shown to reduce tau turnover by inhibiting its ubiquitination, highlighting the competitive nature between acetylation and ubiquitination in regulating tau degradation (<xref rid="CIT0315" ref-type="bibr">Min et al., 2010</xref>).</p><p>Tau acetylation is facilitated by the histone acetyltransferase p300 (<xref rid="CIT0315" ref-type="bibr">Min et al., 2010</xref>) and cAMP-response element-binding protein (CREB)-binding protein (CBP) (<xref rid="CIT0224" ref-type="bibr">Kamah et al., 2014</xref>). Additionally, autoacetylation at residues C291 and C322 within the MBRD contributed to the initiation of tau aggregation (<xref rid="CIT0366" ref-type="bibr">Prifti et al., 2021</xref>). Conversely, deacetylation, orchestrated by sirtuin 1 (<xref rid="CIT0315" ref-type="bibr">Min et al., 2010</xref>) and histone deacetylase 6 (HDAC6), plays divergent roles in relation to tau pathology. Sirtuin1 acts protectively, reducing tau aggregation, whereas HDAC6 is associated with increased tau pathology propagation (<xref rid="CIT0055" ref-type="bibr">Carlomagno et al., 2017</xref>). Furthermore, the deacetylation of residues within the KXGS motif by HDAC6 enhances tau phosphorylation and aggregation, underscoring the complex interplay between acetylation and phosphorylation in the modulation of the PTM landscape of tau (<xref rid="CIT0078" ref-type="bibr">Cook et al., 2014</xref>). Notably, sirtuin 1 levels are reduced, and HDAC6 levels are elevated in AD brains, reflecting their distinct contributions to the progression of the disease (<xref rid="CIT0055" ref-type="bibr">Carlomagno et al., 2017</xref>).</p></sec><sec id="s15"><title>Methylation</title><p>Tau methylation, which occurs on both lysine and arginine residues, has been observed in a significant portion of NFTs in the postmortem brains of AD patients (<xref rid="CIT0456" ref-type="bibr">Thomas et al., 2012</xref>). Specifically, seven lysine residues (K44, K163, K174, K180, K254, K267, and K290) within the projection and MBRD domains of paired helical filament (PHF) tau derived from the AD brain were identified as methylation sites (<xref rid="CIT0456" ref-type="bibr">Thomas et al., 2012</xref>). Methylation can occur on lysine residues as either a mono- or dimethyl modification (<xref rid="CIT0133" ref-type="bibr">Funk et al., 2014</xref>). Additionally, monomethylation of arginine residues R126, R155, and R349 was observed in tau from both wild-type and human APP transgenic mice (<xref rid="CIT0321" ref-type="bibr">Morris et al., 2015</xref>). This methylation process was found to reduce the aggregation of recombinant tau proteins while not affecting their ability to support microtubule assembly (<xref rid="CIT0133" ref-type="bibr">Funk et al., 2014</xref>). The protein lysine methyltransferase SETD7 selectively monomethylates tau protein at K132. Furthermore, K132-monomethylated tau proteins are primarily localized within the cell soma and nuclear compartments and are absent from neurites (<xref rid="CIT0040" ref-type="bibr">Bichmann et al., 2021</xref>).</p></sec><sec id="s16"><title>Glycosylation</title><p>Glycosylation has been identified at 32 lysine residues across the entire length of the tau protein (<xref rid="CIT0329" ref-type="bibr">Nacharaju et al., 1997</xref>). Research has shown that both <italic toggle="yes">N</italic>- and <italic toggle="yes">O</italic>-glycosylation occur in tau (<xref rid="CIT0010" ref-type="bibr">Arnold et al., 1996</xref>; <xref rid="CIT0478" ref-type="bibr">Wang et al., 1996</xref>). Notably, <italic toggle="yes">N</italic>-glycosylation has been specifically observed in PHF tau extracted from postmortem AD brains, distinguishing it from the tau found in healthy individuals (<xref rid="CIT0478" ref-type="bibr">Wang et al., 1996</xref>). <italic toggle="yes">N</italic>-glycosylation is associated with an increased tendency for tau to become hyperphosphorylated (<xref rid="CIT0268" ref-type="bibr">Liu et al., 2002</xref>), but interestingly, it also leads to a reduction in tau aggregation (<xref rid="CIT0281" ref-type="bibr">Losev et al., 2019</xref>). On the other hand, <italic toggle="yes">O</italic>-GlcNAcylation, a particular type of <italic toggle="yes">O</italic>-glycosylation, seems to offer a protective effect against tau-related pathologies. There is a notable decrease in <italic toggle="yes">O</italic>-GlcNAcylated tau in the brains of AD patients. Additionally, experiments have shown that blocking <italic toggle="yes">O</italic>-GlcNAcylation leads to an increase in tau phosphorylation in the rat brain, suggesting a critical role in regulating pathological tau modifications (<xref rid="CIT0269" ref-type="bibr">Liu et al., 2009</xref>).</p></sec><sec id="s17"><title>Truncation</title><p>Proteolytic cleavage of tau by various enzymes, including caspases, asparagine endopeptidase (AEP), calpains, and ADAM10, results in the generation of truncated tau species (<xref rid="CIT0171" ref-type="bibr">Guo et al., 2020</xref>). Caspases 2 and 3 cleave tau at D314 and D421, generating truncated &#x00394;tau-314 and &#x00394;tau-421, respectively. These truncated proteins have been found at elevated levels in the postmortem brains of AD patients (<xref rid="CIT0138" ref-type="bibr">Gamblin et al., 2003</xref>; <xref rid="CIT0529" ref-type="bibr">Zhao et al., 2016b</xref>). Cleavage at D314 is critical for the mislocalization of both full-length tau and &#x00394;tau-314 to dendritic spines, a necessary step for tau-P301L to trigger neurodegeneration in mice expressing EGFP-tau-P301L (D314E). However, &#x00394;tau-314 alone does not impair synaptic function in mice expressing EGFP-&#x00394;tau-314. Interestingly, reducing caspase-2 levels was shown to restore memory function in rTg4510 mice (<xref rid="CIT0529" ref-type="bibr">Zhao et al., 2016b</xref>). Moreover, A&#x003b2; promotes tau cleavage at D421 via caspase-3 and -7, representing an early pathological event in AD, with &#x00394;tau-421 facilitating the assembly of tau filaments <italic toggle="yes">in vitro</italic>, and these filaments in AD brains show immunoreactivity to NFTs (<xref rid="CIT0138" ref-type="bibr">Gamblin et al., 2003</xref>; <xref rid="CIT0379" ref-type="bibr">Rissman et al., 2004</xref>). Additionally, caspase-6 cleaves tau at residues D13 and D402, generating &#x00394;tau-13 and &#x00394;tau-402, respectively (<xref rid="CIT0191" ref-type="bibr">Horowitz et al., 2004</xref>). The presence of active caspase-6 and truncated tau forms (&#x00394;tau-13 and -402) is significant in AD and, to a lesser extent, in PiD but not in argyrophilic grain disease (AGD), CBD, or PSP. These findings suggest that caspase-6 is a potential therapeutic target for AD and possibly PiD (<xref rid="CIT0455" ref-type="bibr">Theofilas et al., 2022</xref>).</p><p>AEP, a lysosomal cysteine proteinase, becomes activated with aging and in the brains of individuals with AD and P301S mice (<xref rid="CIT0523" ref-type="bibr">Zhang et al., 2014</xref>). AEP cleaves tau at residues N167, N255, and N368 (<xref rid="CIT0033" ref-type="bibr">Behrendt et al., 2019</xref>; <xref rid="CIT0523" ref-type="bibr">Zhang et al., 2014</xref>). Depletion of AEP reduced tau hyperphosphorylation and ameliorated synaptic and cognitive deficits in PS19 mice. The ability of truncated tau proteins (amino acids 1&#x02013;255 and 1&#x02013;368) to stabilize microtubules is disrupted, facilitating tau hyperphosphorylation and aggregation. Inhibiting AEP cleavage prevents the neurodegeneration induced by tau P301S in PS19 mice expressing mutant tau-P301S (N255A, N368A) (<xref rid="CIT0523" ref-type="bibr">Zhang et al., 2014</xref>).</p></sec></sec><sec id="s18"><title>Tau seeding and spreading</title><p>NFTs consist of PHFs and straight tau filaments (SFs), as identified in early studies (<xref rid="CIT0233" ref-type="bibr">Kidd, 1963</xref>; <xref rid="CIT0452" ref-type="bibr">Terry, 1963</xref>; <xref rid="CIT0508" ref-type="bibr">Yagishita et al., 1981</xref>). Recent advancements in cryo-EM have revealed that the core of tau filaments (amino acids 306&#x02013;378 of tau protein) is formed from two identical protofilaments. These protofilaments exhibit a unique cross-&#x003b2;/&#x003b2;-helix structure, acting as nucleation sites for further tau aggregation. Notably, PHFs and SFs differ in how their protofilaments are arranged (<xref rid="CIT0124" ref-type="bibr">Fitzpatrick et al., 2017</xref>). Various tauopathies, including AD, chronic traumatic encephalopathy (CTE), CBD, PiD, and PSP, are characterized by distinct tau fold patterns, highlighting the diversity of tau pathology (<xref rid="CIT0115" ref-type="bibr">Falcon et al., 2018a</xref>, <xref rid="CIT0116" ref-type="bibr">2018b</xref>, <xref rid="CIT0117" ref-type="bibr">2019</xref>; <xref rid="CIT0124" ref-type="bibr">Fitzpatrick et al., 2017</xref>; <xref rid="CIT0419" ref-type="bibr">Shi et al., 2021b</xref>; <xref rid="CIT0526" ref-type="bibr">Zhang et al., 2020</xref>). Interestingly, NFTs in primary age-related tauopathies are similar to those in AD (<xref rid="CIT0418" ref-type="bibr">Shi et al., 2021a</xref>).</p><p>Tau aggregation is influenced by a complex interplay of PTMs, genetic mutations, and specific polymerization inducers, leading to the formation of toxic NFTs within neurons (<xref rid="CIT0076" ref-type="bibr">Congdon and Sigurdsson, 2018</xref>). This contributes significantly to neurodegeneration. It has been suggested that smaller, soluble tau oligomers are more detrimental to cellular health than larger, mature filaments are (<xref rid="CIT0054" ref-type="bibr">Cardenas-Aguayo Mdel et al., 2014</xref>; <xref rid="CIT0413" ref-type="bibr">Shafiei et al., 2017</xref>).</p><p>In AD, NFT pathology begins in the transentorhinal and entorhinal cortex, advancing in a predictable pattern through the hippocampus and into the neocortex. The propagation of tau pathology, as determined by Braak staging in postmortem studies, correlates with disease severity (<xref rid="CIT0045" ref-type="bibr">Braak and Braak, 1995</xref>; <xref rid="CIT0046" ref-type="bibr">Braak et al., 2006</xref>). Modern imaging technologies, such as positron emission tomography (PET) and MRI, have confirmed the anticipated spread of tau pathology and its association with brain functional reorganization, supporting the hypothesis of transneuronal tau propagation (<xref rid="CIT0079" ref-type="bibr">Cope et al., 2018</xref>). In primary age-related tauopathy, NFTs predominantly affect the medial temporal lobe and other specific brain regions (<xref rid="CIT0081" ref-type="bibr">Crary et al., 2014</xref>).</p><p>The transmission of tau from cell to cell involves the self-propagation of proteopathic tau seeds, which trigger the accumulation and templated fibrillization of endogenous tau, spreading abnormal tau across the brain in a manner reminiscent of prions (<xref rid="CIT0150" ref-type="bibr">Gibbons et al., 2019</xref>; <xref rid="CIT0475" ref-type="bibr">Walker and Jucker, 2015</xref>). According to experimental models, intracerebral injection of brain extracts containing tau aggregates into tau transgenic mice induces NFT formation and pathological spread (<xref rid="CIT0003" ref-type="bibr">Ahmed et al., 2014</xref>; <xref rid="CIT0070" ref-type="bibr">Clavaguera et al., 2009</xref>), a phenomenon also observed with brain extracts from human tauopathies (<xref rid="CIT0043" ref-type="bibr">Boluda et al., 2015</xref>; <xref rid="CIT0071" ref-type="bibr">Clavaguera et al., 2013</xref>). Intriguingly, peripheral injection of tau aggregates can also trigger tauopathy in transgenic mice (<xref rid="CIT0072" ref-type="bibr">Clavaguera et al., 2014</xref>).</p><p>Extracellular tau, both exosome-associated and freely soluble, plays a role in the dissemination of tau pathology (<xref rid="CIT0012" ref-type="bibr">Asai et al., 2015</xref>; <xref rid="CIT0123" ref-type="bibr">Fiandaca et al., 2015</xref>; <xref rid="CIT0211" ref-type="bibr">Jia et al., 2019</xref>; <xref rid="CIT0227" ref-type="bibr">Kanmert et al., 2015</xref>; <xref rid="CIT0394" ref-type="bibr">Saman et al., 2012</xref>; <xref rid="CIT0481" ref-type="bibr">Wang et al., 2017b</xref>). Neurons and microglia release tau-containing exosomes, facilitating the spread of tau pathology (<xref rid="CIT0012" ref-type="bibr">Asai et al., 2015</xref>; <xref rid="CIT0323" ref-type="bibr">Mothes et al., 2023</xref>; <xref rid="CIT0481" ref-type="bibr">Wang et al., 2017b</xref>). Pathological tau is taken up by interconnected neurons or adjacent glial cells via endocytosis, micropinocytosis, or direct membrane fusion (<xref rid="CIT0012" ref-type="bibr">Asai et al., 2015</xref>; <xref rid="CIT0053" ref-type="bibr">Calafate et al., 2016</xref>; <xref rid="CIT0068" ref-type="bibr">Christianson and Belting, 2014</xref>; <xref rid="CIT0131" ref-type="bibr">Frost et al., 2009</xref>; <xref rid="CIT0324" ref-type="bibr">Mulcahy et al., 2014</xref>; <xref rid="CIT0499" ref-type="bibr">Wu et al., 2013</xref>). Low-molecular-weight (LMW) tau aggregates and short fibrils are particularly prone to endocytosis and subsequent neuron-to-neuron transmission (<xref rid="CIT0131" ref-type="bibr">Frost et al., 2009</xref>; <xref rid="CIT0499" ref-type="bibr">Wu et al., 2013</xref>). Heparan sulfate proteoglycans (HSPGs) also play a crucial role in the binding, internalization, and propagation of tau (<xref rid="CIT0188" ref-type="bibr">Holmes et al., 2013</xref>).</p><p>A key step in the spread of tau fibrils involves endolysosomal damage (<xref rid="CIT0150" ref-type="bibr">Gibbons et al., 2019</xref>). Disrupting lysosomal function with chloroquine reduces the degradation of synthetic tau preformed fibrils (PFFs) and increases the aggregation of endogenous tau in neurons expressing Tau P301L-GFP (<xref rid="CIT0149" ref-type="bibr">Gibbons et al., 2017</xref>). Furthermore, the deletion of PI4K2A, a kinase in the phosphoinositide-initiated membrane tethering and lipid transport (PITT) pathway essential for lysosomal repair, exacerbates tau fibril spreading in cell-based assays (<xref rid="CIT0446" ref-type="bibr">Tan and Finkel, 2022</xref>).</p><p>Increasing evidence indicates that the deposition of A&#x003b2; plaques is essential for the propagation of tau pathology in AD. A&#x003b2; plaques facilitate the rapid amplification of pathological tau derived from human AD brain extracts and promote the formation of large tau aggregates. This process subsequently triggers the formation and dissemination of NFTs and neuropil threads (NTs) in <italic toggle="yes">App</italic><sup><italic toggle="yes">NL-G-F</italic></sup>-knock-in and 5&#x000d7;&#x02005;FAD transgenic mouse models (<xref rid="CIT0182" ref-type="bibr">He et al., 2018</xref>).</p></sec></sec><sec id="s19"><title>Neuronal loss</title><p>Extensive loss of neurons, especially in the regions critical for memory and higher cognitive functions, is a hallmark of AD (<xref rid="CIT0098" ref-type="bibr">DeTure and Dickson, 2019</xref>; <xref rid="CIT0410" ref-type="bibr">Serrano-Pozo et al., 2011</xref>). In the healthy adult brain, mature neurons utilize intricate mechanisms to suppress the activation of cell death signaling (<xref rid="CIT0243" ref-type="bibr">Kole et al., 2013</xref>). However, in the context of AD, these protective mechanisms appear to be compromised, leading to the aberrant activation of various forms of regulated cell death (RCD), including necroptosis, pyroptosis, apoptosis, ferroptosis, and autophagy-dependent cell death (<xref rid="CIT0154" ref-type="bibr">Goel et al., 2022</xref>; <xref rid="CIT0454" ref-type="bibr">Thal et al., 2024</xref>). Neurotoxic A&#x003b2; species trigger synaptic dysfunction and neuronal death through ectopic cell cycle reentry, a process dependent on tau (<xref rid="CIT0041" ref-type="bibr">Bloom, 2014</xref>). Cell cycle reentry is an early and critical event contributing to neuronal loss in AD (<xref rid="CIT0129" ref-type="bibr">Fricker et al., 2018</xref>; <xref rid="CIT0514" ref-type="bibr">Yang et al., 2003</xref>).</p><p>The complex interplay among various RCD cascades is believed to be the primary driver of neuronal death in AD (<xref rid="CIT0154" ref-type="bibr">Goel et al., 2022</xref>; <xref rid="CIT0454" ref-type="bibr">Thal et al., 2024</xref>). Necroptosis has been detected in the brains of postmortem AD patients and is positively associated with tau pathology (<xref rid="CIT0051" ref-type="bibr">Caccamo et al., 2017</xref>). The neuron-specific long non-coding RNA <italic toggle="yes">MEG3</italic>, which is upregulated in AD patients, contributes to neuronal necroptosis. In a xenograft AD model using human neurons transplanted into <italic toggle="yes">Rag2</italic><sup>&#x02212;/&#x02212;</sup>/<italic toggle="yes">App</italic><sup><italic toggle="yes">NL-G-F</italic></sup> transgenic mice, the downregulation of <italic toggle="yes">MEG3</italic> or the inhibition of necroptosis rescued the neurons from death (<xref rid="CIT0024" ref-type="bibr">Balusu et al., 2023</xref>). Both NLRP1 and NLRP3 inflammasomes, which drive pyroptosis, are activated in AD patients (<xref rid="CIT0398" ref-type="bibr">Saresella et al., 2016</xref>). Knockdown of <italic toggle="yes">Nlrp1</italic> or <italic toggle="yes">Casp1</italic> has been shown to reduce neuronal pyroptosis and enhance cognitive function in the APPswe/PS1dE9 mouse model (<xref rid="CIT0447" ref-type="bibr">Tan et al., 2014</xref>). Elevated iron levels and lipid peroxidation, characteristic of ferroptosis, have been observed in AD pathology (<xref rid="CIT0512" ref-type="bibr">Yan et al., 2021</xref>). Blocking ferroptosis has been shown to mitigate neuronal loss and cognitive impairments associated with A&#x003b2; and tau toxicity (<xref rid="CIT0026" ref-type="bibr">Bao et al., 2021</xref>; <xref rid="CIT0524" ref-type="bibr">Zhang et al., 2018</xref>). Furthermore, the accumulation of A&#x003b2; and tau is believed to induce apoptosis, contributing to neuronal loss and AD progression (<xref rid="CIT0246" ref-type="bibr">Kumari et al., 2023</xref>; <xref rid="CIT0501" ref-type="bibr">Wu et al., 2024</xref>). However, several studies have reported that histological evidence of neurons displaying the characteristic morphology of apoptosis is surprisingly rare in the postmortem brains of AD patients (<xref rid="CIT0284" ref-type="bibr">Lucassen et al., 1997</xref>; <xref rid="CIT0360" ref-type="bibr">Perry et al., 1998</xref>; <xref rid="CIT0437" ref-type="bibr">Stadelmann et al., 1998</xref>). This discrepancy might be explained by survivor bias, where neurons that have undergone apoptosis and been cleared are not present in postmortem analyses. Moreover, impaired autophagy in AD brain has been associated with neuronal senescence and intraneuronal A&#x003b2; accumulation (<xref rid="CIT0251" ref-type="bibr">Lee et al., 2022</xref>; <xref rid="CIT0338" ref-type="bibr">Nixon, 2007</xref>; <xref rid="CIT0441" ref-type="bibr">Suelves et al., 2023</xref>), which contrasts with the physiological role of autophagy in preventing the accumulation of misfolded proteins. Additionally, death induced by survival gene elimination (DISE) is a cell death mechanism activated by short RNAs (sRNAs) with specific 6-nucleotide seed sequences. In AD mouse models and iPSC-derived neurons from AD patients, RNA-induced silencing complex (RISC)-bound sRNAs shift to more toxic 6-mer seed sequences. Inhibition of RISC activity or genetic deletion of <italic toggle="yes">Ago2</italic> attenuates A&#x003b2;<sub>42</sub>-induced neuronal cell death and DNA damage (<xref rid="CIT0354" ref-type="bibr">Paudel et al., 2024</xref>).</p><p>These studies suggest that targeting cell death mechanisms may be a potential therapeutic approach to protect neurons and mitigate neurodegeneration in AD. However, the precise triggers and mechanisms underlying RCD remain elusive, necessitating further research to identify specific pathways and their therapeutic potential. The development of suitable imaging techniques to detect neuronal death in the ante-mortem brain could provide valuable insights into this critical aspect of AD pathogenesis.</p></sec><sec id="s20"><title>Demyelination</title><p>Myelin, a glial membrane tightly wrapped around axons in a spiral fashion, plays a crucial role in enhancing conduction speed. Its less compact regions enable oligodendrocytes to support the metabolic needs of neurons (<xref rid="CIT0389" ref-type="bibr">Saab et al., 2016</xref>). Studies utilizing macroscopic brain imaging have revealed early signs of cortical myelin damage in patients with AD during its preclinical phase, suggesting that these changes are potential early indicators of brain pathology (<xref rid="CIT0008" ref-type="bibr">Araque Caballero et al., 2018</xref>; <xref rid="CIT0090" ref-type="bibr">Dean et al., 2017</xref>; <xref rid="CIT0378" ref-type="bibr">Ringman et al., 2007</xref>). Furthermore, abnormalities specific to certain brain regions involved in myelination were detected before the emergence of amyloid and tau pathology in a triple-transgenic AD mouse model (<xref rid="CIT0096" ref-type="bibr">Desai et al., 2009</xref>). A reduction in oligodendrocyte numbers has also been observed in the brains of AD patients after death (<xref rid="CIT0032" ref-type="bibr">Behrendt et al., 2013</xref>).</p><p>Single-cell transcriptomics of AD mouse models revealed distinct changes in oligodendrocytes, especially near amyloid plaques (<xref rid="CIT0059" ref-type="bibr">Chen et al., 2020</xref>; <xref rid="CIT0231" ref-type="bibr">Kenigsbuch et al., 2022</xref>). Moreover, RNA sequencing of postmortem AD samples revealed that the expression of myelin-related genes was significantly altered, indicating that myelination and demyelination processes are key factors in AD progression (<xref rid="CIT0298" ref-type="bibr">Mathys et al., 2019</xref>, <xref rid="CIT0299" ref-type="bibr">2023</xref>; <xref rid="CIT0539" ref-type="bibr">Zhou et al., 2020</xref>). Oligodendrocytes in individuals with AD are notably more susceptible to DNA damage (<xref rid="CIT0299" ref-type="bibr">Mathys et al., 2023</xref>). A specific oligodendrocyte population, referred to as disease-associated oligodendrocytes (DAOs), was identified in both AD mouse models and AD patients and plays a pivotal role in disease pathology (<xref rid="CIT0231" ref-type="bibr">Kenigsbuch et al., 2022</xref>; <xref rid="CIT0349" ref-type="bibr">Pandey et al., 2022</xref>). Targeting DAOs has been shown to improve axonal myelination, reduce A&#x003b2;-related pathologies, and slow cognitive decline in an AD mouse model (<xref rid="CIT0352" ref-type="bibr">Park et al., 2023</xref>).</p><p>Interestingly, individuals with multiple sclerosis (MS) have a greater likelihood and increased risk of being diagnosed with AD or dementia (<xref rid="CIT0290" ref-type="bibr">Mahmoudi et al., 2022</xref>). Experiments have demonstrated that myelin dysfunction and demyelinating injuries can accelerate A&#x003b2; plaque accumulation in models of experimental autoimmune encephalomyelitis (EAE) and in cuprizone-treated AD mice (<xref rid="CIT0095" ref-type="bibr">Depp et al., 2023</xref>). These findings highlight the importance of focusing on oligodendrocyte health and myelin integrity as potential strategies to slow AD progression.</p></sec><sec id="s21"><title>Gliosis and neuroinflammation</title><p>Accumulating evidence indicates that reactive astrogliosis and microgliosis are significant pathological features of AD and play critical roles in its pathogenesis (<xref rid="F3" ref-type="fig">Fig. 3</xref>). <italic toggle="yes">APOE&#x003b5;4</italic>, the most significant genetic risk factor for sporadic AD, can increase the risk of developing the disease by 3&#x02013;15 times. This gene is predominantly expressed by astrocytes and microglia within the CNS (<xref rid="CIT0210" ref-type="bibr">Jansen et al., 2019</xref>). Moreover, a variety of single nucleotide polymorphisms (SNPs) and rare coding variants in genes related to the immune system, which are thought to influence microglial function, have been recognized as risk factors for AD. These genes include <italic toggle="yes">TREM2</italic>, <italic toggle="yes">BIN1</italic>, <italic toggle="yes">CLU</italic>, <italic toggle="yes">CR1</italic>, <italic toggle="yes">PICALM</italic>, <italic toggle="yes">CD33</italic>, and the <italic toggle="yes">MS4A</italic> gene cluster, which were identified through WGS and GWAS (<xref rid="CIT0229" ref-type="bibr">Karch and Goate, 2015</xref>).</p><fig position="float" id="F3"><label>Figure 3.</label><caption><p>Impact of systemic inflammation on AD pathogenesis. Beyond A&#x003b2; and tau, systemic inflammation, triggered by chronic conditions (such as obesity, diabetes, cardiovascular and cerebrovascular diseases) and microbial infections (including those caused by bacteria and viruses), compromises the BBB. This disrupted BBB integrity allows peripheral immune cells (such as T cells and myeloid cells), along with proinflammatory cytokines and microbes, to penetrate the brain parenchyma. This invasion initiates a chain of inflammatory responses that leads to the activation of reactive microglia and astrocytes, thereby accelerating the formation of amyloid plaques and tau pathology, which results in neuronal degeneration. Consequently, this cascade significantly contributes to AD progression. Abbreviations: A&#x003b2;, &#x003b2;-amyloid; AS, astrocyte; B2M, &#x003b2;2-microglobulin; BBB, blood&#x02012;brain barrier; EC, endothelial cell; MG, microglia; NFT, neurofibrillary tangle.</p></caption><graphic xlink:href="pwae026_fig3" position="float"/></fig><sec id="s22"><title>Microglia</title><p>Microglia, the brain&#x02019;s resident immune cells, are thought to originate from primitive macrophages that arise from erythromyeloid precursors in the yolk sac, contributing to the brain&#x02019;s innate immune system throughout life (<xref rid="CIT0151" ref-type="bibr">Ginhoux et al., 2010</xref>; <xref rid="CIT0155" ref-type="bibr">Gomez Perdiguero et al., 2015</xref>; <xref rid="CIT0234" ref-type="bibr">Kierdorf et al., 2013</xref>). A specific subset of microglia, termed repair-associated microglia (RAMs), has been identified for its role in repairing damaged brain vasculature and facilitating functional recovery post-injury (<xref rid="CIT0065" ref-type="bibr">Choi et al., 2023</xref>; <xref rid="CIT0297" ref-type="bibr">Mastorakos et al., 2021</xref>).</p><p>In the AD brain, reactive microglia cluster around amyloid plaques, suggesting a crucial relationship between these immune cells and one of the hallmark pathologies of AD (<xref rid="CIT0304" ref-type="bibr">McGeer et al., 1987</xref>; <xref rid="CIT0460" ref-type="bibr">Tooyama et al., 1990</xref>). This association extends to pathological tau, with studies showing a link between tau accumulation and microglial activation (<xref rid="CIT0089" ref-type="bibr">Dani et al., 2018</xref>; <xref rid="CIT0181" ref-type="bibr">Hayes et al., 2002</xref>). Disease-associated microglia (DAMs) have been discovered in models such as 5&#x000d7;&#x02005;FAD mice, where they localize near amyloid plaques and potentially limit neurodegeneration. The transition to DAM involves a TREM2-independent phase characterized by downregulation of homeostatic genes and upregulation of genes involved in phagocytosis and lipid metabolism in a TREM2-dependent manner (<xref rid="CIT0232" ref-type="bibr">Keren-Shaul et al., 2017</xref>). Lipid droplet-accumulating microglia (LDAM) are abundant in AD patients carrying <italic toggle="yes">APOE&#x003b5;4/&#x003b5;4</italic>. Furthermore, fibrillar A&#x003b2; has been shown to induce lipid droplet accumulation in an APOE-dependent manner (<xref rid="CIT0176" ref-type="bibr">Haney et al., 2024</xref>). Additionally, terminally inflammatory microglia (TIMs) and dystrophic (senescent) microglia, which are associated with impaired A&#x003b2; clearance and tau pathology, respectively, have been identified, highlighting the diverse roles of microglia in AD (<xref rid="CIT0314" ref-type="bibr">Millet et al., 2024</xref>; <xref rid="CIT0439" ref-type="bibr">Streit et al., 2009</xref>).</p><p>Research led by Kellis and Tsai into the transcriptomic and epigenomic landscape of AD has shown that noncoding AD risk loci are uniquely accessible in microglia, with an increase in lipid processing and inflammatory microglia correlating with disease progression and severity (<xref rid="CIT0504" ref-type="bibr">Xiong et al., 2023</xref>). The spatial and disease stage-dependent morphological heterogeneity of microglia underscores the complexity of their roles in AD, with changes in shape and function reflecting their proximity to plaques and disease progression (<xref rid="CIT0362" ref-type="bibr">Plescher et al., 2018</xref>). These findings highlight the need for careful assessment of the spatial and temporal variations in microglial populations.</p><p>Microglia express various A&#x003b2; receptors, including TREM2, LRP1, TLRs, CR3, CD14, CD47, CD36, &#x003b1;6&#x003b2;1 integrin, and RAGE (<xref rid="CIT0101" ref-type="bibr">Doens and Fernandez, 2014</xref>). These receptors facilitate microglial interactions with A&#x003b2;, influencing processes such as phagocytosis, inflammation, and clearance of A&#x003b2;. For instance, CR3 plays a role in microglia-mediated phagocytosis and clearance of A&#x003b2; in conjunction with complement C3 (<xref rid="CIT0132" ref-type="bibr">Fu et al., 2012</xref>). Exposure to soluble A&#x003b2; oligomers triggers reactive microglia to engulf synapses in a CR3-dependent manner (<xref rid="CIT0190" ref-type="bibr">Hong et al., 2016</xref>). Deactivating CR3 has been shown to reduce tau pathology and microglial phagocytosis of synapses in PS19 mice (<xref rid="CIT0267" ref-type="bibr">Litvinchuk et al., 2018</xref>), while a separate study revealed that CR3 ablation decreased A&#x003b2; deposition in T41 APP-transgenic mice (<xref rid="CIT0086" ref-type="bibr">Czirr et al., 2017</xref>). Moreover, TLR2 binds to oligomeric A&#x003b2;<sub>42</sub> aggregates, increasing A&#x003b2;<sub>42</sub>-induced inflammation but decreasing A&#x003b2; phagocytosis by cultured microglia (<xref rid="CIT0270" ref-type="bibr">Liu et al., 2012</xref>). Notably, the microglial lysosomal system plays a crucial role in the propagation of both A&#x003b2; and tau pathology (<xref rid="CIT0025" ref-type="bibr">Bao et al., 2016</xref>; <xref rid="CIT0291" ref-type="bibr">Majumdar et al., 2011</xref>; <xref rid="CIT0466" ref-type="bibr">Van Acker et al., 2021</xref>; <xref rid="CIT0486" ref-type="bibr">Wang et al., 2024</xref>).</p><p>The inflammatory response mediated by microglia is pivotal in the development of AD pathology. Notably, the activation of the NLRP3 inflammasome in microglia, triggered by A&#x003b2;, leads to caspase-1 activation and IL-1&#x003b2; maturation, playing a significant role in the pathogenesis of AD (<xref rid="CIT0184" ref-type="bibr">Heneka et al., 2013</xref>). Moreover, the presence of the NLRP3 inflammasome is essential for the development of A&#x003b2;-induced tau pathology, with its absence reducing tau pathology and ameliorating cognitive deficits in Tau22 transgenic mice (<xref rid="CIT0200" ref-type="bibr">Ising et al., 2019</xref>). The inhibition of microglial NF-&#x003ba;B signaling has also been demonstrated to alleviate A&#x003b2; neurotoxicity and limit the spread of tau (<xref rid="CIT0058" ref-type="bibr">Chen et al., 2005</xref>; <xref rid="CIT0484" ref-type="bibr">Wang et al., 2022</xref>).</p><p>Reactive microglia are crucial for the transmission of pathological tau, facilitating its spread from neuron to neuron via phagocytosis and subsequent exocytosis within exosomes. The use of the CSF1R inhibitor PLX3397 to deplete microglia markedly decreased the progression of tau pathology in mouse models, including those injected with adeno-associated virus (AAV)-GFP-tau and PS19-tau transgenic mice (<xref rid="CIT0012" ref-type="bibr">Asai et al., 2015</xref>). Microglia also play a role in modulating A&#x003b2; pathology; continuous microglial depletion through the CSF1R inhibitor PLX5622 led to a reduction in amyloid plaque deposition in a 5&#x000d7;&#x02005;FAD mouse model (<xref rid="CIT0435" ref-type="bibr">Spangenberg et al., 2019</xref>). However, a contrasting study using PLX3397 for microglial ablation showed similar amyloid plaque burdens between the control and treated groups, with an increase observed in 5&#x000d7;&#x02005;FAD mice following microglial repopulation (<xref rid="CIT0159" ref-type="bibr">Gratuze et al., 2021</xref>). Additionally, depletion or repopulation of microglia significantly affected tau seeding and spreading in neurons adjacent to amyloid plaques in 5&#x000d7;&#x02005;FAD mice injected with tau aggregates from human AD brain extracts (<xref rid="CIT0159" ref-type="bibr">Gratuze et al., 2021</xref>).</p><p>Dysregulated innate and adaptive immune responses are implicated in AD pathogenesis (<xref rid="CIT0175" ref-type="bibr">Hammond et al., 2019</xref>; <xref rid="CIT0185" ref-type="bibr">Heneka et al., 2014</xref>). Specifically, an increase in cytotoxic T cells has been observed in brain regions affected by tauopathy in both tau transgenic mice and individuals with AD. Depletion of microglia via PLX3397 was shown to prevent T-cell infiltration in human <italic toggle="yes">APOE&#x003b5;4</italic>-knock-in PS19 (TE4) mice (<xref rid="CIT0061" ref-type="bibr">Chen et al., 2023</xref>), underscoring the critical interaction between microglia and the adaptive immune system in AD progression. In contrast to the long-standing belief that only adaptive immune cells possess immunological memory, emerging evidence indicates that myeloid cells, including microglia, also exhibit memory-like responses. For instance, a single peripheral administration of low-dose lipopolysaccharide (LPS) exacerbates brain inflammation and amyloid deposition in the APP23 transgenic mouse model. However, repeated LPS injections induce immune tolerance, which in turn mitigates amyloid pathology (<xref rid="CIT0491" ref-type="bibr">Wendeln et al., 2018</xref>). These findings suggest that targeting the memory-like properties of microglia may offer potential therapeutic avenues for AD treatment.</p></sec><sec id="s23"><title>Astrocyte</title><p>Astrocytes, a major glial cell type in the CNS derived from neural progenitor cells, play a vital role in maintaining extracellular fluid and neurotransmitter homeostasis, inducing synapse formation, and providing metabolic and neurotrophic support for synapses (<xref rid="CIT0047" ref-type="bibr">Brandebura et al., 2023</xref>; <xref rid="CIT0254" ref-type="bibr">Leng and Edison, 2021</xref>). Increased reactive astrocytes around amyloid plaques are noted in the postmortem brains of AD patients (<xref rid="CIT0030" ref-type="bibr">Beach and McGeer, 1988</xref>).</p><p>Astrocyte heterogeneity in AD patients indicates differential expression across cortical layers (<xref rid="CIT0391" ref-type="bibr">Sadick et al., 2022</xref>), and a distinct subpopulation of disease-associated astrocytes (DAAs) identified in 5&#x000d7;&#x02005;FAD model mice and aging human brains suggests accelerated astrocyte aging in AD (<xref rid="CIT0173" ref-type="bibr">Habib et al., 2020</xref>).</p><p>Astrocytes also play a key role in the glymphatic system, facilitating interstitial fluid clearance via aquaporin 4 (AQP4). Disruption of this pathway exacerbates A&#x003b2; accumulation and cognitive deficits, highlighting the importance of astrocytic AQP4 in AD pathogenesis (<xref rid="CIT0199" ref-type="bibr">Iliff et al., 2012</xref>; <xref rid="CIT0505" ref-type="bibr">Xu et al., 2015</xref>). Astrocyte reactivity is increasingly recognized as a diverse response within the brain. Notably, certain reactive astrocytes serve a neuroprotective function, slowing the progression of AD. The elimination of these astrocytes in <italic toggle="yes">Gfap</italic> and <italic toggle="yes">Vim</italic> double-knockout APP/PS1 mice led to an increase in amyloid plaque accumulation and associated neuronal damage (<xref rid="CIT0245" ref-type="bibr">Kraft et al., 2013</xref>). Furthermore, the activation of reactive astrocytes through astrocyte-specific <italic toggle="yes">Nrf2</italic> expression has been shown to decrease amyloid deposits and phosphorylated tau levels, ameliorating cognitive impairments in both APP/PS1 and Thy1-hTau P301S mouse models (<xref rid="CIT0215" ref-type="bibr">Jiwaji et al., 2022</xref>). This finding underscores the critical impact of reactive astrocytes in limiting the spread of amyloid and tau pathology. Conversely, when activated by neuroinflammatory cytokines such as IL1&#x003b1;, TNF&#x003b1;, and C1q, reactive astrocytes can become detrimental, leading to neuron and oligodendrocyte death rather than promoting neuronal health and connectivity (<xref rid="CIT0262" ref-type="bibr">Liddelow et al., 2017</xref>).</p><p>In studies using human iPSC-derived astrocyte cultures, these cells were observed to engulf neuronal debris, promoting cell-to-cell propagation of tau pathology. This process suggests that once astrocytes internalize tau, they might become harmful to adjacent neurons (<xref rid="CIT0323" ref-type="bibr">Mothes et al., 2023</xref>). The transcription factor TFEB, a master regulator of lysosome biogenesis, was elevated in the brains of deceased AD and FTD patients and in rTg4510 tau transgenic mice. Increasing TFEB expression boosts lysosomal function and increases the uptake of tau fibrils by primary astrocytes. Additionally, astrocytic TFEB expression can hinder the spread of tau pathology in PS19-tau transgenic mice (<xref rid="CIT0294" ref-type="bibr">Martini-Stoica et al., 2018</xref>). In contrast, disrupting the interaction between TFEB and the v-ATPase impairs lysosomal function and exacerbates tau pathology in PS19 mice (<xref rid="CIT0486" ref-type="bibr">Wang et al., 2024</xref>), underscoring the pivotal role of astrocytes in modulating tau pathology.</p><p>However, the interaction with pathological tau oligomers triggers the release of high mobility group box 1 (HMGB1), a nuclear protein involved in DNA processes, leading to astrocyte senescence. Blocking HMGB1 release not only decreased the number of senescent astrocytes but also reduced tau tangle formation in tauopathy mouse models (<xref rid="CIT0135" ref-type="bibr">Gaikwad et al., 2021</xref>). This finding suggested that a decrease in astrocyte surveillance may be linked to accelerated senescence during AD progression.</p></sec></sec></sec><sec id="s24"><title>Risk factors</title><sec id="s25"><title>Genetic risk factors</title><sec id="s26"><title>APOE</title><p>The <italic toggle="yes">APOE</italic> gene, located on chromosome 19 in humans, is characterized by three allelic forms: <italic toggle="yes">APOE&#x003b5;2</italic>, <italic toggle="yes">APOE&#x003b5;3</italic>, and <italic toggle="yes">APOE&#x003b5;4</italic>. These variants are distinguished by differences at amino acid positions 112 and 158. Specifically, APOE2 carries cysteine at both positions 112 and 158, APOE3 has cysteine at position 112 and arginine at 158, and APOE4 features arginine at both positions (<xref rid="CIT0510" ref-type="bibr">Yamazaki et al., 2019</xref>). These subtle variations in single amino acids significantly influence APOE&#x02019;s structure and function, affecting its ability to bind to lipids and receptors (<xref rid="CIT0510" ref-type="bibr">Yamazaki et al., 2019</xref>). For instance, APOE3 and APOE4 exhibit a high affinity for the low-density lipoprotein receptor (LDLR), in contrast to APOE2, which shows a markedly reduced binding affinity, which is 50 to 100 times lower (<xref rid="CIT0490" ref-type="bibr">Weisgraber et al., 1982</xref>).</p><p>APOE plays a crucial role in the transport of cholesterol and other lipids to neurons through its interaction with cell surface receptors such as LDLR and LDLR-related protein 1 (LRP1) (<xref rid="CIT0048" ref-type="bibr">Bu, 2009</xref>). APOE4 is associated with increased AD risk through mechanisms such as enhanced A&#x003b2; aggregation, intraneuronal A&#x003b2; accumulation, early A&#x003b2; seeding, amyloid plaque formation, and CAA pathology (<xref rid="CIT0067" ref-type="bibr">Christensen et al., 2010</xref>; <xref rid="CIT0241" ref-type="bibr">Koffie et al., 2012</xref>; <xref rid="CIT0242" ref-type="bibr">Kok et al., 2009</xref>; <xref rid="CIT0271" ref-type="bibr">Liu et al., 2017</xref>; <xref rid="CIT0364" ref-type="bibr">Polvikoski et al., 1995</xref>; <xref rid="CIT0372" ref-type="bibr">Rannikmae et al., 2014</xref>; <xref rid="CIT0405" ref-type="bibr">Schmechel et al., 1993</xref>; <xref rid="CIT0421" ref-type="bibr">Shinohara et al., 2016</xref>; <xref rid="CIT0459" ref-type="bibr">Tiraboschi et al., 2004</xref>). In contrast, APOE2 has been shown to protect against the progression of A&#x003b2; pathology over time (<xref rid="CIT0064" ref-type="bibr">Chiang et al., 2010</xref>; <xref rid="CIT0165" ref-type="bibr">Grothe et al., 2017b</xref>; <xref rid="CIT0264" ref-type="bibr">Lim et al., 2017</xref>; <xref rid="CIT0314" ref-type="bibr">Millet et al., 2024</xref>; <xref rid="CIT0320" ref-type="bibr">Morris et al., 2010</xref>).</p><p>In studies involving APOE-targeted replacement of APP-V717F transgenic mice, APOE4 was shown to be less effective at clearing A&#x003b2; from the interstitial fluid (ISF) than APOE2 and APOE3 (<xref rid="CIT0056" ref-type="bibr">Castellano et al., 2011</xref>). APOE4 alters the preferred pathway for rapid A&#x003b2; clearance from being mediated by LRP1 to involving the very low-density lipoprotein receptor (VLDLR), leading to a slower rate of A&#x003b2; internalization and efflux at the BBB (<xref rid="CIT0091" ref-type="bibr">Deane et al., 2008</xref>). Moreover, APOE, when interacting with LRP1, inhibits A&#x003b2; uptake in astrocytes rather than directly binding to A&#x003b2; (<xref rid="CIT0470" ref-type="bibr">Verghese et al., 2013</xref>). Additionally, APOE4 has been found to be less effective in facilitating the microglial uptake and degradation of A&#x003b2; than APOE2 and APOE3 (<xref rid="CIT0212" ref-type="bibr">Jiang et al., 2008</xref>).</p><p>APOE4 is known to worsen tau pathology, neuroinflammation, and brain atrophy in APOE4-targeted replacement PS19 mice compared to APOE2 and APOE3 variants (<xref rid="CIT0417" ref-type="bibr">Shi et al., 2017</xref>). Furthermore, when APOE4 is expressed by microglia, it disrupts lipid metabolism, impairs microglial function, and reduces the ability of microglia to respond to AD pathology. On the other hand, the microglial expression of APOE3 is associated with increased proximity of microglia to amyloid plaques, a reduction in amyloid pathology, and an improvement in cognitive function. Removing APOE4 from microglia restores the response to chronic neurodegeneration and lessens AD pathology in both PS19-tau transgenic mice and APP/PS1 mice, highlighting the critical role of microglial APOE in AD (<xref rid="CIT0273" ref-type="bibr">Liu et al., 2023a</xref>; <xref rid="CIT0520" ref-type="bibr">Yin et al., 2023</xref>).</p><p>APOE is highly expressed in both the brain and peripheral tissues. In the periphery, it is mainly produced by hepatocytes, with a plasma concentration of approximately 40&#x02013;70 &#x003bc;g/mL (<xref rid="CIT0110" ref-type="bibr">Elshourbagy et al., 1985</xref>). A higher ratio of plasma APOE4 to APOE3 has been linked to regional brain volume loss, decreased cerebral glucose metabolism, and impaired cognitive performance (<xref rid="CIT0337" ref-type="bibr">Nielsen et al., 2017</xref>). The expression of human <italic toggle="yes">APOE&#x003b5;4</italic> in the liver showed a toxic gain-of-function effect, impairing synaptic plasticity and cognitive functions by affecting cerebrovascular health, even in the absence of brain-expressed APOE in <italic toggle="yes">Apoe</italic>-null mice. Moreover, plasma from young mice with <italic toggle="yes">APOE&#x003b5;3</italic>, when transfused into older mice, improved cognition and reduced vessel-associated gliosis. Conversely, plasma containing APOE4 negated the beneficial effects of young plasma, underscoring the significant impact of peripheral APOE on AD pathogenesis (<xref rid="CIT0272" ref-type="bibr">Liu et al., 2022</xref>).</p><p>Notably, two missense variants of <italic toggle="yes">APOE</italic>&#x02014;<italic toggle="yes">APOE&#x003b5;3</italic>-V236E and <italic toggle="yes">APOE&#x003b5;4</italic>-R251G&#x02014;are associated with a 2- to 3-fold reduced risk of AD (<xref rid="CIT0252" ref-type="bibr">Le Guen et al., 2022</xref>). Additionally, research involving the largest known family with autosomal dominant AD, carrying the Colombian <italic toggle="yes">PSEN1</italic> E280A mutation, has revealed potentially protective effects against autosomal dominant AD, including homozygosity for the <italic toggle="yes">APOE&#x003b5;3</italic> Christchurch (R136S) mutation (<xref rid="CIT0009" ref-type="bibr">Arboleda-Velasquez et al., 2019</xref>) and heterozygosity for the <italic toggle="yes">RELN</italic> COLBOS (H3447R) mutation (<xref rid="CIT0280" ref-type="bibr">Lopera et al., 2023</xref>). Individuals with these mutations exhibited limited tau pathology and a delayed onset of autosomal dominant AD symptoms despite a high burden of A&#x003b2; plaques. In particular, the <italic toggle="yes">APOE&#x003b5;3</italic>-R136S mutation enhanced the microglial response to amyloid plaques and reduced A&#x003b2;-induced tau seeding and spreading in human <italic toggle="yes">APOE&#x003b5;3</italic>-R136S knock-in APP/PS1 mice injected with tau fibrils from human AD brain extracts (<xref rid="CIT0062" ref-type="bibr">Chen et al., 2024</xref>). Similarly, the <italic toggle="yes">APOE</italic>-R136S mutation alleviated <italic toggle="yes">APOE&#x003b5;4</italic>-associated tau pathology, neurodegeneration, and neuroinflammation in human <italic toggle="yes">APOE&#x003b5;4</italic>-R136S-knock-in PS19 mice (<xref rid="CIT0334" ref-type="bibr">Nelson et al., 2023</xref>). These findings highlight the protective potential of the <italic toggle="yes">APOE&#x003b5;3</italic>-R136S and <italic toggle="yes">RELN</italic>-H3447R mutations against AD pathologies, offering a promising avenue for therapeutic development aimed at preventing cognitive decline and dementia in AD patients.</p></sec><sec id="s27"><title>TREM2</title><p>The triggering receptor expressed on myeloid cells 2 (TREM2) gene is located on chromosome 6 in humans. TREM2, exclusively expressed in microglia within the CNS, is a single-transmembrane immune receptor of the immunoglobulin superfamily (<xref rid="CIT0092" ref-type="bibr">Deczkowska et al., 2020</xref>). The heterozygous TREM2-R47H variant significantly increases the risk of AD by 3&#x02013;4 times (<xref rid="CIT0167" ref-type="bibr">Guerreiro et al., 2013</xref>; <xref rid="CIT0217" ref-type="bibr">Jonsson et al., 2013</xref>).</p><p>The transmembrane helix within TREM2 interacts with the adaptor protein DAP12, which is crucial for TREM2 membrane stabilization and the initiation of downstream signaling pathways (<xref rid="CIT0357" ref-type="bibr">Peng et al., 2010</xref>; <xref rid="CIT0534" ref-type="bibr">Zhong et al., 2015</xref>). Variants linked to AD affect the expression of TREM2, its trafficking to the cell surface, its shedding, its ligand binding, and its downstream signaling (<xref rid="CIT0213" ref-type="bibr">Jiang et al., 2016</xref>; <xref rid="CIT0214" ref-type="bibr">Jin et al., 2014</xref>; <xref rid="CIT0342" ref-type="bibr">Olive et al., 2020</xref>; <xref rid="CIT0350" ref-type="bibr">Parhizkar et al., 2019</xref>; <xref rid="CIT0385" ref-type="bibr">Roussos et al., 2015</xref>; <xref rid="CIT0431" ref-type="bibr">Song et al., 2017</xref>).</p><p>The extracellular immunoglobulin-like domain of TREM2 recognizes various pathological molecules in AD, including phospholipids (<xref rid="CIT0479" ref-type="bibr">Wang et al., 2015</xref>), lapidated particles (<xref rid="CIT0431" ref-type="bibr">Song et al., 2017</xref>), APOE (<xref rid="CIT0017" ref-type="bibr">Atagi et al., 2015</xref>; <xref rid="CIT0020" ref-type="bibr">Bailey et al., 2015</xref>; <xref rid="CIT0519" ref-type="bibr">Yeh et al., 2016</xref>), A&#x003b2; (<xref rid="CIT0530" ref-type="bibr">Zhao et al., 2018</xref>; <xref rid="CIT0536" ref-type="bibr">Zhong et al., 2018</xref>), TDP-43 (<xref rid="CIT0503" ref-type="bibr">Xie et al., 2022</xref>), galectin-3 (<xref rid="CIT0044" ref-type="bibr">Boza-Serrano et al., 2019</xref>), and C1q (<xref rid="CIT0538" ref-type="bibr">Zhong et al., 2023</xref>). For example, the binding of microglial TREM2 to complement C1q restricts complement-mediated synaptic engulfment, thereby reducing synaptic loss in PS19 tau transgenic mice (<xref rid="CIT0538" ref-type="bibr">Zhong et al., 2023</xref>).</p><p>
<italic toggle="yes">Trem2</italic> deficiency results in the inability of microglia to cluster around A&#x003b2; plaques, leading to increased A&#x003b2; accumulation in 5&#x000d7;&#x02005;FAD mice (<xref rid="CIT0479" ref-type="bibr">Wang et al., 2015</xref>). This deficiency disrupts microglial barrier function, affecting amyloid compaction and leading to the formation of longer, branched amyloid fibrils (<xref rid="CIT0521" ref-type="bibr">Yuan et al., 2016</xref>). Furthermore, 5&#x000d7;&#x02005;FAD mice with the TREM2 R47H variant exhibit loss-of-function defects, including impaired microglial clustering and altered plaque morphology (<xref rid="CIT0432" ref-type="bibr">Song et al., 2018</xref>). AD-associated TREM2 variants also show a reduced affinity for A&#x003b2;, which is crucial for initiating TREM2-mediated signaling that promotes microglial migration and clustering (<xref rid="CIT0530" ref-type="bibr">Zhao et al., 2018</xref>; <xref rid="CIT0536" ref-type="bibr">Zhong et al., 2018</xref>). In contrast, a distinct subpopulation of senescent microglia with elevated TREM2 expression was identified in the 5&#x000d7;&#x02005;FAD mouse model. Selective elimination of these senescent microglia subtypes, but not the DAM population, led to improved cognitive performance (<xref rid="CIT0371" ref-type="bibr">Rachmian et al., 2024</xref>). This finding highlights the complex role of TREM2 in regulating distinct microglial phenotypes, which should be carefully considered when evaluating TREM2 as a therapeutic target for AD.</p><p>
<italic toggle="yes">Trem2</italic> deficiency exacerbates tau pathology in a humanized tau mouse model (<xref rid="CIT0034" ref-type="bibr">Bemiller et al., 2017</xref>). While <italic toggle="yes">Trem2</italic> haploinsufficiency intensifies tau pathology and brain atrophy in PS19 mice, complete <italic toggle="yes">Trem2</italic> deficiency surprisingly protects against tau-mediated microglial activation and brain atrophy (<xref rid="CIT0402" ref-type="bibr">Sayed et al., 2018</xref>), although some studies have reported no effect of <italic toggle="yes">Trem2</italic> deficiency on tau pathology in PS19 mice (<xref rid="CIT0260" ref-type="bibr">Leyns et al., 2017</xref>).</p><p>TREM2 undergoes proteolytic cleavage by ADAM10/17 at residue H157, releasing its ectodomain as a soluble form (sTREM2) into the extracellular space (<xref rid="CIT0122" ref-type="bibr">Feuerbach et al., 2017</xref>; <xref rid="CIT0404" ref-type="bibr">Schlepckow et al., 2017</xref>; <xref rid="CIT0458" ref-type="bibr">Thornton et al., 2017</xref>). The TREM2 H157Y variant is associated with increased AD risk (<xref rid="CIT0213" ref-type="bibr">Jiang et al., 2016</xref>). Conversely, elevated levels of sTREM2 in the CSF correlate with reduced AD risk (<xref rid="CIT0094" ref-type="bibr">Deming et al., 2019</xref>), suggesting a protective role for sTREM2. sTREM2 appears to mitigate AD pathology by supporting microglial survival, promoting the release of inflammatory cytokines, enhancing microglial clustering around amyloid plaques, and facilitating microglial uptake and degradation of A&#x003b2; (<xref rid="CIT0535" ref-type="bibr">Zhong et al., 2017</xref>, <xref rid="CIT0537" ref-type="bibr">2019</xref>).</p></sec><sec id="s28"><title>Trisomy 21</title><p>DS is the most common form of intellectual disability, resulting from a complete or partial triplication of chromosome 21. Globally, DS affects approximately one in every 1000 newborns, with an estimated 5.4 million individuals living with DS worldwide (<xref rid="CIT0100" ref-type="bibr">GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016</xref>). By the age of 40, all individuals with DS will have developed neuropathological features characteristic of AD, making trisomy 21 the most significant risk factor for early-onset AD (<xref rid="CIT0257" ref-type="bibr">Leverenz and Raskind, 1998</xref>; <xref rid="CIT0282" ref-type="bibr">Lott and Head, 2019</xref>; <xref rid="CIT0496" ref-type="bibr">Wisniewski et al., 1985</xref>). Research indicates that the levels of A&#x003b2; and tau proteins, both of which are implicated in AD, increase with age in the brains of individuals with DS (<xref rid="CIT0075" ref-type="bibr">Condello et al., 2022</xref>; <xref rid="CIT0208" ref-type="bibr">Janelidze et al., 2022</xref>).</p><p>Furthermore, trisomy 21 exacerbates neuroinflammation and the accumulation of amyloid plaques in DS-AD combined mouse models. These studies pinpointed the chromosome 21-encoded deubiquitinase USP25 as a crucial factor in the development of AD. The genetic deletion or pharmacological inhibition of USP25 was shown to restore microglial homeostasis, curb the release of microglia-driven cytokines and synaptic phagocytosis, diminish A&#x003b2; plaque accumulation, and improve synaptic and cognitive functions in AD mouse models (<xref rid="CIT0532" ref-type="bibr">Zheng et al., 2021</xref>, <xref rid="CIT0533" ref-type="bibr">2022</xref>). These findings illuminate how trisomy 21 influences the pathogenesis of DS and AD, suggesting that USP25 is a viable therapeutic target for both conditions.</p></sec><sec id="s29"><title>Other risk genes</title><p>The bridging integrator 1 (BIN1) gene, located on chromosome 2 in humans, has been identified as a critical risk gene for sporadic AD, ranking second in significance only to APOE according to the AlzGene database (<xref rid="CIT0036" ref-type="bibr">Bertram et al., 2007</xref>). Research indicates that higher levels of BIN1 in the brains of individuals with AD are linked to a later onset of the disease (<xref rid="CIT0230" ref-type="bibr">Karch et al., 2012</xref>). Notably, the SNPs rs59335482 and rs744373 in <italic toggle="yes">BIN1</italic> are associated with an increase in tau pathology but not with A&#x003b2; pathology (<xref rid="CIT0057" ref-type="bibr">Chapuis et al., 2013</xref>; <xref rid="CIT0128" ref-type="bibr">Franzmeier et al., 2019</xref>). Overexpression of BIN1 has been shown to mitigate tau aggregation and reverse deficits in long-term memory in tau transgenic mice (<xref rid="CIT0399" ref-type="bibr">Sartori et al., 2019</xref>). However, a deficiency in BIN1 facilitates the spread of tau pathology (<xref rid="CIT0053" ref-type="bibr">Calafate et al., 2016</xref>). In contrast, a study involving Drosophila demonstrated that reducing the expression of <italic toggle="yes">Amph</italic>, the equivalent of <italic toggle="yes">BIN1</italic> in flies, decreased tau-related neurotoxicity (<xref rid="CIT0057" ref-type="bibr">Chapuis et al., 2013</xref>). Moreover, ablation of <italic toggle="yes">Bin1</italic> specifically in microglia reduced tau spread and hyperphosphorylation in male PS19 transgenic mice (<xref rid="CIT0084" ref-type="bibr">Crotti et al., 2019</xref>).</p><p>Clusterin (CLU), also known as apolipoprotein J (APOJ), is predominantly an extracellular chaperone (<xref rid="CIT0216" ref-type="bibr">Jones and Jomary, 2002</xref>) and is located on chromosome 8 in humans. Elevated plasma levels of clusterin have been significantly linked to both the onset and severity of AD (<xref rid="CIT0408" ref-type="bibr">Schrijvers et al., 2011</xref>). The ability of clusterin to bind and sequester A&#x003b2; oligomers plays a crucial role in hindering their growth or dissociation (<xref rid="CIT0331" ref-type="bibr">Narayan et al., 2011</xref>). The overexpression of clusterin in astrocytes has been shown to reduce A&#x003b2; pathology and ameliorate synaptic deficits in 5&#x000d7;&#x02005;FAD mice (<xref rid="CIT0060" ref-type="bibr">Chen et al., 2021</xref>). Conversely, CLU depletion was found to decrease fibrillar A&#x003b2; deposits and dystrophic neurites in APP-V717F transgenic mice (<xref rid="CIT0093" ref-type="bibr">DeMattos et al., 2002</xref>). Another study noted that while CLU deficiency led to fewer A&#x003b2; plaques in the brain parenchyma, it surprisingly resulted in an increased presence of CAA within the cerebrovasculature in APP/PS1 transgenic mice (<xref rid="CIT0498" ref-type="bibr">Wojtas et al., 2017</xref>).</p><p>CD33, or sialic acid-binding immunoglobulin-like lectin 3 (Siglec-3), is mainly expressed on microglia, monocytes, and macrophages and plays roles in cell adhesion, endocytosis, and the immune response (<xref rid="CIT0083" ref-type="bibr">Crocker et al., 2007</xref>). Increased CD33 expression in microglia in the AD brain is positively correlated with amyloid plaque accumulation. Deleting <italic toggle="yes">CD33</italic> has been shown to enhance microglial A&#x003b2; uptake and reduce A&#x003b2; plaque formation in APP/PS1 transgenic mice (<xref rid="CIT0162" ref-type="bibr">Griciuc et al., 2013</xref>). Moreover, the absence of CD33 boosts the phagocytosis of A&#x003b2; oligomers by microglia (<xref rid="CIT0497" ref-type="bibr">Wissfeld et al., 2021</xref>). Additionally, CD33 deficiency has been shown to decrease A&#x003b2; pathology and improve cognitive function in 5&#x000d7;&#x02005;FAD;<italic toggle="yes">CD33</italic><sup>&#x02212;/&#x02212;</sup> mice. However, these benefits are negated when <italic toggle="yes">Trem2</italic> is also depleted in 5&#x000d7;&#x02005;FAD;<italic toggle="yes">CD33</italic><sup>&#x02212;/&#x02212;</sup>;<italic toggle="yes">Trem2</italic><sup>&#x02212;/&#x02212;</sup> mice, indicating that TREM2 functions downstream of CD33 in this pathway (<xref rid="CIT0163" ref-type="bibr">Griciuc et al., 2019</xref>).</p><p>In addition to <italic toggle="yes">APOE</italic> and <italic toggle="yes">CLU</italic>, genetic variants in <italic toggle="yes">ABCA7</italic> have also been implicated in cholesterol metabolism pathways associated with AD risk. In addition to <italic toggle="yes">TREM2</italic>, common variants in <italic toggle="yes">CD33</italic>, <italic toggle="yes">CR1</italic>, and <italic toggle="yes">MS4A</italic> have been linked to dysregulation of the immune response, a central feature of AD pathogenesis. Furthermore, endocytosis-related genes such as <italic toggle="yes">BIN1</italic>, <italic toggle="yes">PICALM</italic>, <italic toggle="yes">CD2AP</italic>, <italic toggle="yes">EPHA1</italic>, and <italic toggle="yes">SORL1</italic> have been identified as harboring AD-associated genetic variants (<xref rid="CIT0229" ref-type="bibr">Karch and Goate, 2015</xref>). The identification of these novel genetic risk factors has provided new opportunities to understand the underlying pathophysiology of AD, highlighting the role of key pathways involved in the disease process.</p></sec></sec><sec id="s30"><title>Aging</title><p>Aging is the primary risk factor for sporadic AD. As organisms age, DNA damage accumulates, leading to an increase in the number of senescent cells. These cells then adopt a senescence-associated secretory phenotype (SASP), which releases proinflammatory cytokines, contributing to the development of age-related diseases (<xref rid="CIT0168" ref-type="bibr">Guerrero et al., 2021</xref>).</p><p>The accumulation of somatic mutations in neurons during aging and the AD process is thought to be due to increased oxidative damage (<xref rid="CIT0277" ref-type="bibr">Lodato et al., 2018</xref>; <xref rid="CIT0313" ref-type="bibr">Miller et al., 2022</xref>). Furthermore, elevated levels of DNA double-strand breaks have been linked to structural variations in the genome and disruptions in 3D genome organization in excitatory neurons in the postmortem brains of AD patients (<xref rid="CIT0099" ref-type="bibr">Dileep et al., 2023</xref>). Severe DNA damage has also been shown to induce senescence in various neurons, including Purkinje cells and cortical and hippocampal neurons, in aged mice (<xref rid="CIT0222" ref-type="bibr">Jurk et al., 2012</xref>).</p><p>An increase in the number of senescent astrocytes has been observed in aging brains and in those with AD (<xref rid="CIT0038" ref-type="bibr">Bhat et al., 2012</xref>; <xref rid="CIT0463" ref-type="bibr">Turnquist et al., 2016</xref>). Similarly, dystrophic (senescent) microglia, which proliferate in aged and AD brains, have been associated with the early stages of tau pathology and neurodegeneration (<xref rid="CIT0414" ref-type="bibr">Shahidehpour et al., 2021</xref>; <xref rid="CIT0439" ref-type="bibr">Streit et al., 2009</xref>). Additionally, lipid droplet accumulation in microglia during aging has been documented in both mouse and human brains (<xref rid="CIT0293" ref-type="bibr">Marschallinger et al., 2020</xref>).</p><p>Elimination of p16<sup>INK4A</sup>-positive senescent cells using the INK-ATTAC system has been shown to delay aging-associated disorders (<xref rid="CIT0022" ref-type="bibr">Baker et al., 2011</xref>). Specifically, clearing senescent microglia and astrocytes in the brain using INK-ATTAC transgenic mice led to reductions in hyperphosphorylated tau, NFT formation and cognitive deficits in PS19 transgenic mice (<xref rid="CIT0050" ref-type="bibr">Bussian et al., 2018</xref>). Senolytic treatment with dasatinib and quercetin selectively removes senescent oligodendrocyte progenitor cells (OPCs) from the plaque environment, resulting in decreased neuroinflammation and A&#x003b2; plaque deposition and improved cognitive function in APP/PS1 transgenic mice (<xref rid="CIT0525" ref-type="bibr">Zhang et al., 2019</xref>). Moreover, the inhibition of microglial proliferation using the CSF1R inhibitor GW2580 has been shown to prevent the onset of senescence and reduce A&#x003b2; pathology in APP/PS1 transgenic mice (<xref rid="CIT0192" ref-type="bibr">Hu et al., 2021</xref>).</p><p>Heterochronic parabiosis combined with intravenous injections of young mouse plasma has been shown to restore synaptic and neuronal protein levels, leading to improvements in working and associative memory in APP-transgenic mice, albeit without affecting amyloid plaque levels (<xref rid="CIT0310" ref-type="bibr">Middeldorp et al., 2016</xref>). This approach was further explored in a phase 1 clinical trial (NCT02256306) (<xref rid="CIT0412" ref-type="bibr">Sha et al., 2019</xref>). In a phase 2b/3 trial (NCT01561053), plasma exchange with albumin replacement in patients with mild-to-moderate AD resulted in improved memory, language abilities, processing speed, and quality of life (<xref rid="CIT0042" ref-type="bibr">Boada et al., 2022</xref>).</p></sec><sec id="s31"><title>Environmental factors</title><p>In 2016, approximately 3.752 billion people (66.6% of the global population under the age of 49) were estimated to be infected with herpes simplex virus type 1 (HSV1) (<xref rid="CIT0206" ref-type="bibr">James et al., 2020</xref>). Autopsy studies of AD specimens have detected HSV1 DNA in the brain (<xref rid="CIT0207" ref-type="bibr">Jamieson et al., 1991</xref>). Moreover, HSV1 infection has been linked to an increased risk of AD, particularly in individuals carrying the <italic toggle="yes">APOE&#x003b5;4</italic> allele (<xref rid="CIT0201" ref-type="bibr">Itzhaki et al., 1997</xref>; <xref rid="CIT0266" ref-type="bibr">Linard et al., 2020</xref>; <xref rid="CIT0279" ref-type="bibr">Lopatko Lindman et al., 2019</xref>). HSV1 infection dramatically accelerated A&#x003b2; plaque deposition both in 5&#x000d7;&#x02005;FAD mice and in a 3D human neural cell model (<xref rid="CIT0052" ref-type="bibr">Cairns et al., 2020</xref>; <xref rid="CIT0107" ref-type="bibr">Eimer et al., 2018</xref>). The use of anti-herpetic medications has been found to lower the risk of dementia in HSV-infected patients (<xref rid="CIT0464" ref-type="bibr">Tzeng et al., 2018</xref>), and the administration of the herpes zoster vaccine has been demonstrated to protect against dementia (<xref rid="CIT0114" ref-type="bibr">Eyting et al., 2023</xref>). Approximately 20%&#x02013;60% of individuals with human immunodeficiency virus (HIV) infection experience cognitive impairment, known as HIV-associated neurocognitive disorder (HAND) (<xref rid="CIT0340" ref-type="bibr">Nyamayaro et al., 2019</xref>; <xref rid="CIT0483" ref-type="bibr">Wang et al., 2020b</xref>; <xref rid="CIT0488" ref-type="bibr">Wei et al., 2020</xref>). The presence of amyloid plaques has been noted in the brains of individuals infected with HIV (<xref rid="CIT0113" ref-type="bibr">Esiri et al., 1998</xref>). Moreover, human cytomegalovirus (CMV) infection has been associated with a 2.15-fold increased risk of developing AD (<xref rid="CIT0027" ref-type="bibr">Barnes et al., 2015</xref>), and murine CMV infection has been shown to accelerate tau pathology in mouse fibroblasts and rat primary neurons (<xref rid="CIT0316" ref-type="bibr">Mody et al., 2023</xref>).</p><p>Three specific bacterial species&#x02014;<italic toggle="yes">Borrelia burgdorferi</italic> (<xref rid="CIT0311" ref-type="bibr">Miklossy, 2016</xref>), <italic toggle="yes">Chlamydia pneumoniae</italic> (<xref rid="CIT0023" ref-type="bibr">Balin et al., 1998</xref>; <xref rid="CIT0146" ref-type="bibr">Gerard et al., 2006</xref>), and <italic toggle="yes">Porphyromonas gingivalis</italic> (<xref rid="CIT0103" ref-type="bibr">Dominy et al., 2019</xref>)&#x02014;have been implicated in the brains of AD patients. The presence of <italic toggle="yes">Helicobacter pylori</italic> in the gastric mucous membrane, serum, and plasma has also been observed to increase in individuals with AD (<xref rid="CIT0244" ref-type="bibr">Kountouras et al., 2006</xref>; <xref rid="CIT0292" ref-type="bibr">Malaguarnera et al., 2004</xref>). However, the role of infections in the pathogenesis of AD remains a topic of debate (<xref rid="CIT0202" ref-type="bibr">Itzhaki et al., 2020</xref>).</p><p>Long-term exposure to air pollution has been linked to an increased risk of dementia, with heart failure and ischemic heart disease potentially amplifying the association between air pollution and dementia (<xref rid="CIT0158" ref-type="bibr">Grande et al., 2020</xref>). Additionally, smoking has been associated with greater risks of both AD and vascular dementia than never smoking (<xref rid="CIT0007" ref-type="bibr">Anstey et al., 2007</xref>; <xref rid="CIT0386" ref-type="bibr">Rusanen et al., 2011</xref>).</p></sec><sec id="s32"><title>Lifestyle habits</title><p>Sleep disturbances have been linked to an increased risk of AD (<xref rid="CIT0327" ref-type="bibr">Musiek and Ju, 2022</xref>). Extensive research indicates that conditions such as obstructive sleep apnea (OSA) and insufficient sleep duration are associated with a greater likelihood of cognitive impairment (<xref rid="CIT0390" ref-type="bibr">Sabia et al., 2021</xref>; <xref rid="CIT0507" ref-type="bibr">Yaffe et al., 2011</xref>). Notably, high sleep fragmentation, rather than short sleep duration, in adults aged 30&#x02013;40 years, observed over a decade, is strongly associated with memory decline and cognitive impairment (<xref rid="CIT0255" ref-type="bibr">Leng et al., 2024</xref>). Disturbed sleep quality and fragmented circadian rhythms are common in the years preceding AD, even before symptoms manifest (<xref rid="CIT0218" ref-type="bibr">Ju et al., 2013</xref>; <xref rid="CIT0328" ref-type="bibr">Musiek et al., 2018</xref>). Sleep deprivation hinders molecular clearance mechanisms in the brain (<xref rid="CIT0106" ref-type="bibr">Eide et al., 2021</xref>), and disrupted sleep patterns, especially a lack of deep (slow-wave) sleep, are linked to elevated levels of A&#x003b2; and tau in the brain (<xref rid="CIT0189" ref-type="bibr">Holth et al., 2019</xref>; <xref rid="CIT0219" ref-type="bibr">Ju et al., 2017</xref>; <xref rid="CIT0226" ref-type="bibr">Kang et al., 2009</xref>; <xref rid="CIT0285" ref-type="bibr">Lucey et al., 2018</xref>). Sleep deprivation significantly increased A&#x003b2; deposition and tau pathology in APP/PS1 transgenic mice with the <italic toggle="yes">APOE&#x003b5;4</italic> allele but not in those with the <italic toggle="yes">APOE&#x003b5;3</italic> allele (<xref rid="CIT0485" ref-type="bibr">Wang et al., 2023</xref>). Conversely, natural sleep or anesthesia significantly enhances the convective exchange of CSF with the ISF, promoting A&#x003b2; clearance (<xref rid="CIT0502" ref-type="bibr">Xie et al., 2013</xref>).</p><p>Type 2 diabetes mellitus (T2DM), which is characterized by hyperglycemia, insulin resistance and peripheral inflammation, is implicated in increased AD risk (<xref rid="CIT0367" ref-type="bibr">Profenno et al., 2010</xref>; <xref rid="CIT0465" ref-type="bibr">Vagelatos and Eslick, 2013</xref>). T2DM is also associated with cerebrovascular disease and cognitive deficits (<xref rid="CIT0308" ref-type="bibr">Messier et al., 2004</xref>; <xref rid="CIT0387" ref-type="bibr">Ryan and Geckle, 2000</xref>). A&#x003b2; and hyperphosphorylated tau have been found in the pancreas of T2DM patients (<xref rid="CIT0312" ref-type="bibr">Miklossy et al., 2010</xref>). Emerging evidence suggests that glucose hypometabolism, insulin resistance, and impaired insulin-like growth factor (IGF) signaling are linked to AD progression, leading to the characterization of AD as &#x0201c;type 3 diabetes&#x0201d; (<xref rid="CIT0380" ref-type="bibr">Rivera et al., 2005</xref>; <xref rid="CIT0438" ref-type="bibr">Steen et al., 2005</xref>).</p><p>High-fat diets (HFDs) are known to predispose individuals to obesity and diabetes by promoting insulin resistance (<xref rid="CIT0318" ref-type="bibr">Morio et al., 2016</xref>). High intakes of saturated and trans-unsaturated fats have been associated with increased AD risk, while &#x003c9;-6 polyunsaturated and monounsaturated fats appear to be protective (<xref rid="CIT0319" ref-type="bibr">Morris et al., 2003</xref>). High caloric and fat intake levels are linked to an elevated AD risk, especially in individuals with the <italic toggle="yes">APOE&#x003b5;4</italic> allele (<xref rid="CIT0286" ref-type="bibr">Luchsinger et al., 2002</xref>).</p><p>HFD-induced insulin resistance has been shown to promote A&#x003b2; generation, amyloid plaque deposition, and cognitive impairment in transgenic AD mice (<xref rid="CIT0186" ref-type="bibr">Ho et al., 2004</xref>; <xref rid="CIT0474" ref-type="bibr">Wakabayashi et al., 2019</xref>). However, one study revealed that HFD feeding induced microglial activation and cognitive deficits in both wild-type and 3&#x000d7;&#x02005;Tg AD mice without affecting A&#x003b2; or tau pathology (<xref rid="CIT0238" ref-type="bibr">Knight et al., 2014</xref>). In contrast, early HFD feeding, before severe AD pathology, reduced A&#x003b2; plaque deposition and improved cognitive function in Tg6799 AD mice (<xref rid="CIT0006" ref-type="bibr">Amelianchik et al., 2021</xref>).</p><p>High dietary sodium intake (&#x02265;12 g/d) has been associated with a 330% increased risk of cognitive impairment in older adults (<xref rid="CIT0274" ref-type="bibr">Liu et al., 2023b</xref>). A high-salt diet (HSD) led to cerebral endothelial dysfunction and reduced cerebral blood flow through the gut-brain axis, resulting in cognitive impairment in mice (<xref rid="CIT0118" ref-type="bibr">Faraco et al., 2018</xref>). Furthermore, HSD consumption induced tau hyperphosphorylation through the activation of calpain and CDK5, resulting in cognitive dysfunction in both wild-type and rTg4510 mice, although it did not affect A&#x003b2; levels in Tg2576 mice (<xref rid="CIT0119" ref-type="bibr">Faraco et al., 2019</xref>).</p><p>Notably, a high dietary intake of vitamins C and E has been associated with a lower AD risk (<xref rid="CIT0111" ref-type="bibr">Engelhart et al., 2002</xref>), possibly due to antioxidants reducing neuronal loss by protecting against oxidative damage (<xref rid="CIT0066" ref-type="bibr">Christen, 2000</xref>).</p></sec><sec id="s33"><title>Cardiovascular and cerebrovascular disease</title><p>Cardiovascular disease (CVD) ranks as a leading cause of morbidity and mortality among older adults, underscoring its critical public health impact (<xref rid="CIT0392" ref-type="bibr">Saeed et al., 2023</xref>). Increasing evidence connects the heightened risk of CVD, especially vascular dementia, with a greater likelihood of developing dementia. The key risk factors for CVD include high blood pressure, dyslipidemia, obesity, and diabetes, all of which have been well-documented in the literature (<xref rid="CIT0289" ref-type="bibr">European et al., 2023</xref>; <xref rid="CIT0275" ref-type="bibr">Livingston et al., 2017</xref>; <xref rid="CIT0339" ref-type="bibr">Norton et al., 2014</xref>; <xref rid="CIT0495" ref-type="bibr">Winblad et al., 2016</xref>). Notably, heart failure has been shown to increase AD risk by 1.8 times. Moreover, the use of antihypertensive medications appears promising for mitigating dementia risk. Additionally, a low diastolic pressure (below 70 mm Hg) further increases the risk of developing dementia (<xref rid="CIT0369" ref-type="bibr">Qiu et al., 2006</xref>). Cerebral hypoperfusion is an early abnormality in both AD and vascular dementia patients, suggesting that it is a common abnormality. Midlife cardiovascular risk profiles have been associated with reduced cerebral perfusion later in life, highlighting the importance of cardiovascular health across the lifespan (<xref rid="CIT0443" ref-type="bibr">Suri et al., 2019</xref>). Conversely, maintaining cardiovascular health is linked to reduced dementia risk and slower cognitive decline (<xref rid="CIT0396" ref-type="bibr">Samieri et al., 2018</xref>).</p><p>Autopsy samples from up to 75% of individuals with AD reveal concurrent cerebral vascular pathology, indicating a significant overlap between AD and vascular conditions. Increased severity of cerebral atherosclerosis or arteriolosclerotic neuropathology is significantly associated with increased odds of AD (<xref rid="CIT0011" ref-type="bibr">Arvanitakis et al., 2016</xref>). Furthermore, cerebral infarctions have been associated with an elevated risk of cognitive impairment and AD dementia, emphasizing the intertwined nature of cerebrovascular health and cognitive function (<xref rid="CIT0406" ref-type="bibr">Schneider et al., 2004</xref>, <xref rid="CIT0407" ref-type="bibr">2007</xref>).</p><p>CAA is a prevalent cerebrovascular disease characterized by the deposition of A&#x003b2; in vessel walls (<xref rid="CIT0509" ref-type="bibr">Yamada and Naiki, 2012</xref>). CAA frequently co-occurs with AD pathology in aging brains, accelerating the progression toward AD dementia. (<xref rid="CIT0370" ref-type="bibr">Rabin et al., 2022</xref>).</p><p>Stroke, including both ischemic and hemorrhagic stroke, is the most prevalent form of cerebrovascular disease (<xref rid="CIT0348" ref-type="bibr">Pan et al., 2020</xref>). In 2019, 12.2 million new cases of stroke were diagnosed, with a global prevalence of 101 million people living with this condition. Stroke has led to 6.55 million deaths worldwide, making it the second leading cause of death (<xref rid="CIT0074" ref-type="bibr">GBD 2016 Stroke Collaborators, 2021</xref>). Approximately one in four adults is at risk of experiencing a stroke during their lifetime (<xref rid="CIT0121" ref-type="bibr">GBD 2016 Lifetime Risk of Stroke 2018</xref>). The risk of developing dementia is notably greater in patients with severe stroke than in the general population, although this risk decreases significantly following milder strokes, such as transient ischemic attacks and minor strokes (<xref rid="CIT0305" ref-type="bibr">McHutchison et al., 2019</xref>; <xref rid="CIT0356" ref-type="bibr">Pendlebury et al., 2019</xref>). Ischemic stroke surgery has been shown to increase plasma and CSF tau levels, as well as ipsilateral cerebral tau pathology, in a transient middle cerebral artery occlusion (MCAO) mouse model (<xref rid="CIT0248" ref-type="bibr">Laing et al., 2020</xref>).</p><p>Over 70% of individuals aged 50 and older show signs of at least one form of cerebral small vessel disease (CSVD), which can lead to acute stroke syndromes, MCI, and even dementia due to a chronic damage, small vessel blockage or leakage, blood&#x02012;brain barrier breakdown, and cerebral blood flow deficits (<xref rid="CIT0174" ref-type="bibr">Hachinski et al., 2019</xref>; <xref rid="CIT0487" ref-type="bibr">Wardlaw et al., 2019</xref>). Neurovascular dysfunction is known to exacerbate A&#x003b2; and tau pathology, further contributing to cognitive decline (<xref rid="CIT0237" ref-type="bibr">Kisler et al., 2017</xref>). CSVD is a prevalent cause of vascular dementia and frequently coexists with AD pathology, highlighting the complex interplay between vascular and neurodegenerative processes in cognitive impairment (<xref rid="CIT0487" ref-type="bibr">Wardlaw et al., 2019</xref>).</p></sec><sec id="s34"><title>Traumatic brain injury (TBI)</title><p>Substantial research has established a link between TBI and a heightened risk of developing AD at an earlier age (<xref rid="CIT0127" ref-type="bibr">Fleminger et al., 2003</xref>; <xref rid="CIT0166" ref-type="bibr">Gu et al., 2022</xref>; <xref rid="CIT0335" ref-type="bibr">Nemetz et al., 1999</xref>; <xref rid="CIT0489" ref-type="bibr">Weiner et al., 2014</xref>). Furthermore, postmortem examinations have revealed A&#x003b2; plaque accumulation in approximately one-third of TBI patients (<xref rid="CIT0145" ref-type="bibr">Gentleman et al., 1997</xref>; <xref rid="CIT0381" ref-type="bibr">Roberts et al., 1991</xref>; <xref rid="CIT0427" ref-type="bibr">Smith et al., 2003</xref>). Studies on 5&#x000d7;&#x02005;FAD transgenic mice have shown that even mild TBI can precipitate and worsen BBB leakage, A&#x003b2; plaque formation, and cognitive impairments (<xref rid="CIT0500" ref-type="bibr">Wu et al., 2021</xref>). Additionally, the levels of tau protein in CSF and peripheral blood increase following TBI, suggesting an acceleration of tau pathology (<xref rid="CIT0343" ref-type="bibr">Olivera et al., 2015</xref>; <xref rid="CIT0346" ref-type="bibr">Ost et al., 2006</xref>; <xref rid="CIT0415" ref-type="bibr">Shahim et al., 2014</xref>). Moreover, repetitive mild TBI is associated with the development of chronic traumatic encephalopathy (CTE), a progressive tauopathy characterized by the absence of amyloid pathology (<xref rid="CIT0306" ref-type="bibr">McKee et al., 2009</xref>).</p></sec><sec id="s35"><title>Other factors</title><p>High levels of inflammation have been associated with a 1.66-fold greater risk of dementia in individuals with metabolic syndrome (<xref rid="CIT0506" ref-type="bibr">Yaffe et al., 2004</xref>). Additionally, chronic low-grade inflammation in the periphery has been connected to a 2.64-fold greater risk of AD in individuals possessing the <italic toggle="yes">APOE&#x003b5;4</italic> allele, particularly in the absence of CVD, leading to a 6.63-fold greater risk of AD (<xref rid="CIT0448" ref-type="bibr">Tao et al., 2018</xref>). Notably, individuals who underwent systemic inflammatory challenges were more likely to experience cognitive impairment in subsequent years (<xref rid="CIT0203" ref-type="bibr">Iwashyna et al., 2010</xref>).</p><p>Additionally, neuropsychiatric symptoms such as depression, aggression, anxiety, and sleep disorders are prevalent among AD patients (<xref rid="CIT0528" ref-type="bibr">Zhao et al., 2016a</xref>). Notably, depression and anxiety have been identified as significant predictors of an increased risk for AD, with a 2.13-fold increase in depression and a 1.53-fold increase in anxiety (<xref rid="CIT0031" ref-type="bibr">Becker et al., 2018</xref>; <xref rid="CIT0160" ref-type="bibr">Green et al., 2003</xref>).</p><p>A lack of social engagement has been linked to an increased risk of developing dementia (<xref rid="CIT0358" ref-type="bibr">Penninkilampi et al., 2018</xref>), whereas strong social ties have been shown to reduce the risk of dementia by 30%&#x02013;50% (<xref rid="CIT0429" ref-type="bibr">Sommerlad et al., 2023</xref>). Furthermore, risk factors such as heavy alcohol use (<xref rid="CIT0373" ref-type="bibr">Rehm et al., 2019</xref>) and hearing loss (<xref rid="CIT0457" ref-type="bibr">Thomson et al., 2017</xref>) have been identified as contributing to an increased risk of dementia. On a more positive note, higher levels of education have consistently demonstrated a protective effect against the development of AD (<xref rid="CIT0303" ref-type="bibr">McDowell et al., 2007</xref>; <xref rid="CIT0397" ref-type="bibr">Sando et al., 2008</xref>), suggesting that cognitive reserve may play a role in mitigating risk.</p></sec></sec><sec id="s36"><title>Biomarkers</title><p>In 2018, the National Institute on Aging and Alzheimer&#x02019;s Association (NIA-AA) introduced the ATN biomarker framework (as described previously), which provides guidelines for categorizing biomarkers and classifying AD patients according to their biomarker profiles (<xref rid="CIT0205" ref-type="bibr">Jack et al., 2018</xref>) (<xref rid="T1" ref-type="table">Table 1</xref>). Despite its introduction, there remains a discussion regarding its efficacy, given that it does not entirely capture the multifaceted nature of AD pathophysiology.</p><table-wrap position="float" id="T1"><label>Table 1.</label><caption><p>Biomarkers in Alzheimer&#x02019;s disease.</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Category</th><th align="left" rowspan="1" colspan="1">Biomarker</th><th align="left" rowspan="1" colspan="1">Change in AD</th><th align="left" rowspan="1" colspan="1">Disease stage</th><th align="left" rowspan="1" colspan="1">Additional notes</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Imaging</bold>
</td><td align="left" rowspan="1" colspan="1">MRI</td><td align="left" rowspan="1" colspan="1">Reduced volume in hippocampus and entorhinal cortex</td><td align="left" rowspan="1" colspan="1">Preclinical and early AD</td><td align="left" rowspan="1" colspan="1">Sensitive to early changes, but not specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<sup>18</sup>F-FDG PET</td><td align="left" rowspan="1" colspan="1">Decreased glucose metabolism in affected areas</td><td align="left" rowspan="1" colspan="1">Early and later AD</td><td align="left" rowspan="1" colspan="1">Reflects neuronal dysfunction, but not specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x003b2; PET</td><td align="left" rowspan="1" colspan="1">Increased amyloid plaques</td><td align="left" rowspan="1" colspan="1">Preclinical and early AD</td><td align="left" rowspan="1" colspan="1">High specificity for AD pathology</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Tau PET</td><td align="left" rowspan="1" colspan="1">Increased tau tangles</td><td align="left" rowspan="1" colspan="1">Early and later AD</td><td align="left" rowspan="1" colspan="1">Emerging technology with promising results, but still under development</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CSF</bold>
</td><td align="left" rowspan="1" colspan="1">A&#x003b2;<sub>42</sub>/A&#x003b2;<sub>40</sub></td><td align="left" rowspan="1" colspan="1">Decreased</td><td align="left" rowspan="1" colspan="1">Preclinical and early AD</td><td align="left" rowspan="1" colspan="1">Early detection</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total tau</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Early and later AD</td><td align="left" rowspan="1" colspan="1">Reflects neuronal damage and tau pathology, but not specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p-Tau</td><td align="left" rowspan="1" colspan="1">Increased, particularly pTau217, pTau181, and pTau231</td><td align="left" rowspan="1" colspan="1">Preclinical and later AD</td><td align="left" rowspan="1" colspan="1">More specific to AD than total tau, pTau217 performs best</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NfL</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Later AD</td><td align="left" rowspan="1" colspan="1">Reflects axonal damage and neurodegeneration, but not specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GFAP</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Early AD</td><td align="left" rowspan="1" colspan="1">Reflects astrocyte activation and neuroinflammation</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Blood</bold>
</td><td align="left" rowspan="1" colspan="1">A&#x003b2;<sub>42</sub>/A&#x003b2;<sub>40</sub></td><td align="left" rowspan="1" colspan="1">Potentially decreased, but research is ongoing</td><td align="left" rowspan="1" colspan="1">Preclinical and early AD</td><td align="left" rowspan="1" colspan="1">Non-invasive and accessible, but results not yet definitive</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total tau</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Early and later AD</td><td align="left" rowspan="1" colspan="1">Reflects neuronal damage and tau pathology, but not specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Brain-derived tau</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Early and later AD</td><td align="left" rowspan="1" colspan="1">Specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p-Tau</td><td align="left" rowspan="1" colspan="1">Increased, particularly pTau217, pTau181, and pTau231</td><td align="left" rowspan="1" colspan="1">Preclinical and later AD</td><td align="left" rowspan="1" colspan="1">Specific to AD, pTau217 performs best, still under development</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NfL</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Later AD</td><td align="left" rowspan="1" colspan="1">Reflects axonal damage and neurodegeneration, but not specific to AD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GFAP</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1">Early AD</td><td align="left" rowspan="1" colspan="1">Reflects astrocyte activation and neuroinflammation</td></tr></tbody></table></table-wrap><sec id="s37"><title>Imaging biomarkers</title><p>MRI is recommended for assessing cognitive impairment, as it aids in excluding other potential causes and evaluating brain atrophy (<xref rid="CIT0263" ref-type="bibr">Likeman et al., 2005</xref>; <xref rid="CIT0540" ref-type="bibr">Zivanovic et al., 2023</xref>). Elevated levels of A&#x003b2;, identified through PET scans, are linked to increased atrophy in specific brain regions, such as the temporal and parietal lobes, which is associated with cognitive decline (<xref rid="CIT0239" ref-type="bibr">Knopman et al., 2016</xref>). While hippocampal atrophy detected by MRI is a marker of AD, it can also be detected in various other conditions, including cerebrovascular disease, FTD, and hippocampal sclerosis (<xref rid="CIT0064" ref-type="bibr">Chiang et al., 2010</xref>).</p><p>A&#x003b2; PET imaging plays a crucial role in excluding AD by tracking A&#x003b2; accumulation and facilitating early detection in the disease&#x02019;s initial stages (<xref rid="CIT0164" ref-type="bibr">Grothe et al., 2017a</xref>). <sup>18</sup>F-FDG PET is valuable for diagnosing neurodegenerative diseases and forecasting short-term outcomes, with the extent of hypometabolism observed correlating with cognitive decline severity, thus serving as an important marker of AD progression (<xref rid="CIT0197" ref-type="bibr">Iaccarino et al., 2019</xref>; <xref rid="CIT0376" ref-type="bibr">Rhodius-Meester et al., 2020</xref>). Tau PET imaging allows for the detection of tau pathology, although it is not exclusive to AD (<xref rid="CIT0345" ref-type="bibr">Ossenkoppele et al., 2018</xref>). Unlike A&#x003b2; PET, tau PET imaging patterns are strongly correlated with cognitive function and clinical AD phenotypes (<xref rid="CIT0013" ref-type="bibr">Aschenbrenner et al., 2018</xref>; <xref rid="CIT0344" ref-type="bibr">Ossenkoppele et al., 2016</xref>), and tau PET abnormalities are closely aligned with <sup>18</sup>F-FDG PET hypometabolism (<xref rid="CIT0344" ref-type="bibr">Ossenkoppele et al., 2016</xref>).</p><p>However, the use of PET tracers is limited by their high costs and the need for specialized infrastructure (<xref rid="CIT0014" ref-type="bibr">Ashton et al., 2021</xref>). To overcome these limitations, fluid-based biomarkers have been developed that offer increased sensitivity and convenience for detecting AD-related pathologies.</p></sec><sec id="s38"><title>Fluid biomarkers</title><p>Compared to A&#x003b2;<sub>40</sub>, A&#x003b2;<sub>42</sub> monomers are more prone to forming insoluble plaques, resulting in a decrease in the extracellular A&#x003b2;<sub>42</sub> concentration and the A&#x003b2;<sub>42</sub>/A&#x003b2;<sub>40</sub> ratio (<xref rid="CIT0259" ref-type="bibr">Lewczuk et al., 2017</xref>; <xref rid="CIT0384" ref-type="bibr">Roher et al., 1993</xref>). A lower A&#x003b2;<sub>42</sub>/A&#x003b2;<sub>40</sub> ratio in CSF and plasma is associated with A&#x003b2; PET findings, allowing for the specific monitoring of disease progression by measuring A&#x003b2;<sub>42</sub> and A&#x003b2;<sub>40</sub> levels (<xref rid="CIT0259" ref-type="bibr">Lewczuk et al., 2017</xref>; <xref rid="CIT0261" ref-type="bibr">Li et al., 2022</xref>).</p><p>Owing to its soluble nature and multiple PTMs in CSF and plasma, tau protein is recognized as a sensitive and robust biomarker for tau pathology and neurodegeneration in AD (<xref rid="CIT0409" ref-type="bibr">Self and Holtzman, 2023</xref>). Compared to total tau, plasma brain-derived tau (BD-tau) shows a better ability to distinguish AD from other neurodegenerative diseases (<xref rid="CIT0157" ref-type="bibr">Gonzalez-Ortiz et al., 2023</xref>). Increases in CSF levels of phosphorylated tau at T181, T217, and T231 in early preclinical AD stages can accurately differentiate between A&#x003b2; PET-positive and A&#x003b2; PET-negative individuals (<xref rid="CIT0440" ref-type="bibr">Suarez-Calvet et al., 2020</xref>). pTau181, which is closely correlated with total tau levels in CSF, is markedly elevated in AD but not in most other neurodegenerative conditions, making it the gold standard for assessing phosphorylated tau levels and an AD-specific marker (<xref rid="CIT0426" ref-type="bibr">Skillback et al., 2015</xref>). Among these, plasma pTau217 shows the most promise in distinguishing patients with MCI who have abnormal brain A&#x003b2; levels or are likely to progress to AD dementia (<xref rid="CIT0015" ref-type="bibr">Ashton et al., 2024</xref>; <xref rid="CIT0028" ref-type="bibr">Barthelemy et al., 2024</xref>; <xref rid="CIT0209" ref-type="bibr">Janelidze et al., 2023</xref>; <xref rid="CIT0347" ref-type="bibr">Palmqvist et al., 2020</xref>). Notably, plasma pTau217 exhibits clinical performance comparable to or even better than that of currently FDA-approved CSF-based tests for classifying A&#x003b2; and tau PET status (<xref rid="CIT0028" ref-type="bibr">Barthelemy et al., 2024</xref>).</p><p>Although neurofilament light chain (NfL), a marker of neuroaxonal degeneration, may not serve as an ideal standalone diagnostic marker for AD (<xref rid="CIT0035" ref-type="bibr">Benkert et al., 2022</xref>; <xref rid="CIT0228" ref-type="bibr">Karantali et al., 2022</xref>; <xref rid="CIT0300" ref-type="bibr">Mattsson et al., 2017</xref>; <xref rid="CIT0467" ref-type="bibr">van der Ende et al., 2022</xref>), it is useful for monitoring and predicting disease severity (<xref rid="CIT0221" ref-type="bibr">Jung and Damoiseaux, 2024</xref>). Elevated NfL levels in the blood or CSF correlate with reduced cognitive function, advanced neurodegeneration, and rapid cognitive decline in patients with AD (<xref rid="CIT0302" ref-type="bibr">Mattsson et al., 2019</xref>; <xref rid="CIT0322" ref-type="bibr">Moscoso et al., 2021</xref>; <xref rid="CIT0442" ref-type="bibr">Sugarman et al., 2020</xref>; <xref rid="CIT0493" ref-type="bibr">Weston et al., 2017</xref>). Additionally, lower levels of neuronal pentraxin-2 (NPTX2) and higher levels of synaptosomal-associated protein 25 (SNAP25) in CSF are linked to AD progression (<xref rid="CIT0136" ref-type="bibr">Galasko et al., 2019</xref>). Blood levels of glial fibrillary acidic protein (GFAP), a marker for neuroinflammation, have shown potential in differentiating AD from FTD and predicting the progression from MCI to AD dementia (<xref rid="CIT0069" ref-type="bibr">Cicognola et al., 2021</xref>; <xref rid="CIT0341" ref-type="bibr">Oeckl et al., 2022</xref>).</p><p>CSF-based biomarkers, while scalable and cost-effective, allowing for the evaluation of multiple markers from a single sample, lack pathological localization and require invasive procedures such as lumbar puncture (<xref rid="CIT0256" ref-type="bibr">Leuzy et al., 2021</xref>). Blood-based biomarkers offer a more accessible and scalable option, although they also lack pathological localization (<xref rid="CIT0453" ref-type="bibr">Teunissen et al., 2022</xref>). However, challenges remain in identifying effective biomarkers, validating them in real-world populations, and developing diagnostic assays for clinical use (<xref rid="CIT0453" ref-type="bibr">Teunissen et al., 2022</xref>).</p><p>Enhancing the depth and precision of biomarker characterization across the AD continuum is necessary. Such advancements will support the development of targeted therapeutic approaches in the future.</p></sec></sec><sec id="s39"><title>Prevention strategies</title><p>Pharmacological treatments for AD are limited to symptom relief, with three cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the NMDA receptor antagonist memantine. These drugs can improve cognitive function and daily living activities but do not halt disease progression (<xref rid="CIT0240" ref-type="bibr">Knopman et al., 2021</xref>).</p><p>To date, 187 clinical trials have tested 141 treatments for AD across various phases. These trials have focused on diverse mechanisms, including A&#x003b2; (16%), neurotransmitters (29%), inflammation (17%), synaptic plasticity/neuroprotection (13%), and tau (9%) (<xref rid="CIT0085" ref-type="bibr">Cummings et al., 2023</xref>).</p><p>Recent advancements in clinical trials with anti-A&#x003b2; antibodies, such as donanemab, lecanemab, and aducanumab, have shown promise in reducing A&#x003b2; levels and decelerating cognitive decline (<xref rid="CIT0049" ref-type="bibr">Budd Haeberlein et al., 2022</xref>; <xref rid="CIT0423" ref-type="bibr">Sims et al., 2023</xref>; <xref rid="CIT0468" ref-type="bibr">van Dyck et al., 2023</xref>). Notably, compared with the placebo, lecanemab (leqembi), a humanized IgG1 monoclonal antibody targeting soluble A&#x003b2; protofibrils, has been shown to delay cognitive decline by 5.3 months over 18 months, leading to its traditional approval by the FDA in 2023 for AD treatment (<xref rid="CIT0468" ref-type="bibr">van Dyck et al., 2023</xref>). The success of A&#x003b2;-targeting antibodies in early AD therapy offers the first clinicopathological indication that a disease-modifying treatment for AD is feasible (<xref rid="CIT0220" ref-type="bibr">Jucker and Walker, 2023</xref>). Despite showing promise in clearing amyloid from the brain, the clinical benefits of anti-A&#x003b2; antibodies are limited, and safety concerns, including amyloid-related imaging abnormalities (ARIAs), necessitate a deeper understanding of the underlying mechanisms of AD to refine treatments.</p><p>Patients undergoing immunotherapy may experience significant side effects, such as ARIAs, including edema/effusion (ARIA-E) and microhemorrhages (ARIA-H), which are particularly linked to CAA and the presence of the <italic toggle="yes">APOE&#x003b5;4</italic> allele (<xref rid="CIT0161" ref-type="bibr">Greenberg et al., 2020</xref>; <xref rid="CIT0393" ref-type="bibr">Salloway et al., 2022</xref>; <xref rid="CIT0423" ref-type="bibr">Sims et al., 2023</xref>; <xref rid="CIT0444" ref-type="bibr">Sveikata et al., 2022</xref>; <xref rid="CIT0468" ref-type="bibr">van Dyck et al., 2023</xref>; <xref rid="CIT0472" ref-type="bibr">Villain et al., 2022</xref>). Early diagnosis through precise biomarkers is crucial for minimizing these risks and enhancing treatment efficacy (<xref rid="CIT0220" ref-type="bibr">Jucker and Walker, 2023</xref>).</p><p>Given the challenge of transporting antibodies across the BBB, with less than 0.1% of circulating antibodies penetrating it (<xref rid="CIT0363" ref-type="bibr">Poduslo et al., 1994</xref>), high doses are needed. Techniques such as ultrasound to temporarily open the barrier may facilitate amyloid removal and reduce necessary antibody dosages, despite potential adverse effects (<xref rid="CIT0375" ref-type="bibr">Rezai et al., 2024</xref>).</p><p>In addition to passive A&#x003b2; immunization, five A&#x003b2;-targeting vaccine candidates are currently undergoing clinical trials: ACI-24, ABvac40, UB-311, AV-1959D, and ALZ-101 (<xref rid="CIT0501" ref-type="bibr">Wu et al., 2024</xref>).</p><p>Considering the stronger correlation between tau pathologies and the severity of dementia compared to amyloid plaques, targeting tau has emerged as a potentially more effective strategy for combating AD. Among the most promising avenues in this regard is tau immunotherapy, which encompasses both active vaccines, such as AADvac1 and ACI-35, and a range of antibodies, including APNmAb005, E2814, JNJ-63733657, Lu AF87908, MK-2214, PNT001, PRX005, semorinemab, and bepranemab. These therapies are currently being evaluated in clinical trials (<xref rid="CIT0077" ref-type="bibr">Congdon et al., 2023</xref>). Notably, E2814, a humanized monoclonal IgG1 antibody targeting the HVPGG epitope in the microtubule-binding domain of tau, has demonstrated potential in reducing tau seeding, spreading, and intracellular deposition in tau-P301S transgenic mice (<xref rid="CIT0382" ref-type="bibr">Roberts et al., 2020</xref>) and is now in a phase III trial (NCT01760005). Moreover, the tau-targeting antisense oligonucleotide (ASO) MAPTRx has shown safety and a sustained reduction in CSF tau levels in a first-in-human phase 1b trial for patients with mild AD (NCT03186989) (<xref rid="CIT0325" ref-type="bibr">Mummery et al., 2023</xref>). However, TRx0237 (LMTX), a second-generation tau protein aggregation inhibitor, did not demonstrate benefits for patients with mild-to-moderate AD or FTD in phase 3 trials (<xref rid="CIT0142" ref-type="bibr">Gauthier et al., 2016</xref>; <xref rid="CIT0420" ref-type="bibr">Shiells et al., 2020</xref>).</p><p>In parallel, targeting the innate immune system has shown promise. Repeated administration of a TREM2 agonist antibody (AL002) increased plaque-associated microglia and reduced amyloid deposition in 5&#x000d7;&#x02005;FAD mice, including those expressing both the common variant and the R47H variant of human TREM2 (<xref rid="CIT0482" ref-type="bibr">Wang et al., 2020a</xref>), and has progressed to phase 2 trials for early AD (NCT04592874). Furthermore, masitinib, an orally administered tyrosine kinase inhibitor targeting mast cells and microglia, has shown efficacy in a phase 3 trial (NCT01872598) by significantly reducing cognitive decline in patients with mild-to-moderate AD (<xref rid="CIT0104" ref-type="bibr">Dubois et al., 2023</xref>).</p><p>Additionally, 40 Hz gamma-sensory stimulation has been investigated as a novel therapeutic approach, with studies demonstrating its potential to enhance glymphatic clearance of A&#x003b2; and reduce the microglial inflammatory response, synapse loss, amyloid plaque deposition, and tau pathology, thereby restoring cognitive function in AD mice (<xref rid="CIT0002" ref-type="bibr">Adaikkan et al., 2019</xref>; <xref rid="CIT0196" ref-type="bibr">Iaccarino et al., 2016</xref>; <xref rid="CIT0295" ref-type="bibr">Martorell et al., 2019</xref>; <xref rid="CIT0326" ref-type="bibr">Murdock et al., 2024</xref>). However, contrasting findings were reported in another study in which neither amyloid plaque nor microglial morphology was affected by 40 Hz stimulation in AD mice (<xref rid="CIT0434" ref-type="bibr">Soula et al., 2023</xref>). A recent phase 2 trial exploring combined visual and auditory 40 Hz gamma-sensory stimulation over six months (NCT03556280) indicated reduced total and regional white matter atrophy and myelin content loss in participants receiving active treatment compared to those receiving sham treatment (<xref rid="CIT0088" ref-type="bibr">Da et al., 2024</xref>). These findings underscore the diverse and innovative strategies being explored to address the complex pathology of AD, with a shift toward more targeted and potentially disease-modifying therapies.</p></sec><sec id="s40"><title>Conclusion</title><p>AD remains a challenging and complex neurodegenerative condition, and significant advancements in understanding its pathology have been achieved over the last three decades. Despite extensive research efforts aimed at identifying key proteins such as A&#x003b2; and tau and strategies to mitigate neuroinflammation, achieving breakthrough clinical outcomes has been challenging. These challenges stem from a variety of factors, including the properties of the drugs, the timing of treatment, and the inherent variability of the disease itself.</p><p>The pathophysiology of AD is intricate and influenced by a combination of genetic predispositions, the natural aging process, systemic inflammation, chronic diseases, infections, TBI, lifestyle choices, and environmental factors (<xref rid="F4" ref-type="fig">Fig. 4</xref>). These elements collectively drive the progressive neurodegeneration that spans from the initial amyloid pathology to the manifestation of overt dementia over a period of 15&#x02013;20 years. Certain modifiable risk factors may further accelerate the progression of the disease, highlighting the importance of ongoing, intensive research to uncover new therapeutic strategies.</p><fig position="float" id="F4"><label>Figure 4.</label><caption><p>Diverse risk factors contributing to AD pathogenesis. AD is a complex neurodegenerative disease influenced by a multitude of risk factors. These include genetic predisposition, the natural aging process, systemic inflammation, the presence of chronic diseases (type 2 diabetes, cardiovascular and cerebrovascular diseases), infections, traumatic brain injury (TBI), lifestyle choices (sleep patterns, high-fat, and high-salt diets), and environmental exposures. Additional factors that may affect AD incidence include neuropsychiatric symptoms, social engagement, alcohol consumption, hearing impairment, and educational attainment. The intricate interactions among these factors lead to the progressive neurodegeneration characteristic of AD.</p></caption><graphic xlink:href="pwae026_fig4" position="float"/></fig><p>The critical role of early intervention in the effective management of AD has become increasingly apparent, underscoring the need for the identification of sensitive and specific biomarkers. Biomarkers detectable in easily accessible biofluids, such as blood, are particularly crucial for early diagnosis, disease monitoring, and personalized treatment approaches. Although the recent FDA approval of anti-A&#x003b2; monoclonal antibodies represents a step forward, their limited clinical efficacy highlights the necessity for more targeted pharmacological interventions. These interventions should be informed by biomarkers, moving beyond the traditional one-size-fits-all treatment approach. The adoption of biomarker-guided therapies that target specific molecular pathways offers a promising avenue for improving treatment outcomes and ultimately reducing the burden of AD.</p></sec></body><back><ack id="a1"><title>Acknowledgements</title><p>We acknowledge the contributions of many significant studies that we cannot reference in this review due to space limitations.</p></ack><sec sec-type="COI-statement" id="s41"><title>Conflict of interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s42"><title>Funding</title><p>This work was supported by the National Key R&#x00026;D Program of China (2021ZD0202402 and 2021YFA1101401 to X.W.), the National Natural Science Foundation of China (82325018 and U21A20358 to X.W.; 82271451 to Q.Z.), the Natural Science Foundation of Fujian Province of China (2021J02004 to X.W.), the Guangdong Basic and Applied Basic Research Foundation (2021B1515120081 to X.W.), and the Fundamental Research Funds for the Chinese Central Universities (20720230070 to X.W. and Q.Z.; 20720220052 to Q.Z.).</p></sec><sec id="s43"><title>Author contributions</title><p>Q.Z. and X.W. conceived and wrote the manuscript. Q.Z. constructed the model diagram. All the authors validated and approved the final manuscript.</p></sec><sec id="s44"><title>Consent for publication</title><p>All the authors listed have approved the manuscript.</p></sec><sec sec-type="data-availability" id="s45"><title>Data availability</title><p>Not applicable.</p></sec><ref-list id="r1"><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Abelein</surname>
<given-names>A.</given-names>
</string-name>
</person-group>
<article-title>Metal binding of Alzheimer&#x02019;s amyloid-beta and its effect on peptide self-assembly</article-title>. <source>Acc Chem Res</source><year>2023</year>;<volume>56</volume>:<fpage>2653</fpage>&#x02013;<lpage>2663</lpage>.<pub-id pub-id-type="pmid">37733746</pub-id>
</mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Adaikkan</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Middleton</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Marco</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Gamma entrainment binds higher-order brain regions and offers neuroprotection</article-title>. <source>Neuron</source><year>2019</year>;<volume>102</volume>:<fpage>929</fpage>&#x02013;<lpage>943.e8</lpage>.<pub-id pub-id-type="pmid">31076275</pub-id>
</mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ahmed</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Cooper</surname><given-names>J</given-names></string-name>, <string-name><surname>Murray</surname><given-names>TK</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A novel <italic toggle="yes">in vivo</italic> model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity</article-title>. <source>Acta Neuropathol</source><year>2014</year>;<volume>127</volume>:<fpage>667</fpage>&#x02013;<lpage>683</lpage>.<pub-id pub-id-type="pmid">24531916</pub-id>
</mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Altmann</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ng</surname><given-names>B</given-names></string-name>, <string-name><surname>Landau</surname><given-names>SM</given-names></string-name></person-group>
<etal>et al</etal>
<collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab>. <article-title>Regional brain hypometabolism is unrelated to regional amyloid plaque burden</article-title>. <source>Brain</source><year>2015</year>;<volume>138</volume>:<fpage>3734</fpage>&#x02013;<lpage>3746</lpage>.<pub-id pub-id-type="pmid">26419799</pub-id>
</mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal">
<collab>Alzheimer's Association</collab>. <article-title>2023 Alzheimer&#x02019;s disease facts and figures</article-title>. <source>Alzheimers Dement</source><year>2023</year>;<volume>19</volume>:<fpage>1598</fpage>&#x02013;<lpage>1695</lpage>.<pub-id pub-id-type="pmid">36918389</pub-id>
</mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alzheimer</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Stelzmann</surname><given-names>RA</given-names></string-name>, <string-name><surname>Schnitzlein</surname><given-names>HN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>An English translation of Alzheimer&#x02019;s 1907 paper, &#x0201c;Uber eine eigenartige Erkankung der Hirnrinde&#x0201d;</article-title>. <source>Clin Anat</source><year>1995</year>;<volume>8</volume>:<fpage>429</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">8713166</pub-id>
</mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Amelianchik</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Merkel</surname><given-names>J</given-names></string-name>, <string-name><surname>Palanisamy</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The protective effect of early dietary fat consumption on Alzheimer&#x02019;s disease-related pathology and cognitive function in mice</article-title>. <source>Alzheimers Dement (N Y)</source><year>2021</year>;<volume>7</volume>:<fpage>e12173</fpage>.<pub-id pub-id-type="pmid">34084889</pub-id>
</mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Anstey</surname>
<given-names>KJ</given-names>
</string-name>, <string-name><surname>von Sanden</surname><given-names>C</given-names></string-name>, <string-name><surname>Salim</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies</article-title>. <source>Am J Epidemiol</source><year>2007</year>;<volume>166</volume>:<fpage>367</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">17573335</pub-id>
</mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Araque Caballero</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Suarez-Calvet</surname><given-names>M</given-names></string-name>, <string-name><surname>Duering</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer&#x02019;s disease</article-title>. <source>Brain</source><year>2018</year>;<volume>141</volume>:<fpage>3065</fpage>&#x02013;<lpage>3080</lpage>.<pub-id pub-id-type="pmid">30239611</pub-id>
</mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Arboleda-Velasquez</surname>
<given-names>JF</given-names>
</string-name>, <string-name><surname>Lopera</surname><given-names>F</given-names></string-name>, <string-name><surname>O&#x02019;Hare</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Resistance to autosomal dominant Alzheimer&#x02019;s disease in an APOE3 Christchurch homozygote: a case report</article-title>. <source>Nat Med</source><year>2019</year>;<volume>25</volume>:<fpage>1680</fpage>&#x02013;<lpage>1683</lpage>.<pub-id pub-id-type="pmid">31686034</pub-id>
</mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Arnold</surname>
<given-names>CS</given-names>
</string-name>, <string-name><surname>Johnson</surname><given-names>GV</given-names></string-name>, <string-name><surname>Cole</surname><given-names>RN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine</article-title>. <source>J Biol Chem</source><year>1996</year>;<volume>271</volume>:<fpage>28741</fpage>&#x02013;<lpage>28744</lpage>.<pub-id pub-id-type="pmid">8910513</pub-id>
</mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Arvanitakis</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Capuano</surname><given-names>AW</given-names></string-name>, <string-name><surname>Leurgans</surname><given-names>SE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Relation of cerebral vessel disease to Alzheimer&#x02019;s disease dementia and cognitive function in elderly people: a cross-sectional study</article-title>. <source>Lancet Neurol</source><year>2016</year>;<volume>15</volume>:<fpage>934</fpage>&#x02013;<lpage>943</lpage>.<pub-id pub-id-type="pmid">27312738</pub-id>
</mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Asai</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Ikezu</surname><given-names>S</given-names></string-name>, <string-name><surname>Tsunoda</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Depletion of microglia and inhibition of exosome synthesis halt tau propagation</article-title>. <source>Nat Neurosci</source><year>2015</year>;<volume>18</volume>:<fpage>1584</fpage>&#x02013;<lpage>1593</lpage>.<pub-id pub-id-type="pmid">26436904</pub-id>
</mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Aschenbrenner</surname>
<given-names>AJ</given-names>
</string-name>, <string-name><surname>Gordon</surname><given-names>BA</given-names></string-name>, <string-name><surname>Benzinger</surname><given-names>TLS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease</article-title>. <source>Neurology</source><year>2018</year>;<volume>91</volume>:<fpage>e859</fpage>&#x02013;<lpage>e866</lpage>.<pub-id pub-id-type="pmid">30068637</pub-id>
</mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ashton</surname>
<given-names>NJ</given-names>
</string-name>, <string-name><surname>Leuzy</surname><given-names>A</given-names></string-name>, <string-name><surname>Karikari</surname><given-names>TK</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2021</year>;<volume>48</volume>:<fpage>2140</fpage>&#x02013;<lpage>2156</lpage>.<pub-id pub-id-type="pmid">33677733</pub-id>
</mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ashton</surname>
<given-names>NJ</given-names>
</string-name>, <string-name><surname>Brum</surname><given-names>WS</given-names></string-name>, <string-name><surname>Di Molfetta</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology</article-title>. <source>JAMA Neurol</source><year>2024</year>;<volume>81</volume>:<fpage>255</fpage>&#x02013;<lpage>263</lpage>.<pub-id pub-id-type="pmid">38252443</pub-id>
</mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Atagi</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>CC</given-names></string-name>, <string-name><surname>Painter</surname><given-names>MM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E is a ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)</article-title>. <source>J Biol Chem</source><year>2015</year>;<volume>290</volume>:<fpage>26043</fpage>&#x02013;<lpage>26050</lpage>.<pub-id pub-id-type="pmid">26374899</pub-id>
</mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Augustinack</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Schneider</surname><given-names>A</given-names></string-name>, <string-name><surname>Mandelkow</surname><given-names>EM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol</source><year>2002</year>;<volume>103</volume>:<fpage>26</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">11837744</pub-id>
</mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Babu</surname>
<given-names>JR</given-names>
</string-name>, <string-name><surname>Geetha</surname><given-names>T</given-names></string-name>, <string-name><surname>Wooten</surname><given-names>MW.</given-names></string-name></person-group>
<article-title>Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation</article-title>. <source>J Neurochem</source><year>2005</year>;<volume>94</volume>:<fpage>192</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">15953362</pub-id>
</mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bailey</surname>
<given-names>CC</given-names>
</string-name>, <string-name><surname>DeVaux</surname><given-names>LB</given-names></string-name>, <string-name><surname>Farzan</surname><given-names>M.</given-names></string-name></person-group>
<article-title>The Triggering Receptor Expressed on Myeloid Cells 2 binds Apolipoprotein E</article-title>. <source>J Biol Chem</source><year>2015</year>;<volume>290</volume>:<fpage>26033</fpage>&#x02013;<lpage>26042</lpage>.<pub-id pub-id-type="pmid">26374897</pub-id>
</mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Baker</surname>
<given-names>HF</given-names>
</string-name>, <string-name><surname>Ridley</surname><given-names>RM</given-names></string-name>, <string-name><surname>Duchen</surname><given-names>LW</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Evidence for the experimental transmission of cerebral beta-amyloidosis to primates</article-title>. <source>Int J Exp Pathol</source><year>1993</year>;<volume>74</volume>:<fpage>441</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">8217779</pub-id>
</mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Baker</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Wijshake</surname><given-names>T</given-names></string-name>, <string-name><surname>Tchkonia</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders</article-title>. <source>Nature</source><year>2011</year>;<volume>479</volume>:<fpage>232</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">22048312</pub-id>
</mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Balin</surname>
<given-names>BJ</given-names>
</string-name>, <string-name><surname>Gerard</surname><given-names>HC</given-names></string-name>, <string-name><surname>Arking</surname><given-names>EJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Identification and localization of <italic toggle="yes">Chlamydia pneumoniae</italic> in the Alzheimer&#x02019;s brain</article-title>. <source>Med Microbiol Immunol</source><year>1998</year>;<volume>187</volume>:<fpage>23</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">9749980</pub-id>
</mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Balusu</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Horre</surname><given-names>K</given-names></string-name>, <string-name><surname>Thrupp</surname><given-names>N</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer&#x02019;s disease</article-title>. <source>Science</source><year>2023</year>;<volume>381</volume>:<fpage>1176</fpage>&#x02013;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">37708272</pub-id>
</mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bao</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Zheng</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Deacetylation of TFEB promotes fibrillar Abeta degradation by upregulating lysosomal biogenesis in microglia</article-title>. <source>Protein Cell</source><year>2016</year>;<volume>7</volume>:<fpage>417</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">27209302</pub-id>
</mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bao</surname>
<given-names>WD</given-names>
</string-name>, <string-name><surname>Pang</surname><given-names>P</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>XT</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer&#x02019;s disease</article-title>. <source>Cell Death Differ</source><year>2021</year>;<volume>28</volume>:<fpage>1548</fpage>&#x02013;<lpage>1562</lpage>.<pub-id pub-id-type="pmid">33398092</pub-id>
</mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Barnes</surname>
<given-names>LL</given-names>
</string-name>, <string-name><surname>Capuano</surname><given-names>AW</given-names></string-name>, <string-name><surname>Aiello</surname><given-names>AE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals</article-title>. <source>J Infect Dis</source><year>2015</year>;<volume>211</volume>:<fpage>230</fpage>&#x02013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">25108028</pub-id>
</mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Barthelemy</surname>
<given-names>NR</given-names>
</string-name>, <string-name><surname>Salvado</surname><given-names>G</given-names></string-name>, <string-name><surname>Schindler</surname><given-names>SE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Highly accurate blood test for Alzheimer&#x02019;s disease is similar or superior to clinical cerebrospinal fluid tests</article-title>. <source>Nat Med</source><year>2024</year>;<volume>30</volume>:<fpage>1085</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">38382645</pub-id>
</mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bateman</surname>
<given-names>RJ</given-names>
</string-name>, <string-name><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name><surname>De Strooper</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Autosomal-dominant Alzheimer&#x02019;s disease: a review and proposal for the prevention of Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Res Ther</source><year>2011</year>;<volume>3</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">21211070</pub-id>
</mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Beach</surname>
<given-names>TG</given-names>
</string-name>, <string-name><surname>McGeer</surname><given-names>EG.</given-names></string-name></person-group>
<article-title>Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer&#x02019;s disease visual cortex</article-title>. <source>Brain Res</source><year>1988</year>;<volume>463</volume>:<fpage>357</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">3196922</pub-id>
</mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Becker</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Orellana Rios</surname><given-names>CL</given-names></string-name>, <string-name><surname>Lahmann</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Anxiety as a risk factor of Alzheimer&#x02019;s disease and vascular dementia</article-title>. <source>Br J Psychiatry</source><year>2018</year>;<volume>213</volume>:<fpage>654</fpage>&#x02013;<lpage>660</lpage>.<pub-id pub-id-type="pmid">30339108</pub-id>
</mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Behrendt</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Baer</surname><given-names>K</given-names></string-name>, <string-name><surname>Buffo</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men</article-title>. <source>Glia</source><year>2013</year>;<volume>61</volume>:<fpage>273</fpage>&#x02013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">23090919</pub-id>
</mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Behrendt</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Bichmann</surname><given-names>M</given-names></string-name>, <string-name><surname>Ercan-Herbst</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Asparagine endopeptidase cleaves tau at N167 after uptake into microglia</article-title>. <source>Neurobiol Dis</source><year>2019</year>;<volume>130</volume>:<fpage>104518</fpage>.<pub-id pub-id-type="pmid">31229689</pub-id>
</mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bemiller</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>McCray</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Allan</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy</article-title>. <source>Mol Neurodegener</source><year>2017</year>;<volume>12</volume>:<fpage>74</fpage>.<pub-id pub-id-type="pmid">29037207</pub-id>
</mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Benkert</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Meier</surname><given-names>S</given-names></string-name>, <string-name><surname>Schaedelin</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<collab>NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group</collab>. <article-title>Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study</article-title>. <source>Lancet Neurol</source><year>2022</year>;<volume>21</volume>:<fpage>246</fpage>&#x02013;<lpage>257</lpage>.<pub-id pub-id-type="pmid">35182510</pub-id>
</mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bertram</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>McQueen</surname><given-names>MB</given-names></string-name>, <string-name><surname>Mullin</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database</article-title>. <source>Nat Genet</source><year>2007</year>;<volume>39</volume>:<fpage>17</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">17192785</pub-id>
</mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bertram</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Lill</surname><given-names>CM</given-names></string-name>, <string-name><surname>Tanzi</surname><given-names>RE.</given-names></string-name></person-group>
<article-title>The genetics of Alzheimer disease: back to the future</article-title>. <source>Neuron</source><year>2010</year>;<volume>68</volume>:<fpage>270</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">20955934</pub-id>
</mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bhat</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Crowe</surname><given-names>EP</given-names></string-name>, <string-name><surname>Bitto</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Astrocyte senescence as a component of Alzheimer&#x02019;s disease</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>e45069</fpage>.<pub-id pub-id-type="pmid">22984612</pub-id>
</mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bibl</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Mollenhauer</surname><given-names>B</given-names></string-name>, <string-name><surname>Esselmann</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>CSF amyloid-beta-peptides in Alzheimer&#x02019;s disease, dementia with Lewy bodies and Parkinson&#x02019;s disease dementia</article-title>. <source>Brain</source><year>2006</year>;<volume>129</volume>:<fpage>1177</fpage>&#x02013;<lpage>1187</lpage>.<pub-id pub-id-type="pmid">16600985</pub-id>
</mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bichmann</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Prat Oriol</surname><given-names>N</given-names></string-name>, <string-name><surname>Ercan-Herbst</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer&#x02019;s disease</article-title>. <source>Mol Neurodegener</source><year>2021</year>;<volume>16</volume>:<fpage>46</fpage>.<pub-id pub-id-type="pmid">34215303</pub-id>
</mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bloom</surname>
<given-names>GS.</given-names>
</string-name>
</person-group>
<article-title>Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis</article-title>. <source>JAMA Neurol</source><year>2014</year>;<volume>71</volume>:<fpage>505</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">24493463</pub-id>
</mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boada</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Lopez</surname><given-names>OL</given-names></string-name>, <string-name><surname>Olazaran</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<collab>AMBAR Trial Group</collab>. <article-title>Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer&#x02019;s disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study</article-title>. <source>Alzheimers Dement</source><year>2022</year>;<volume>18</volume>:<fpage>1314</fpage>&#x02013;<lpage>1324</lpage>.<pub-id pub-id-type="pmid">34726348</pub-id>
</mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boluda</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Iba</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer&#x02019;s disease or corticobasal degeneration brains</article-title>. <source>Acta Neuropathol</source><year>2015</year>;<volume>129</volume>:<fpage>221</fpage>&#x02013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">25534024</pub-id>
</mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boza-Serrano</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ruiz</surname><given-names>R</given-names></string-name>, <string-name><surname>Sanchez-Varo</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol</source><year>2019</year>;<volume>138</volume>:<fpage>251</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">31006066</pub-id>
</mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Braak</surname><given-names>E.</given-names></string-name></person-group>
<article-title>Staging of Alzheimer&#x02019;s disease-related neurofibrillary changes</article-title>. <source>Neurobiol Aging</source><year>1995</year>;<volume>16</volume>:<fpage>271</fpage>&#x02013;<lpage>8; discussion 278</lpage>.<pub-id pub-id-type="pmid">7566337</pub-id>
</mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Alafuzoff</surname><given-names>I</given-names></string-name>, <string-name><surname>Arzberger</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry</article-title>. <source>Acta Neuropathol</source><year>2006</year>;<volume>112</volume>:<fpage>389</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">16906426</pub-id>
</mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brandebura</surname>
<given-names>AN</given-names>
</string-name>, <string-name><surname>Paumier</surname><given-names>A</given-names></string-name>, <string-name><surname>Onur</surname><given-names>TS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders</article-title>. <source>Nat Rev Neurosci</source><year>2023</year>;<volume>24</volume>:<fpage>23</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">36316501</pub-id>
</mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bu</surname>
<given-names>G.</given-names>
</string-name>
</person-group>
<article-title>Apolipoprotein E and its receptors in Alzheimer&#x02019;s disease: pathways, pathogenesis and therapy</article-title>. <source>Nat Rev Neurosci</source><year>2009</year>;<volume>10</volume>:<fpage>333</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">19339974</pub-id>
</mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Budd Haeberlein</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name><surname>Barkhof</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Two randomized phase 3 studies of Aducanumab in early Alzheimer&#x02019;s disease</article-title>. <source>J Prev Alzheimers Dis</source><year>2022</year>;<volume>9</volume>:<fpage>197</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">35542991</pub-id>
</mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bussian</surname>
<given-names>TJ</given-names>
</string-name>, <string-name><surname>Aziz</surname><given-names>A</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>CF</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline</article-title>. <source>Nature</source><year>2018</year>;<volume>562</volume>:<fpage>578</fpage>&#x02013;<lpage>582</lpage>.<pub-id pub-id-type="pmid">30232451</pub-id>
</mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Caccamo</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Branca</surname><given-names>C</given-names></string-name>, <string-name><surname>Piras</surname><given-names>IS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Necroptosis activation in Alzheimer&#x02019;s disease</article-title>. <source>Nat Neurosci</source><year>2017</year>;<volume>20</volume>:<fpage>1236</fpage>&#x02013;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">28758999</pub-id>
</mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cairns</surname>
<given-names>DM</given-names>
</string-name>, <string-name><surname>Rouleau</surname><given-names>N</given-names></string-name>, <string-name><surname>Parker</surname><given-names>RN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A 3D human brain-like tissue model of herpes-induced Alzheimer&#x02019;s disease</article-title>. <source>Sci Adv</source><year>2020</year>;<volume>6</volume>:<fpage>eaay8828</fpage>.<pub-id pub-id-type="pmid">32494701</pub-id>
</mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Calafate</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Flavin</surname><given-names>W</given-names></string-name>, <string-name><surname>Verstreken</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Loss of Bin1 promotes the propagation of Tau pathology</article-title>. <source>Cell Rep</source><year>2016</year>;<volume>17</volume>:<fpage>931</fpage>&#x02013;<lpage>940</lpage>.<pub-id pub-id-type="pmid">27760323</pub-id>
</mixed-citation></ref><ref id="CIT0054"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cardenas-Aguayo Mdel</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Gomez-Virgilio</surname><given-names>L</given-names></string-name>, <string-name><surname>DeRosa</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The role of tau oligomers in the onset of Alzheimer&#x02019;s disease neuropathology</article-title>. <source>ACS Chem Neurosci</source><year>2014</year>;<volume>5</volume>:<fpage>1178</fpage>&#x02013;<lpage>1191</lpage>.<pub-id pub-id-type="pmid">25268947</pub-id>
</mixed-citation></ref><ref id="CIT0055"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Carlomagno</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Chung</surname><given-names>DC</given-names></string-name>, <string-name><surname>Yue</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>An acetylation-phosphorylation switch that regulates tau aggregation propensity and function</article-title>. <source>J Biol Chem</source><year>2017</year>;<volume>292</volume>:<fpage>15277</fpage>&#x02013;<lpage>15286</lpage>.<pub-id pub-id-type="pmid">28760828</pub-id>
</mixed-citation></ref><ref id="CIT0056"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Castellano</surname>
<given-names>JM</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>FR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance</article-title>. <source>Sci Transl Med</source><year>2011</year>;<volume>3</volume>:<fpage>89ra57</fpage>.</mixed-citation></ref><ref id="CIT0057"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chapuis</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Hansmannel</surname><given-names>F</given-names></string-name>, <string-name><surname>Gistelinck</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<collab>GERAD consortium</collab>. <article-title>Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology</article-title>. <source>Mol Psychiatry</source><year>2013</year>;<volume>18</volume>:<fpage>1225</fpage>&#x02013;<lpage>1234</lpage>.<pub-id pub-id-type="pmid">23399914</pub-id>
</mixed-citation></ref><ref id="CIT0058"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Mueller-Steiner</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling</article-title>. <source>J Biol Chem</source><year>2005</year>;<volume>280</volume>:<fpage>40364</fpage>&#x02013;<lpage>40374</lpage>.<pub-id pub-id-type="pmid">16183991</pub-id>
</mixed-citation></ref><ref id="CIT0059"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>WT</given-names>
</string-name>, <string-name><surname>Lu</surname><given-names>A</given-names></string-name>, <string-name><surname>Craessaerts</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Spatial transcriptomics and <italic toggle="yes">in situ</italic> sequencing to study Alzheimer&#x02019;s disease</article-title>. <source>Cell</source><year>2020</year>;<volume>182</volume>:<fpage>976</fpage>&#x02013;<lpage>991.e19</lpage>.<pub-id pub-id-type="pmid">32702314</pub-id>
</mixed-citation></ref><ref id="CIT0060"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Swartzlander</surname><given-names>DB</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer&#x02019;s disease neuropathology</article-title>. <source>Mol Neurodegener</source><year>2021</year>;<volume>16</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">33517893</pub-id>
</mixed-citation></ref><ref id="CIT0061"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Firulyova</surname><given-names>M</given-names></string-name>, <string-name><surname>Manis</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy</article-title>. <source>Nature</source><year>2023</year>;<volume>615</volume>:<fpage>668</fpage>&#x02013;<lpage>677</lpage>.<pub-id pub-id-type="pmid">36890231</pub-id>
</mixed-citation></ref><ref id="CIT0062"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Song</surname><given-names>S</given-names></string-name>, <string-name><surname>Parhizkar</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread</article-title>. <source>Cell</source><year>2024</year>;<volume>187</volume>:<fpage>428</fpage>&#x02013;<lpage>445.e20</lpage>.<pub-id pub-id-type="pmid">38086389</pub-id>
</mixed-citation></ref><ref id="CIT0063"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chia</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Flagmeier</surname><given-names>P</given-names></string-name>, <string-name><surname>Habchi</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Monomeric and fibrillar alpha-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Abeta42 aggregates</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2017</year>;<volume>114</volume>:<fpage>8005</fpage>&#x02013;<lpage>8010</lpage>.<pub-id pub-id-type="pmid">28698377</pub-id>
</mixed-citation></ref><ref id="CIT0064"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chiang</surname>
<given-names>GC</given-names>
</string-name>, <string-name><surname>Insel</surname><given-names>PS</given-names></string-name>, <string-name><surname>Tosun</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<collab>Alzheimer's Disease Neuroimaging Initiative</collab>. <article-title>Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects</article-title>. <source>Neurology</source><year>2010</year>;<volume>75</volume>:<fpage>1976</fpage>&#x02013;<lpage>1981</lpage>.<pub-id pub-id-type="pmid">20980669</pub-id>
</mixed-citation></ref><ref id="CIT0065"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Choi</surname>
<given-names>BR</given-names>
</string-name>, <string-name><surname>Johnson</surname><given-names>KR</given-names></string-name>, <string-name><surname>Maric</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Monocyte-derived IL-6 programs microglia to rebuild damaged brain vasculature</article-title>. <source>Nat Immunol</source><year>2023</year>;<volume>24</volume>:<fpage>1110</fpage>&#x02013;<lpage>1123</lpage>.<pub-id pub-id-type="pmid">37248420</pub-id>
</mixed-citation></ref><ref id="CIT0066"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Christen</surname>
<given-names>Y.</given-names>
</string-name>
</person-group>
<article-title>Oxidative stress and Alzheimer disease</article-title>. <source>Am J Clin Nutr</source><year>2000</year>;<volume>71</volume>:<fpage>621S</fpage>&#x02013;<lpage>629S</lpage>.<pub-id pub-id-type="pmid">10681270</pub-id>
</mixed-citation></ref><ref id="CIT0067"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Christensen</surname>
<given-names>DZ</given-names>
</string-name>, <string-name><surname>Schneider-Axmann</surname><given-names>T</given-names></string-name>, <string-name><surname>Lucassen</surname><given-names>PJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Accumulation of intraneuronal Abeta correlates with ApoE4 genotype</article-title>. <source>Acta Neuropathol</source><year>2010</year>;<volume>119</volume>:<fpage>555</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">20217101</pub-id>
</mixed-citation></ref><ref id="CIT0068"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Christianson</surname>
<given-names>HC</given-names>
</string-name>, <string-name><surname>Belting</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Heparan sulfate proteoglycan as a cell-surface endocytosis receptor</article-title>. <source>Matrix Biol</source><year>2014</year>;<volume>35</volume>:<fpage>51</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">24145152</pub-id>
</mixed-citation></ref><ref id="CIT0069"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cicognola</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name><surname>Hertze</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment</article-title>. <source>Alzheimers Res Ther</source><year>2021</year>;<volume>13</volume>:<fpage>68</fpage>.<pub-id pub-id-type="pmid">33773595</pub-id>
</mixed-citation></ref><ref id="CIT0070"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Clavaguera</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Bolmont</surname><given-names>T</given-names></string-name>, <string-name><surname>Crowther</surname><given-names>RA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Transmission and spreading of tauopathy in transgenic mouse brain</article-title>. <source>Nat Cell Biol</source><year>2009</year>;<volume>11</volume>:<fpage>909</fpage>&#x02013;<lpage>913</lpage>.<pub-id pub-id-type="pmid">19503072</pub-id>
</mixed-citation></ref><ref id="CIT0071"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Clavaguera</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Akatsu</surname><given-names>H</given-names></string-name>, <string-name><surname>Fraser</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Brain homogenates from human tauopathies induce tau inclusions in mouse brain</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2013</year>;<volume>110</volume>:<fpage>9535</fpage>&#x02013;<lpage>9540</lpage>.<pub-id pub-id-type="pmid">23690619</pub-id>
</mixed-citation></ref><ref id="CIT0072"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Clavaguera</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Hench</surname><given-names>J</given-names></string-name>, <string-name><surname>Lavenir</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice</article-title>. <source>Acta Neuropathol</source><year>2014</year>;<volume>127</volume>:<fpage>299</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">24362441</pub-id>
</mixed-citation></ref><ref id="CIT0073"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cohen</surname>
<given-names>TJ</given-names>
</string-name>, <string-name><surname>Guo</surname><given-names>JL</given-names></string-name>, <string-name><surname>Hurtado</surname><given-names>DE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The acetylation of tau inhibits its function and promotes pathological tau aggregation</article-title>. <source>Nat Commun</source><year>2011</year>;<volume>2</volume>:<fpage>252</fpage>.<pub-id pub-id-type="pmid">21427723</pub-id>
</mixed-citation></ref><ref id="CIT0075"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Condello</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Maxwell</surname><given-names>AM</given-names></string-name>, <string-name><surname>Castillo</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Abeta and tau prions feature in the neuropathogenesis of Down syndrome</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2022</year>;<volume>119</volume>:<fpage>e2212954119</fpage>.<pub-id pub-id-type="pmid">36343257</pub-id>
</mixed-citation></ref><ref id="CIT0076"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Congdon</surname>
<given-names>EE</given-names>
</string-name>, <string-name><surname>Sigurdsson</surname><given-names>EM.</given-names></string-name></person-group>
<article-title>Tau-targeting therapies for Alzheimer disease</article-title>. <source>Nat Rev Neurol</source><year>2018</year>;<volume>14</volume>:<fpage>399</fpage>&#x02013;<lpage>415</lpage>.<pub-id pub-id-type="pmid">29895964</pub-id>
</mixed-citation></ref><ref id="CIT0077"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Congdon</surname>
<given-names>EE</given-names>
</string-name>, <string-name><surname>Ji</surname><given-names>C</given-names></string-name>, <string-name><surname>Tetlow</surname><given-names>AM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau-targeting therapies for Alzheimer disease: current status and future directions</article-title>. <source>Nat Rev Neurol</source><year>2023</year>;<volume>19</volume>:<fpage>715</fpage>&#x02013;<lpage>736</lpage>.<pub-id pub-id-type="pmid">37875627</pub-id>
</mixed-citation></ref><ref id="CIT0078"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cook</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Stankowski</surname><given-names>JN</given-names></string-name>, <string-name><surname>Carlomagno</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Acetylation: a new key to unlock tau&#x02019;s role in neurodegeneration</article-title>. <source>Alzheimers Res Ther</source><year>2014</year>;<volume>6</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">25031639</pub-id>
</mixed-citation></ref><ref id="CIT0079"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cope</surname>
<given-names>TE</given-names>
</string-name>, <string-name><surname>Rittman</surname><given-names>T</given-names></string-name>, <string-name><surname>Borchert</surname><given-names>RJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau burden and the functional connectome in Alzheimer&#x02019;s disease and progressive supranuclear palsy</article-title>. <source>Brain</source><year>2018</year>;<volume>141</volume>:<fpage>550</fpage>&#x02013;<lpage>567</lpage>.<pub-id pub-id-type="pmid">29293892</pub-id>
</mixed-citation></ref><ref id="CIT0080"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Corder</surname>
<given-names>EH</given-names>
</string-name>, <string-name><surname>Saunders</surname><given-names>AM</given-names></string-name>, <string-name><surname>Strittmatter</surname><given-names>WJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x02019;s disease in late onset families</article-title>. <source>Science</source><year>1993</year>;<volume>261</volume>:<fpage>921</fpage>&#x02013;<lpage>923</lpage>.<pub-id pub-id-type="pmid">8346443</pub-id>
</mixed-citation></ref><ref id="CIT0081"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crary</surname>
<given-names>JF</given-names>
</string-name>, <string-name><surname>Trojanowski</surname><given-names>JQ</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>JA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Primary age-related tauopathy (PART): a common pathology associated with human aging</article-title>. <source>Acta Neuropathol</source><year>2014</year>;<volume>128</volume>:<fpage>755</fpage>&#x02013;<lpage>766</lpage>.<pub-id pub-id-type="pmid">25348064</pub-id>
</mixed-citation></ref><ref id="CIT0082"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cresswell</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Ackerman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Giodini</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Mechanisms of MHC class I-restricted antigen processing and cross-presentation</article-title>. <source>Immunol Rev</source><year>2005</year>;<volume>207</volume>:<fpage>145</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">16181333</pub-id>
</mixed-citation></ref><ref id="CIT0083"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crocker</surname>
<given-names>PR</given-names>
</string-name>, <string-name><surname>Paulson</surname><given-names>JC</given-names></string-name>, <string-name><surname>Varki</surname><given-names>A.</given-names></string-name></person-group>
<article-title>Siglecs and their roles in the immune system</article-title>. <source>Nat Rev Immunol</source><year>2007</year>;<volume>7</volume>:<fpage>255</fpage>&#x02013;<lpage>266</lpage>.<pub-id pub-id-type="pmid">17380156</pub-id>
</mixed-citation></ref><ref id="CIT0084"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crotti</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Sait</surname><given-names>HR</given-names></string-name>, <string-name><surname>McAvoy</surname><given-names>KM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>BIN1 favors the spreading of Tau via extracellular vesicles</article-title>. <source>Sci Rep</source><year>2019</year>;<volume>9</volume>:<fpage>9477</fpage>.<pub-id pub-id-type="pmid">31263146</pub-id>
</mixed-citation></ref><ref id="CIT0085"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cummings</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lee</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease drug development pipeline: 2023</article-title>. <source>Alzheimers Dement (N Y)</source><year>2023</year>;<volume>9</volume>:<fpage>e12385</fpage>.<pub-id pub-id-type="pmid">37251912</pub-id>
</mixed-citation></ref><ref id="CIT0086"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Czirr</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Castello</surname><given-names>NA</given-names></string-name>, <string-name><surname>Mosher</surname><given-names>KI</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Microglial complement receptor 3 regulates brain Abeta levels through secreted proteolytic activity</article-title>. <source>J Exp Med</source><year>2017</year>;<volume>214</volume>:<fpage>1081</fpage>&#x02013;<lpage>1092</lpage>.<pub-id pub-id-type="pmid">28298456</pub-id>
</mixed-citation></ref><ref id="CIT0087"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>D&#x02019;Onofrio</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Sancarlo</surname><given-names>D</given-names></string-name>, <string-name><surname>Panza</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neuropsychiatric symptoms and functional status in Alzheimer&#x02019;s disease and vascular dementia patients</article-title>. <source>Curr Alzheimer Res</source><year>2012</year>;<volume>9</volume>:<fpage>759</fpage>&#x02013;<lpage>771</lpage>.<pub-id pub-id-type="pmid">22715983</pub-id>
</mixed-citation></ref><ref id="CIT0088"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Da</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Hempel</surname><given-names>E</given-names></string-name>, <string-name><surname>Ou</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Noninvasive gamma sensory stimulation may reduce White matter and myelin loss in Alzheimer&#x02019;s Disease</article-title>. <source>J Alzheimers Dis</source><year>2024</year>;<volume>97</volume>:<fpage>359</fpage>&#x02013;<lpage>372</lpage>.<pub-id pub-id-type="pmid">38073386</pub-id>
</mixed-citation></ref><ref id="CIT0089"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dani</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Wood</surname><given-names>M</given-names></string-name>, <string-name><surname>Mizoguchi</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Microglial activation correlates <italic toggle="yes">in vivo</italic> with both tau and amyloid in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source><year>2018</year>;<volume>141</volume>:<fpage>2740</fpage>&#x02013;<lpage>2754</lpage>.<pub-id pub-id-type="pmid">30052812</pub-id>
</mixed-citation></ref><ref id="CIT0090"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dean</surname>
<given-names>DC</given-names>
<suffix>3rd</suffix>
</string-name>, <string-name><surname>Hurley</surname><given-names>SA</given-names></string-name>, <string-name><surname>Kecskemeti</surname><given-names>SR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of amyloid pathology with myelin alteration in preclinical Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2017</year>;<volume>74</volume>:<fpage>41</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">27842175</pub-id>
</mixed-citation></ref><ref id="CIT0091"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deane</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Sagare</surname><given-names>A</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain</article-title>. <source>J Clin Invest</source><year>2008</year>;<volume>118</volume>:<fpage>4002</fpage>&#x02013;<lpage>4013</lpage>.<pub-id pub-id-type="pmid">19033669</pub-id>
</mixed-citation></ref><ref id="CIT0092"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deczkowska</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Weiner</surname><given-names>A</given-names></string-name>, <string-name><surname>Amit</surname><given-names>I.</given-names></string-name></person-group>
<article-title>The physiology, pathology, and potential therapeutic applications of the TREM2 Signaling Pathway</article-title>. <source>Cell</source><year>2020</year>;<volume>181</volume>:<fpage>1207</fpage>&#x02013;<lpage>1217</lpage>.<pub-id pub-id-type="pmid">32531244</pub-id>
</mixed-citation></ref><ref id="CIT0093"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>DeMattos</surname>
<given-names>RB</given-names>
</string-name>, <string-name><surname>O&#x02019;Dell</surname><given-names>MA</given-names></string-name>, <string-name><surname>Parsadanian</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer&#x02019;s disease</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2002</year>;<volume>99</volume>:<fpage>10843</fpage>&#x02013;<lpage>10848</lpage>.<pub-id pub-id-type="pmid">12145324</pub-id>
</mixed-citation></ref><ref id="CIT0094"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deming</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Filipello</surname><given-names>F</given-names></string-name>, <string-name><surname>Cignarella</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer&#x02019;s disease risk</article-title>. <source>Sci Transl Med</source><year>2019</year>;<volume>11</volume>:<fpage>1</fpage>&#x02013;<lpage>18</lpage>.</mixed-citation></ref><ref id="CIT0095"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Depp</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Sun</surname><given-names>T</given-names></string-name>, <string-name><surname>Sasmita</surname><given-names>AO</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer&#x02019;s disease</article-title>. <source>Nature</source><year>2023</year>;<volume>618</volume>:<fpage>349</fpage>&#x02013;<lpage>357</lpage>.<pub-id pub-id-type="pmid">37258678</pub-id>
</mixed-citation></ref><ref id="CIT0096"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Desai</surname>
<given-names>MK</given-names>
</string-name>, <string-name><surname>Sudol</surname><given-names>KL</given-names></string-name>, <string-name><surname>Janelsins</surname><given-names>MC</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Triple-transgenic Alzheimer&#x02019;s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology</article-title>. <source>Glia</source><year>2009</year>;<volume>57</volume>:<fpage>54</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">18661556</pub-id>
</mixed-citation></ref><ref id="CIT0097"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>De Strooper</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Karran</surname><given-names>E.</given-names></string-name></person-group>
<article-title>The cellular phase of Alzheimer&#x02019;s disease</article-title>. <source>Cell</source><year>2016</year>;<volume>164</volume>:<fpage>603</fpage>&#x02013;<lpage>615</lpage>.<pub-id pub-id-type="pmid">26871627</pub-id>
</mixed-citation></ref><ref id="CIT0098"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>DeTure</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Dickson</surname><given-names>DW.</given-names></string-name></person-group>
<article-title>The neuropathological diagnosis of Alzheimer&#x02019;s disease</article-title>. <source>Mol Neurodegener</source><year>2019</year>;<volume>14</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">31375134</pub-id>
</mixed-citation></ref><ref id="CIT0099"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dileep</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Boix</surname><given-names>CA</given-names></string-name>, <string-name><surname>Mathys</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neuronal DNA double-strand breaks lead to genome structural variations and 3D genome disruption in neurodegeneration</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>4404</fpage>&#x02013;<lpage>4421.e20</lpage>.<pub-id pub-id-type="pmid">37774679</pub-id>
</mixed-citation></ref><ref id="CIT0101"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Doens</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Fernandez</surname><given-names>PL.</given-names></string-name></person-group>
<article-title>Microglia receptors and their implications in the response to amyloid beta for Alzheimer&#x02019;s disease pathogenesis</article-title>. <source>J Neuroinflammation</source><year>2014</year>;<volume>11</volume>:<fpage>48</fpage>.<pub-id pub-id-type="pmid">24625061</pub-id>
</mixed-citation></ref><ref id="CIT0102"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Domert</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Rao</surname><given-names>SB</given-names></string-name>, <string-name><surname>Agholme</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance</article-title>. <source>Neurobiol Dis</source><year>2014</year>;<volume>65</volume>:<fpage>82</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">24412310</pub-id>
</mixed-citation></ref><ref id="CIT0103"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dominy</surname>
<given-names>SS</given-names>
</string-name>, <string-name><surname>Lynch</surname><given-names>C</given-names></string-name>, <string-name><surname>Ermini</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Porphyromonas gingivalis in Alzheimer&#x02019;s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors</article-title>. <source>Sci Adv</source><year>2019</year>;<volume>5</volume>:<fpage>eaau3333</fpage>.<pub-id pub-id-type="pmid">30746447</pub-id>
</mixed-citation></ref><ref id="CIT0104"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dubois</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Lopez-Arrieta</surname><given-names>J</given-names></string-name>, <string-name><surname>Lipschitz</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<collab>AB09004 Study Group Investigators</collab>. <article-title>Correction: Masitinib for mild-to-moderate Alzheimer&#x02019;s disease: results from a randomized, placebo-controlled, phase 3, clinical trial</article-title>. <source>Alzheimers Res Ther</source><year>2023</year>;<volume>15</volume>:<fpage>85</fpage>.<pub-id pub-id-type="pmid">37087449</pub-id>
</mixed-citation></ref><ref id="CIT0105"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dyrks</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Weidemann</surname><given-names>A</given-names></string-name>, <string-name><surname>Multhaup</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer&#x02019;s disease</article-title>. <source>EMBO J</source><year>1988</year>;<volume>7</volume>:<fpage>949</fpage>&#x02013;<lpage>957</lpage>.<pub-id pub-id-type="pmid">2900137</pub-id>
</mixed-citation></ref><ref id="CIT0106"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eide</surname>
<given-names>PK</given-names>
</string-name>, <string-name><surname>Vinje</surname><given-names>V</given-names></string-name>, <string-name><surname>Pripp</surname><given-names>AH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Sleep deprivation impairs molecular clearance from the human brain</article-title>. <source>Brain</source><year>2021</year>;<volume>144</volume>:<fpage>863</fpage>&#x02013;<lpage>874</lpage>.<pub-id pub-id-type="pmid">33829232</pub-id>
</mixed-citation></ref><ref id="CIT0107"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eimer</surname>
<given-names>WA</given-names>
</string-name>, <string-name><surname>Vijaya Kumar</surname><given-names>DK</given-names></string-name>, <string-name><surname>Navalpur Shanmugam</surname><given-names>NK</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease-associated beta-amyloid is rapidly seeded by herpesviridae to protect against brain infection</article-title>. <source>Neuron</source><year>2018</year>;<volume>99</volume>:<fpage>56</fpage>&#x02013;<lpage>63.e3</lpage>.<pub-id pub-id-type="pmid">30001512</pub-id>
</mixed-citation></ref><ref id="CIT0108"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eisele</surname>
<given-names>YS</given-names>
</string-name>, <string-name><surname>Bolmont</surname><given-names>T</given-names></string-name>, <string-name><surname>Heikenwalder</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2009</year>;<volume>106</volume>:<fpage>12926</fpage>&#x02013;<lpage>12931</lpage>.<pub-id pub-id-type="pmid">19622727</pub-id>
</mixed-citation></ref><ref id="CIT0109"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eisele</surname>
<given-names>YS</given-names>
</string-name>, <string-name><surname>Obermuller</surname><given-names>U</given-names></string-name>, <string-name><surname>Heilbronner</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis</article-title>. <source>Science</source><year>2010</year>;<volume>330</volume>:<fpage>980</fpage>&#x02013;<lpage>982</lpage>.<pub-id pub-id-type="pmid">20966215</pub-id>
</mixed-citation></ref><ref id="CIT0110"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Elshourbagy</surname>
<given-names>NA</given-names>
</string-name>, <string-name><surname>Liao</surname><given-names>WS</given-names></string-name>, <string-name><surname>Mahley</surname><given-names>RW</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1985</year>;<volume>82</volume>:<fpage>203</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="pmid">3918303</pub-id>
</mixed-citation></ref><ref id="CIT0111"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Engelhart</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Geerlings</surname><given-names>MI</given-names></string-name>, <string-name><surname>Ruitenberg</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dietary intake of antioxidants and risk of Alzheimer disease</article-title>. <source>JAMA</source><year>2002</year>;<volume>287</volume>:<fpage>3223</fpage>&#x02013;<lpage>3229</lpage>.<pub-id pub-id-type="pmid">12076218</pub-id>
</mixed-citation></ref><ref id="CIT0112"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Esch</surname>
<given-names>FS</given-names>
</string-name>, <string-name><surname>Keim</surname><given-names>PS</given-names></string-name>, <string-name><surname>Beattie</surname><given-names>EC</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cleavage of amyloid beta peptide during constitutive processing of its precursor</article-title>. <source>Science</source><year>1990</year>;<volume>248</volume>:<fpage>1122</fpage>&#x02013;<lpage>1124</lpage>.<pub-id pub-id-type="pmid">2111583</pub-id>
</mixed-citation></ref><ref id="CIT0113"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Esiri</surname>
<given-names>MM</given-names>
</string-name>, <string-name><surname>Biddolph</surname><given-names>SC</given-names></string-name>, <string-name><surname>Morris</surname><given-names>CS.</given-names></string-name></person-group>
<article-title>Prevalence of Alzheimer plaques in AIDS</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>1998</year>;<volume>65</volume>:<fpage>29</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">9667557</pub-id>
</mixed-citation></ref><ref id="CIT0114"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eyting</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Xie</surname><given-names>M</given-names></string-name>, <string-name><surname>Hess</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Causal evidence that herpes zoster vaccination prevents a proportion of dementia cases</article-title>. <source>medRxiv</source><year>2023</year>.</mixed-citation></ref><ref id="CIT0115"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Falcon</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Murzin</surname><given-names>AG</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Structures of filaments from Pick&#x02019;s disease reveal a novel tau protein fold</article-title>. <source>Nature</source><year>2018a</year>;<volume>561</volume>:<fpage>137</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">30158706</pub-id>
</mixed-citation></ref><ref id="CIT0116"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Falcon</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Schweighauser</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x02019;s disease adopt a common fold</article-title>. <source>Acta Neuropathol</source><year>2018b</year>;<volume>136</volume>:<fpage>699</fpage>&#x02013;<lpage>708</lpage>.<pub-id pub-id-type="pmid">30276465</pub-id>
</mixed-citation></ref><ref id="CIT0117"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Falcon</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Zivanov</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules</article-title>. <source>Nature</source><year>2019</year>;<volume>568</volume>:<fpage>420</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">30894745</pub-id>
</mixed-citation></ref><ref id="CIT0118"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Faraco</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Brea</surname><given-names>D</given-names></string-name>, <string-name><surname>Garcia-Bonilla</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response</article-title>. <source>Nat Neurosci</source><year>2018</year>;<volume>21</volume>:<fpage>240</fpage>&#x02013;<lpage>249</lpage>.<pub-id pub-id-type="pmid">29335605</pub-id>
</mixed-citation></ref><ref id="CIT0119"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Faraco</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Hochrainer</surname><given-names>K</given-names></string-name>, <string-name><surname>Segarra</surname><given-names>SG</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dietary salt promotes cognitive impairment through tau phosphorylation</article-title>. <source>Nature</source><year>2019</year>;<volume>574</volume>:<fpage>686</fpage>&#x02013;<lpage>690</lpage>.<pub-id pub-id-type="pmid">31645758</pub-id>
</mixed-citation></ref><ref id="CIT0120"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Farrer</surname>
<given-names>LA</given-names>
</string-name>, <string-name><surname>Cupples</surname><given-names>LA</given-names></string-name>, <string-name><surname>Haines</surname><given-names>JL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium</article-title>. <source>JAMA</source><year>1997</year>;<volume>278</volume>:<fpage>1349</fpage>&#x02013;<lpage>1356</lpage>.<pub-id pub-id-type="pmid">9343467</pub-id>
</mixed-citation></ref><ref id="CIT0122"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Feuerbach</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Schindler</surname><given-names>P</given-names></string-name>, <string-name><surname>Barske</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157</article-title>. <source>Neurosci Lett</source><year>2017</year>;<volume>660</volume>:<fpage>109</fpage>&#x02013;<lpage>114</lpage>.<pub-id pub-id-type="pmid">28923481</pub-id>
</mixed-citation></ref><ref id="CIT0123"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fiandaca</surname>
<given-names>MS</given-names>
</string-name>, <string-name><surname>Kapogiannis</surname><given-names>D</given-names></string-name>, <string-name><surname>Mapstone</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Identification of preclinical Alzheimer&#x02019;s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study</article-title>. <source>Alzheimers Dement</source><year>2015</year>;<volume>11</volume>:<fpage>600</fpage>&#x02013;<lpage>607 e601</lpage>.<pub-id pub-id-type="pmid">25130657</pub-id>
</mixed-citation></ref><ref id="CIT0124"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fitzpatrick</surname>
<given-names>AWP</given-names>
</string-name>, <string-name><surname>Falcon</surname><given-names>B</given-names></string-name>, <string-name><surname>He</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cryo-EM structures of tau filaments from Alzheimer&#x02019;s disease</article-title>. <source>Nature</source><year>2017</year>;<volume>547</volume>:<fpage>185</fpage>&#x02013;<lpage>190</lpage>.<pub-id pub-id-type="pmid">28678775</pub-id>
</mixed-citation></ref><ref id="CIT0125"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Flach</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ramminger</surname><given-names>E</given-names></string-name>, <string-name><surname>Hilbrich</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein <italic toggle="yes">in vitro</italic> impairing microtubule binding</article-title>. <source>Biochim Biophys Acta</source><year>2014</year>;<volume>1842</volume>:<fpage>1527</fpage>&#x02013;<lpage>1538</lpage>.<pub-id pub-id-type="pmid">24905733</pub-id>
</mixed-citation></ref><ref id="CIT0126"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fleisher</surname>
<given-names>AS</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>K</given-names></string-name>, <string-name><surname>Quiroz</surname><given-names>YT</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer&#x02019;s disease kindred: a cross-sectional study</article-title>. <source>Lancet Neurol</source><year>2012</year>;<volume>11</volume>:<fpage>1057</fpage>&#x02013;<lpage>1065</lpage>.<pub-id pub-id-type="pmid">23137949</pub-id>
</mixed-citation></ref><ref id="CIT0127"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fleminger</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Oliver</surname><given-names>DL</given-names></string-name>, <string-name><surname>Lovestone</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Head injury as a risk factor for Alzheimer&#x02019;s disease: the evidence 10 years on; a partial replication</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2003</year>;<volume>74</volume>:<fpage>857</fpage>&#x02013;<lpage>862</lpage>.<pub-id pub-id-type="pmid">12810767</pub-id>
</mixed-citation></ref><ref id="CIT0128"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Franzmeier</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Rubinski</surname><given-names>A</given-names></string-name>, <string-name><surname>Neitzel</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory</article-title>. <source>Nat Commun</source><year>2019</year>;<volume>10</volume>:<fpage>1766</fpage>.<pub-id pub-id-type="pmid">30992433</pub-id>
</mixed-citation></ref><ref id="CIT0129"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fricker</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Tolkovsky</surname><given-names>AM</given-names></string-name>, <string-name><surname>Borutaite</surname><given-names>V</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neuronal cell death</article-title>. <source>Physiol Rev</source><year>2018</year>;<volume>98</volume>:<fpage>813</fpage>&#x02013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">29488822</pub-id>
</mixed-citation></ref><ref id="CIT0130"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fritschi</surname>
<given-names>SK</given-names>
</string-name>, <string-name><surname>Langer</surname><given-names>F</given-names></string-name>, <string-name><surname>Kaeser</surname><given-names>SA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal fluid</article-title>. <source>Brain</source><year>2014</year>;<volume>137</volume>:<fpage>2909</fpage>&#x02013;<lpage>2915</lpage>.<pub-id pub-id-type="pmid">25212850</pub-id>
</mixed-citation></ref><ref id="CIT0131"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Frost</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Jacks</surname><given-names>RL</given-names></string-name>, <string-name><surname>Diamond</surname><given-names>MI.</given-names></string-name></person-group>
<article-title>Propagation of tau misfolding from the outside to the inside of a cell</article-title>. <source>J Biol Chem</source><year>2009</year>;<volume>284</volume>:<fpage>12845</fpage>&#x02013;<lpage>12852</lpage>.<pub-id pub-id-type="pmid">19282288</pub-id>
</mixed-citation></ref><ref id="CIT0132"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fu</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name><surname>Frost</surname><given-names>JL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Abeta by microglia</article-title>. <source>Glia</source><year>2012</year>;<volume>60</volume>:<fpage>993</fpage>&#x02013;<lpage>1003</lpage>.<pub-id pub-id-type="pmid">22438044</pub-id>
</mixed-citation></ref><ref id="CIT0133"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Funk</surname>
<given-names>KE</given-names>
</string-name>, <string-name><surname>Thomas</surname><given-names>SN</given-names></string-name>, <string-name><surname>Schafer</surname><given-names>KN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity</article-title>. <source>Biochem J</source><year>2014</year>;<volume>462</volume>:<fpage>77</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">24869773</pub-id>
</mixed-citation></ref><ref id="CIT0134"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Furukawa</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Sopher</surname><given-names>BL</given-names></string-name>, <string-name><surname>Rydel</surname><given-names>RE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain</article-title>. <source>J Neurochem</source><year>1996</year>;<volume>67</volume>:<fpage>1882</fpage>&#x02013;<lpage>1896</lpage>.<pub-id pub-id-type="pmid">8863493</pub-id>
</mixed-citation></ref><ref id="CIT0135"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gaikwad</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Puangmalai</surname><given-names>N</given-names></string-name>, <string-name><surname>Bittar</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer&#x02019;s disease and frontotemporal dementia</article-title>. <source>Cell Rep</source><year>2021</year>;<volume>36</volume>:<fpage>109419</fpage>.<pub-id pub-id-type="pmid">34289368</pub-id>
</mixed-citation></ref><ref id="CIT0136"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Galasko</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Xiao</surname><given-names>M</given-names></string-name>, <string-name><surname>Xu</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement (N Y)</source><year>2019</year>;<volume>5</volume>:<fpage>871</fpage>&#x02013;<lpage>882</lpage>.<pub-id pub-id-type="pmid">31853477</pub-id>
</mixed-citation></ref><ref id="CIT0137"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Galvan</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Gorostiza</surname><given-names>OF</given-names></string-name>, <string-name><surname>Banwait</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Reversal of Alzheimer&#x02019;s-like pathology and behavior in human APP transgenic mice by mutation of Asp664</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2006</year>;<volume>103</volume>:<fpage>7130</fpage>&#x02013;<lpage>7135</lpage>.<pub-id pub-id-type="pmid">16641106</pub-id>
</mixed-citation></ref><ref id="CIT0138"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gamblin</surname>
<given-names>TC</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>F</given-names></string-name>, <string-name><surname>Zambrano</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer&#x02019;s disease</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2003</year>;<volume>100</volume>:<fpage>10032</fpage>&#x02013;<lpage>10037</lpage>.<pub-id pub-id-type="pmid">12888622</pub-id>
</mixed-citation></ref><ref id="CIT0139"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gao</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Hong</surname><given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>beta2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>1026</fpage>&#x02013;<lpage>1038.e20</lpage>.<pub-id pub-id-type="pmid">36868208</pub-id>
</mixed-citation></ref><ref id="CIT0140"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Garai</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Verghese</surname><given-names>PB</given-names></string-name>, <string-name><surname>Baban</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation</article-title>. <source>Biochemistry</source><year>2014</year>;<volume>53</volume>:<fpage>6323</fpage>&#x02013;<lpage>6331</lpage>.<pub-id pub-id-type="pmid">25207746</pub-id>
</mixed-citation></ref><ref id="CIT0141"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gatz</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Reynolds</surname><given-names>CA</given-names></string-name>, <string-name><surname>Fratiglioni</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Role of genes and environments for explaining Alzheimer disease</article-title>. <source>Arch Gen Psychiatry</source><year>2006</year>;<volume>63</volume>:<fpage>168</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">16461860</pub-id>
</mixed-citation></ref><ref id="CIT0142"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gauthier</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Feldman</surname><given-names>HH</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>LS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer&#x02019;s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial</article-title>. <source>Lancet</source><year>2016</year>;<volume>388</volume>:<fpage>2873</fpage>&#x02013;<lpage>2884</lpage>.<pub-id pub-id-type="pmid">27863809</pub-id>
</mixed-citation></ref><ref id="CIT0100"><mixed-citation publication-type="journal">
<collab>GBD 2015 Disease and Injury Incidence and Prevalence Collaborators</collab>. <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015</article-title>. <source>Lancet</source><year>2016</year>;<volume>388</volume>:<fpage>1545</fpage>&#x02013;<lpage>1602</lpage>.<pub-id pub-id-type="pmid">27733282</pub-id>
</mixed-citation></ref><ref id="CIT0121"><mixed-citation publication-type="journal">
<collab>GBD 2016 Lifetime Risk of Stroke Collaborators</collab>, <person-group person-group-type="author"><string-name><surname>Feigin</surname><given-names>VL</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>2429</fpage>&#x02013;<lpage>2437</lpage>.<pub-id pub-id-type="pmid">30575491</pub-id>
</mixed-citation></ref><ref id="CIT0074"><mixed-citation publication-type="journal">
<collab>GBD 2016 Stroke Collaborators</collab>. <article-title>Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Neurol</source><year>2021</year>;<volume>20</volume>:<fpage>795</fpage>&#x02013;<lpage>820</lpage>.<pub-id pub-id-type="pmid">34487721</pub-id>
</mixed-citation></ref><ref id="CIT0143"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Geiss-Friedlander</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Melchior</surname><given-names>F.</given-names></string-name></person-group>
<article-title>Concepts in sumoylation: a decade on</article-title>. <source>Nat Rev Mol Cell Biol</source><year>2007</year>;<volume>8</volume>:<fpage>947</fpage>&#x02013;<lpage>956</lpage>.<pub-id pub-id-type="pmid">18000527</pub-id>
</mixed-citation></ref><ref id="CIT0144"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Genin</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Hannequin</surname><given-names>D</given-names></string-name>, <string-name><surname>Wallon</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE and Alzheimer disease: a major gene with semi-dominant inheritance</article-title>. <source>Mol Psychiatry</source><year>2011</year>;<volume>16</volume>:<fpage>903</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">21556001</pub-id>
</mixed-citation></ref><ref id="CIT0145"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gentleman</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>Greenberg</surname><given-names>BD</given-names></string-name>, <string-name><surname>Savage</surname><given-names>MJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury</article-title>. <source>Neuroreport</source><year>1997</year>;<volume>8</volume>:<fpage>1519</fpage>&#x02013;<lpage>1522</lpage>.<pub-id pub-id-type="pmid">9172166</pub-id>
</mixed-citation></ref><ref id="CIT0146"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gerard</surname>
<given-names>HC</given-names>
</string-name>, <string-name><surname>Dreses-Werringloer</surname><given-names>U</given-names></string-name>, <string-name><surname>Wildt</surname><given-names>KS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>
<italic toggle="yes">Chlamydophila (Chlamydia) pneumoniae</italic> in the Alzheimer&#x02019;s brain</article-title>. <source>FEMS Immunol Med Microbiol</source><year>2006</year>;<volume>48</volume>:<fpage>355</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">17052268</pub-id>
</mixed-citation></ref><ref id="CIT0147"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gervais</surname>
<given-names>FG</given-names>
</string-name>, <string-name><surname>Xu</surname><given-names>D</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>GS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Involvement of caspases in proteolytic cleavage of Alzheimer&#x02019;s amyloid-beta precursor protein and amyloidogenic A beta peptide formation</article-title>. <source>Cell</source><year>1999</year>;<volume>97</volume>:<fpage>395</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">10319819</pub-id>
</mixed-citation></ref><ref id="CIT0148"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giannakopoulos</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Herrmann</surname><given-names>FR</given-names></string-name>, <string-name><surname>Bussiere</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x02019;s disease</article-title>. <source>Neurology</source><year>2003</year>;<volume>60</volume>:<fpage>1495</fpage>&#x02013;<lpage>1500</lpage>.<pub-id pub-id-type="pmid">12743238</pub-id>
</mixed-citation></ref><ref id="CIT0149"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gibbons</surname>
<given-names>GS</given-names>
</string-name>, <string-name><surname>Banks</surname><given-names>RA</given-names></string-name>, <string-name><surname>Kim</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>GFP-mutant human Tau transgenic mice develop tauopathy following CNS injections of Alzheimer&#x02019;s brain-derived pathological Tau or synthetic mutant human Tau Fibrils</article-title>. <source>J Neurosci</source><year>2017</year>;<volume>37</volume>:<fpage>11485</fpage>&#x02013;<lpage>11494</lpage>.<pub-id pub-id-type="pmid">28986461</pub-id>
</mixed-citation></ref><ref id="CIT0150"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gibbons</surname>
<given-names>GS</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>VMY</given-names></string-name>, <string-name><surname>Trojanowski</surname><given-names>JQ.</given-names></string-name></person-group>
<article-title>Mechanisms of cell-to-cell transmission of pathological Tau: a review</article-title>. <source>JAMA Neurol</source><year>2019</year>;<volume>76</volume>:<fpage>101</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">30193298</pub-id>
</mixed-citation></ref><ref id="CIT0151"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ginhoux</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Greter</surname><given-names>M</given-names></string-name>, <string-name><surname>Leboeuf</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Fate mapping analysis reveals that adult microglia derive from primitive macrophages</article-title>. <source>Science</source><year>2010</year>;<volume>330</volume>:<fpage>841</fpage>&#x02013;<lpage>845</lpage>.<pub-id pub-id-type="pmid">20966214</pub-id>
</mixed-citation></ref><ref id="CIT0152"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Glenner</surname>
<given-names>GG</given-names>
</string-name>, <string-name><surname>Wong</surname><given-names>CW.</given-names></string-name></person-group>
<article-title>Alzheimer&#x02019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</article-title>. <source>Biochem Biophys Res Commun</source><year>1984</year>;<volume>120</volume>:<fpage>885</fpage>&#x02013;<lpage>890</lpage>.<pub-id pub-id-type="pmid">6375662</pub-id>
</mixed-citation></ref><ref id="CIT0153"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Goedert</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Spillantini</surname><given-names>MG</given-names></string-name>, <string-name><surname>Jakes</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x02019;s disease</article-title>. <source>Neuron</source><year>1989</year>;<volume>3</volume>:<fpage>519</fpage>&#x02013;<lpage>526</lpage>.<pub-id pub-id-type="pmid">2484340</pub-id>
</mixed-citation></ref><ref id="CIT0154"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Goel</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Chakrabarti</surname><given-names>S</given-names></string-name>, <string-name><surname>Goel</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neuronal cell death mechanisms in Alzheimer&#x02019;s disease: an insight</article-title>. <source>Front Mol Neurosci</source><year>2022</year>;<volume>15</volume>:<fpage>937133</fpage>.<pub-id pub-id-type="pmid">36090249</pub-id>
</mixed-citation></ref><ref id="CIT0155"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gomez Perdiguero</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Klapproth</surname><given-names>K</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors</article-title>. <source>Nature</source><year>2015</year>;<volume>518</volume>:<fpage>547</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">25470051</pub-id>
</mixed-citation></ref><ref id="CIT0156"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gong</surname>
<given-names>CX</given-names>
</string-name>, <string-name><surname>Singh</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Grundke-Iqbal</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Phosphoprotein phosphatase activities in Alzheimer disease brain</article-title>. <source>J Neurochem</source><year>1993</year>;<volume>61</volume>:<fpage>921</fpage>&#x02013;<lpage>927</lpage>.<pub-id pub-id-type="pmid">8395566</pub-id>
</mixed-citation></ref><ref id="CIT0157"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gonzalez-Ortiz</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Turton</surname><given-names>M</given-names></string-name>, <string-name><surname>Kac</surname><given-names>PR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Brain-derived tau: a novel blood-based biomarker for Alzheimer&#x02019;s disease-type neurodegeneration</article-title>. <source>Brain</source><year>2023</year>;<volume>146</volume>:<fpage>1152</fpage>&#x02013;<lpage>1165</lpage>.<pub-id pub-id-type="pmid">36572122</pub-id>
</mixed-citation></ref><ref id="CIT0158"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grande</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Ljungman</surname><given-names>PLS</given-names></string-name>, <string-name><surname>Eneroth</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association between cardiovascular disease and long-term exposure to air pollution with the risk of dementia</article-title>. <source>JAMA Neurol</source><year>2020</year>;<volume>77</volume>:<fpage>801</fpage>&#x02013;<lpage>809</lpage>.<pub-id pub-id-type="pmid">32227140</pub-id>
</mixed-citation></ref><ref id="CIT0159"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gratuze</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Parhizkar</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Activated microglia mitigate Abeta-associated tau seeding and spreading</article-title>. <source>J Exp Med</source><year>2021</year>;<volume>218</volume>:<fpage>e20210542</fpage>.<pub-id pub-id-type="pmid">34100905</pub-id>
</mixed-citation></ref><ref id="CIT0160"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Green</surname>
<given-names>RC</given-names>
</string-name>, <string-name><surname>Cupples</surname><given-names>LA</given-names></string-name>, <string-name><surname>Kurz</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Depression as a risk factor for Alzheimer disease: the MIRAGE Study</article-title>. <source>Arch Neurol</source><year>2003</year>;<volume>60</volume>:<fpage>753</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">12756140</pub-id>
</mixed-citation></ref><ref id="CIT0161"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Greenberg</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>Bacskai</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Hernandez-Guillamon</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways</article-title>. <source>Nat Rev Neurol</source><year>2020</year>;<volume>16</volume>:<fpage>30</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">31827267</pub-id>
</mixed-citation></ref><ref id="CIT0162"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Griciuc</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Serrano-Pozo</surname><given-names>A</given-names></string-name>, <string-name><surname>Parrado</surname><given-names>AR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta</article-title>. <source>Neuron</source><year>2013</year>;<volume>78</volume>:<fpage>631</fpage>&#x02013;<lpage>643</lpage>.<pub-id pub-id-type="pmid">23623698</pub-id>
</mixed-citation></ref><ref id="CIT0163"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Griciuc</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Patel</surname><given-names>S</given-names></string-name>, <string-name><surname>Federico</surname><given-names>AN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer&#x02019;s disease</article-title>. <source>Neuron</source><year>2019</year>;<volume>103</volume>:<fpage>820</fpage>&#x02013;<lpage>835.e7</lpage>.<pub-id pub-id-type="pmid">31301936</pub-id>
</mixed-citation></ref><ref id="CIT0164"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grothe</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Barthel</surname><given-names>H</given-names></string-name>, <string-name><surname>Sepulcre</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>
<italic toggle="yes">In vivo</italic> staging of regional amyloid deposition</article-title>. <source>Neurology</source><year>2017a</year>;<volume>89</volume>:<fpage>2031</fpage>&#x02013;<lpage>2038</lpage>.<pub-id pub-id-type="pmid">29046362</pub-id>
</mixed-citation></ref><ref id="CIT0165"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grothe</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Villeneuve</surname><given-names>S</given-names></string-name>, <string-name><surname>Dyrba</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load</article-title>. <source>Neurology</source><year>2017b</year>;<volume>88</volume>:<fpage>569</fpage>&#x02013;<lpage>576</lpage>.<pub-id pub-id-type="pmid">28062720</pub-id>
</mixed-citation></ref><ref id="CIT0166"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gu</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Ou</surname><given-names>S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G.</given-names></string-name></person-group>
<article-title>Traumatic brain injury and risk of dementia and Alzheimer&#x02019;s disease: a systematic review and meta-analysis</article-title>. <source>Neuroepidemiology</source><year>2022</year>;<volume>56</volume>:<fpage>4</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">34818648</pub-id>
</mixed-citation></ref><ref id="CIT0167"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guerreiro</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Wojtas</surname><given-names>A</given-names></string-name>, <string-name><surname>Bras</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 variants in Alzheimer&#x02019;s disease</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>368</volume>:<fpage>117</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">23150934</pub-id>
</mixed-citation></ref><ref id="CIT0168"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guerrero</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>De Strooper</surname><given-names>B</given-names></string-name>, <string-name><surname>Arancibia-Carcamo</surname><given-names>IL.</given-names></string-name></person-group>
<article-title>Cellular senescence at the crossroads of inflammation and Alzheimer&#x02019;s disease</article-title>. <source>Trends Neurosci</source><year>2021</year>;<volume>44</volume>:<fpage>714</fpage>&#x02013;<lpage>727</lpage>.<pub-id pub-id-type="pmid">34366147</pub-id>
</mixed-citation></ref><ref id="CIT0169"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guo</surname>
<given-names>JP</given-names>
</string-name>, <string-name><surname>Arai</surname><given-names>T</given-names></string-name>, <string-name><surname>Miklossy</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer&#x02019;s disease</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2006</year>;<volume>103</volume>:<fpage>1953</fpage>&#x02013;<lpage>1958</lpage>.<pub-id pub-id-type="pmid">16446437</pub-id>
</mixed-citation></ref><ref id="CIT0170"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guo</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Noble</surname><given-names>W</given-names></string-name>, <string-name><surname>Hanger</surname><given-names>DP.</given-names></string-name></person-group>
<article-title>Roles of tau protein in health and disease</article-title>. <source>Acta Neuropathol</source><year>2017</year>;<volume>133</volume>:<fpage>665</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">28386764</pub-id>
</mixed-citation></ref><ref id="CIT0171"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guo</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#x02019;s disease</article-title>. <source>Mol Neurodegener</source><year>2020</year>;<volume>15</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">32677986</pub-id>
</mixed-citation></ref><ref id="CIT0172"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Haass</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Hung</surname><given-names>AY</given-names></string-name>, <string-name><surname>Schlossmacher</surname><given-names>MG</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms</article-title>. <source>J Biol Chem</source><year>1993</year>;<volume>268</volume>:<fpage>3021</fpage>&#x02013;<lpage>3024</lpage>.<pub-id pub-id-type="pmid">8428976</pub-id>
</mixed-citation></ref><ref id="CIT0173"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Habib</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>McCabe</surname><given-names>C</given-names></string-name>, <string-name><surname>Medina</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Disease-associated astrocytes in Alzheimer&#x02019;s disease and aging</article-title>. <source>Nat Neurosci</source><year>2020</year>;<volume>23</volume>:<fpage>701</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">32341542</pub-id>
</mixed-citation></ref><ref id="CIT0174"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hachinski</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Einhaupl</surname><given-names>K</given-names></string-name>, <string-name><surname>Ganten</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Preventing dementia by preventing stroke: The Berlin Manifesto</article-title>. <source>Alzheimers Dement</source><year>2019</year>;<volume>15</volume>:<fpage>961</fpage>&#x02013;<lpage>984</lpage>.<pub-id pub-id-type="pmid">31327392</pub-id>
</mixed-citation></ref><ref id="CIT0175"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hammond</surname>
<given-names>TR</given-names>
</string-name>, <string-name><surname>Marsh</surname><given-names>SE</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>B.</given-names></string-name></person-group>
<article-title>Immune signaling in neurodegeneration</article-title>. <source>Immunity</source><year>2019</year>;<volume>50</volume>:<fpage>955</fpage>&#x02013;<lpage>974</lpage>.<pub-id pub-id-type="pmid">30995509</pub-id>
</mixed-citation></ref><ref id="CIT0176"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Haney</surname>
<given-names>MS</given-names>
</string-name>, <string-name><surname>Palovics</surname><given-names>R</given-names></string-name>, <string-name><surname>Munson</surname><given-names>CN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE4/4 is linked to damaging lipid droplets in Alzheimer&#x02019;s disease microglia</article-title>. <source>Nature</source><year>2024</year>;<volume>628</volume>:<fpage>154</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">38480892</pub-id>
</mixed-citation></ref><ref id="CIT0177"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hanger</surname>
<given-names>DP</given-names>
</string-name>, <string-name><surname>Wray</surname><given-names>S.</given-names></string-name></person-group>
<article-title>Tau cleavage and tau aggregation in neurodegenerative disease</article-title>. <source>Biochem Soc Trans</source><year>2010</year>;<volume>38</volume>:<fpage>1016</fpage>&#x02013;<lpage>1020</lpage>.<pub-id pub-id-type="pmid">20658996</pub-id>
</mixed-citation></ref><ref id="CIT0178"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hardy</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Higgins</surname><given-names>GA.</given-names></string-name></person-group>
<article-title>Alzheimer&#x02019;s disease: the amyloid cascade hypothesis</article-title>. <source>Science</source><year>1992</year>;<volume>256</volume>:<fpage>184</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">1566067</pub-id>
</mixed-citation></ref><ref id="CIT0179"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Harold</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Abraham</surname><given-names>R</given-names></string-name>, <string-name><surname>Hollingworth</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x02019;s disease</article-title>. <source>Nat Genet</source><year>2009</year>;<volume>41</volume>:<fpage>1088</fpage>&#x02013;<lpage>1093</lpage>.<pub-id pub-id-type="pmid">19734902</pub-id>
</mixed-citation></ref><ref id="CIT0180"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Serrano-Pozo</surname><given-names>A</given-names></string-name>, <string-name><surname>Hori</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide</article-title>. <source>J Neurosci</source><year>2012</year>;<volume>32</volume>:<fpage>15181</fpage>&#x02013;<lpage>15192</lpage>.<pub-id pub-id-type="pmid">23100439</pub-id>
</mixed-citation></ref><ref id="CIT0181"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hayes</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Thaker</surname><given-names>U</given-names></string-name>, <string-name><surname>Iwatsubo</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer&#x02019;s disease</article-title>. <source>Neurosci Lett</source><year>2002</year>;<volume>331</volume>:<fpage>171</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">12383924</pub-id>
</mixed-citation></ref><ref id="CIT0182"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>He</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Guo</surname><given-names>JL</given-names></string-name>, <string-name><surname>McBride</surname><given-names>JD</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid-beta plaques enhance Alzheimer&#x02019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation</article-title>. <source>Nat Med</source><year>2018</year>;<volume>24</volume>:<fpage>29</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">29200205</pub-id>
</mixed-citation></ref><ref id="CIT0183"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Helboe</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Rosenqvist</surname><given-names>N</given-names></string-name>, <string-name><surname>Volbracht</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Highly specific and sensitive target binding by the humanized pS396-Tau antibody hC10.2 across a wide spectrum of Alzheimer&#x02019;s disease and primary tauopathy postmortem brains</article-title>. <source>J Alzheimers Dis</source><year>2022</year>;<volume>88</volume>:<fpage>207</fpage>&#x02013;<lpage>228</lpage>.<pub-id pub-id-type="pmid">35570492</pub-id>
</mixed-citation></ref><ref id="CIT0184"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</string-name>, <string-name><surname>Kummer</surname><given-names>MP</given-names></string-name>, <string-name><surname>Stutz</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>NLRP3 is activated in Alzheimer&#x02019;s disease and contributes to pathology in APP/PS1 mice</article-title>. <source>Nature</source><year>2013</year>;<volume>493</volume>:<fpage>674</fpage>&#x02013;<lpage>678</lpage>.<pub-id pub-id-type="pmid">23254930</pub-id>
</mixed-citation></ref><ref id="CIT0185"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</string-name>, <string-name><surname>Kummer</surname><given-names>MP</given-names></string-name>, <string-name><surname>Latz</surname><given-names>E.</given-names></string-name></person-group>
<article-title>Innate immune activation in neurodegenerative disease</article-title>. <source>Nat Rev Immunol</source><year>2014</year>;<volume>14</volume>:<fpage>463</fpage>&#x02013;<lpage>477</lpage>.<pub-id pub-id-type="pmid">24962261</pub-id>
</mixed-citation></ref><ref id="CIT0186"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ho</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Qin</surname><given-names>W</given-names></string-name>, <string-name><surname>Pompl</surname><given-names>PN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer&#x02019;s disease</article-title>. <source>FASEB J</source><year>2004</year>;<volume>18</volume>:<fpage>902</fpage>&#x02013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">15033922</pub-id>
</mixed-citation></ref><ref id="CIT0187"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hollingworth</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Harold</surname><given-names>D</given-names></string-name>, <string-name><surname>Sims</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x02019;s disease</article-title>. <source>Nat Genet</source><year>2011</year>;<volume>43</volume>:<fpage>429</fpage>&#x02013;<lpage>435</lpage>.<pub-id pub-id-type="pmid">21460840</pub-id>
</mixed-citation></ref><ref id="CIT0188"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Holmes</surname>
<given-names>BB</given-names>
</string-name>, <string-name><surname>DeVos</surname><given-names>SL</given-names></string-name>, <string-name><surname>Kfoury</surname><given-names>N</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2013</year>;<volume>110</volume>:<fpage>E3138</fpage>&#x02013;<lpage>E3147</lpage>.<pub-id pub-id-type="pmid">23898162</pub-id>
</mixed-citation></ref><ref id="CIT0189"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Holth</surname>
<given-names>JK</given-names>
</string-name>, <string-name><surname>Fritschi</surname><given-names>SK</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans</article-title>. <source>Science</source><year>2019</year>;<volume>363</volume>:<fpage>880</fpage>&#x02013;<lpage>884</lpage>.<pub-id pub-id-type="pmid">30679382</pub-id>
</mixed-citation></ref><ref id="CIT0190"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hong</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Beja-Glasser</surname><given-names>VF</given-names></string-name>, <string-name><surname>Nfonoyim</surname><given-names>BM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title>. <source>Science</source><year>2016</year>;<volume>352</volume>:<fpage>712</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">27033548</pub-id>
</mixed-citation></ref><ref id="CIT0191"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Horowitz</surname>
<given-names>PM</given-names>
</string-name>, <string-name><surname>Patterson</surname><given-names>KR</given-names></string-name>, <string-name><surname>Guillozet-Bongaarts</surname><given-names>AL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer&#x02019;s disease</article-title>. <source>J Neurosci</source><year>2004</year>;<volume>24</volume>:<fpage>7895</fpage>&#x02013;<lpage>7902</lpage>.<pub-id pub-id-type="pmid">15356202</pub-id>
</mixed-citation></ref><ref id="CIT0192"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Fryatt</surname><given-names>GL</given-names></string-name>, <string-name><surname>Ghorbani</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Replicative senescence dictates the emergence of disease-associated microglia and contributes to Abeta pathology</article-title>. <source>Cell Rep</source><year>2021</year>;<volume>35</volume>:<fpage>109228</fpage>.<pub-id pub-id-type="pmid">34107254</pub-id>
</mixed-citation></ref><ref id="CIT0193"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huse</surname>
<given-names>JT</given-names>
</string-name>, <string-name><surname>Pijak</surname><given-names>DS</given-names></string-name>, <string-name><surname>Leslie</surname><given-names>GJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer&#x02019;s disease beta-secretase</article-title>. <source>J Biol Chem</source><year>2000</year>;<volume>275</volume>:<fpage>33729</fpage>&#x02013;<lpage>33737</lpage>.<pub-id pub-id-type="pmid">10924510</pub-id>
</mixed-citation></ref><ref id="CIT0194"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huse</surname>
<given-names>JT</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>K</given-names></string-name>, <string-name><surname>Pijak</surname><given-names>DS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer&#x02019;s disease brain</article-title>. <source>J Biol Chem</source><year>2002</year>;<volume>277</volume>:<fpage>16278</fpage>&#x02013;<lpage>16284</lpage>.<pub-id pub-id-type="pmid">11847218</pub-id>
</mixed-citation></ref><ref id="CIT0195"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hussain</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Powell</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Howlett</surname><given-names>DR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site</article-title>. <source>Mol Cell Neurosci</source><year>2000</year>;<volume>16</volume>:<fpage>609</fpage>&#x02013;<lpage>619</lpage>.<pub-id pub-id-type="pmid">11083922</pub-id>
</mixed-citation></ref><ref id="CIT0196"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Iaccarino</surname>
<given-names>HF</given-names>
</string-name>, <string-name><surname>Singer</surname><given-names>AC</given-names></string-name>, <string-name><surname>Martorell</surname><given-names>AJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Gamma frequency entrainment attenuates amyloid load and modifies microglia</article-title>. <source>Nature</source><year>2016</year>;<volume>540</volume>:<fpage>230</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">27929004</pub-id>
</mixed-citation></ref><ref id="CIT0197"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Iaccarino</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Sala</surname><given-names>A</given-names></string-name>, <string-name><surname>Perani</surname><given-names>D</given-names></string-name></person-group>; <collab>Alzheimer's Disease Neuroimaging Initiative</collab>. <article-title>Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET</article-title>. <source>Ann Clin Transl Neurol</source><year>2019</year>;<volume>6</volume>:<fpage>1113</fpage>&#x02013;<lpage>1120</lpage>.<pub-id pub-id-type="pmid">31211176</pub-id>
</mixed-citation></ref><ref id="CIT0198"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Iannuzzi</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Irace</surname><given-names>G</given-names></string-name>, <string-name><surname>Sirangelo</surname><given-names>I.</given-names></string-name></person-group>
<article-title>The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity</article-title>. <source>Molecules</source><year>2015</year>;<volume>20</volume>:<fpage>2510</fpage>&#x02013;<lpage>2528</lpage>.<pub-id pub-id-type="pmid">25648594</pub-id>
</mixed-citation></ref><ref id="CIT0199"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Iliff</surname>
<given-names>JJ</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Liao</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta</article-title>. <source>Sci Transl Med</source><year>2012</year>;<volume>4</volume>:<fpage>147ra</fpage>&#x02013;<lpage>14111</lpage>.</mixed-citation></ref><ref id="CIT0200"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ising</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Venegas</surname><given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>NLRP3 inflammasome activation drives tau pathology</article-title>. <source>Nature</source><year>2019</year>;<volume>575</volume>:<fpage>669</fpage>&#x02013;<lpage>673</lpage>.<pub-id pub-id-type="pmid">31748742</pub-id>
</mixed-citation></ref><ref id="CIT0201"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Itzhaki</surname>
<given-names>RF</given-names>
</string-name>, <string-name><surname>Lin</surname><given-names>WR</given-names></string-name>, <string-name><surname>Shang</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Herpes simplex virus type 1 in brain and risk of Alzheimer&#x02019;s disease</article-title>. <source>Lancet</source><year>1997</year>;<volume>349</volume>:<fpage>241</fpage>&#x02013;<lpage>244</lpage>.<pub-id pub-id-type="pmid">9014911</pub-id>
</mixed-citation></ref><ref id="CIT0202"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Itzhaki</surname>
<given-names>RF</given-names>
</string-name>, <string-name><surname>Golde</surname><given-names>TE</given-names></string-name>, <string-name><surname>Heneka</surname><given-names>MT</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Do infections have a role in the pathogenesis of Alzheimer disease</article-title>? <source>Nat Rev Neurol</source><year>2020</year>;<volume>16</volume>:<fpage>193</fpage>&#x02013;<lpage>197</lpage>.<pub-id pub-id-type="pmid">32152461</pub-id>
</mixed-citation></ref><ref id="CIT0203"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Iwashyna</surname>
<given-names>TJ</given-names>
</string-name>, <string-name><surname>Ely</surname><given-names>EW</given-names></string-name>, <string-name><surname>Smith</surname><given-names>DM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Long-term cognitive impairment and functional disability among survivors of severe sepsis</article-title>. <source>JAMA</source><year>2010</year>;<volume>304</volume>:<fpage>1787</fpage>&#x02013;<lpage>1794</lpage>.<pub-id pub-id-type="pmid">20978258</pub-id>
</mixed-citation></ref><ref id="CIT0204"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name><surname>Jagust</surname><given-names>WJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Hypothetical model of dynamic biomarkers of the Alzheimer&#x02019;s pathological cascade</article-title>. <source>Lancet Neurol</source><year>2010</year>;<volume>9</volume>:<fpage>119</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">20083042</pub-id>
</mixed-citation></ref><ref id="CIT0205"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name><surname>Blennow</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>NIA-AA research framework: toward a biological definition of Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source><year>2018</year>;<volume>14</volume>:<fpage>535</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">29653606</pub-id>
</mixed-citation></ref><ref id="CIT0206"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>James</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Harfouche</surname><given-names>M</given-names></string-name>, <string-name><surname>Welton</surname><given-names>NJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Herpes simplex virus: global infection prevalence and incidence estimates, 2016</article-title>. <source>Bull World Health Organ</source><year>2020</year>;<volume>98</volume>:<fpage>315</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">32514197</pub-id>
</mixed-citation></ref><ref id="CIT0207"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jamieson</surname>
<given-names>GA</given-names>
</string-name>, <string-name><surname>Maitland</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Wilcock</surname><given-names>GK</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Latent herpes simplex virus type 1 in normal and Alzheimer&#x02019;s disease brains</article-title>. <source>J Med Virol</source><year>1991</year>;<volume>33</volume>:<fpage>224</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">1649907</pub-id>
</mixed-citation></ref><ref id="CIT0208"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Christian</surname><given-names>BT</given-names></string-name>, <string-name><surname>Price</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Detection of brain Tau pathology in down syndrome using plasma biomarkers</article-title>. <source>JAMA Neurol</source><year>2022</year>;<volume>79</volume>:<fpage>797</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">35789365</pub-id>
</mixed-citation></ref><ref id="CIT0209"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Bali</surname><given-names>D</given-names></string-name>, <string-name><surname>Ashton</surname><given-names>NJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer&#x02019;s disease</article-title>. <source>Brain</source><year>2023</year>;<volume>146</volume>:<fpage>1592</fpage>&#x02013;<lpage>1601</lpage>.<pub-id pub-id-type="pmid">36087307</pub-id>
</mixed-citation></ref><ref id="CIT0210"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jansen</surname>
<given-names>IE</given-names>
</string-name>, <string-name><surname>Savage</surname><given-names>JE</given-names></string-name>, <string-name><surname>Watanabe</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x02019;s disease risk</article-title>. <source>Nat Genet</source><year>2019</year>;<volume>51</volume>:<fpage>404</fpage>&#x02013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">30617256</pub-id>
</mixed-citation></ref><ref id="CIT0211"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jia</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Qiu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid</article-title>. <source>Alzheimers Dement</source><year>2019</year>;<volume>15</volume>:<fpage>1071</fpage>&#x02013;<lpage>1080</lpage>.<pub-id pub-id-type="pmid">31422798</pub-id>
</mixed-citation></ref><ref id="CIT0212"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jiang</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>CY</given-names></string-name>, <string-name><surname>Mandrekar</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>ApoE promotes the proteolytic degradation of Abeta</article-title>. <source>Neuron</source><year>2008</year>;<volume>58</volume>:<fpage>681</fpage>&#x02013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">18549781</pub-id>
</mixed-citation></ref><ref id="CIT0213"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jiang</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Tan</surname><given-names>L</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A rare coding variant in TREM2 increases risk for Alzheimer&#x02019;s disease in Han Chinese</article-title>. <source>Neurobiol Aging</source><year>2016</year>;<volume>42</volume>:<fpage>217.e1</fpage>&#x02013;<lpage>217.e3</lpage>.</mixed-citation></ref><ref id="CIT0214"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jin</surname>
<given-names>SC</given-names>
</string-name>, <string-name><surname>Benitez</surname><given-names>BA</given-names></string-name>, <string-name><surname>Karch</surname><given-names>CM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Coding variants in TREM2 increase risk for Alzheimer&#x02019;s disease</article-title>. <source>Hum Mol Genet</source><year>2014</year>;<volume>23</volume>:<fpage>5838</fpage>&#x02013;<lpage>5846</lpage>.<pub-id pub-id-type="pmid">24899047</pub-id>
</mixed-citation></ref><ref id="CIT0215"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jiwaji</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Tiwari</surname><given-names>SS</given-names></string-name>, <string-name><surname>Aviles-Reyes</surname><given-names>RX</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Ass pathology</article-title>. <source>Nat Commun</source><year>2022</year>;<volume>13</volume>:<fpage>135</fpage>.<pub-id pub-id-type="pmid">35013236</pub-id>
</mixed-citation></ref><ref id="CIT0216"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jones</surname>
<given-names>SE</given-names>
</string-name>, <string-name><surname>Jomary</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Clusterin</article-title>. <source>Int J Biochem Cell Biol</source><year>2002</year>;<volume>34</volume>:<fpage>427</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">11906815</pub-id>
</mixed-citation></ref><ref id="CIT0217"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jonsson</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Stefansson</surname><given-names>H</given-names></string-name>, <string-name><surname>Steinberg</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Variant of TREM2 associated with the risk of Alzheimer&#x02019;s disease</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>368</volume>:<fpage>107</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">23150908</pub-id>
</mixed-citation></ref><ref id="CIT0218"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ju</surname>
<given-names>YE</given-names>
</string-name>, <string-name><surname>McLeland</surname><given-names>JS</given-names></string-name>, <string-name><surname>Toedebusch</surname><given-names>CD</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Sleep quality and preclinical Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2013</year>;<volume>70</volume>:<fpage>587</fpage>&#x02013;<lpage>593</lpage>.<pub-id pub-id-type="pmid">23479184</pub-id>
</mixed-citation></ref><ref id="CIT0219"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ju</surname>
<given-names>YS</given-names>
</string-name>, <string-name><surname>Ooms</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Sutphen</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels</article-title>. <source>Brain</source><year>2017</year>;<volume>140</volume>:<fpage>2104</fpage>&#x02013;<lpage>2111</lpage>.<pub-id pub-id-type="pmid">28899014</pub-id>
</mixed-citation></ref><ref id="CIT0220"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jucker</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Walker</surname><given-names>LC.</given-names></string-name></person-group>
<article-title>Alzheimer&#x02019;s disease: from immunotherapy to immunoprevention</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>4260</fpage>&#x02013;<lpage>4270</lpage>.<pub-id pub-id-type="pmid">37729908</pub-id>
</mixed-citation></ref><ref id="CIT0221"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jung</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Damoiseaux</surname><given-names>JS.</given-names></string-name></person-group>
<article-title>The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer&#x02019;s disease</article-title>. <source>Brain</source><year>2024</year>;<volume>147</volume>:<fpage>12</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">37540027</pub-id>
</mixed-citation></ref><ref id="CIT0222"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jurk</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Miwa</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response</article-title>. <source>Aging Cell</source><year>2012</year>;<volume>11</volume>:<fpage>996</fpage>&#x02013;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">22882466</pub-id>
</mixed-citation></ref><ref id="CIT0223"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kadavath</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Cabrales Fontela</surname><given-names>Y</given-names></string-name>, <string-name><surname>Jaremko</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The binding mode of a Tau peptide with tubulin</article-title>. <source>Angew Chem Int Ed Engl</source><year>2018</year>;<volume>57</volume>:<fpage>3246</fpage>&#x02013;<lpage>3250</lpage>.<pub-id pub-id-type="pmid">29314492</pub-id>
</mixed-citation></ref><ref id="CIT0224"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kamah</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Huvent</surname><given-names>I</given-names></string-name>, <string-name><surname>Cantrelle</surname><given-names>FX</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein</article-title>. <source>Biochemistry</source><year>2014</year>;<volume>53</volume>:<fpage>3020</fpage>&#x02013;<lpage>3032</lpage>.<pub-id pub-id-type="pmid">24708343</pub-id>
</mixed-citation></ref><ref id="CIT0225"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kang</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Lemaire</surname><given-names>HG</given-names></string-name>, <string-name><surname>Unterbeck</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The precursor of Alzheimer&#x02019;s disease amyloid A4 protein resembles a cell-surface receptor</article-title>. <source>Nature</source><year>1987</year>;<volume>325</volume>:<fpage>733</fpage>&#x02013;<lpage>736</lpage>.<pub-id pub-id-type="pmid">2881207</pub-id>
</mixed-citation></ref><ref id="CIT0226"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kang</surname>
<given-names>JE</given-names>
</string-name>, <string-name><surname>Lim</surname><given-names>MM</given-names></string-name>, <string-name><surname>Bateman</surname><given-names>RJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle</article-title>. <source>Science</source><year>2009</year>;<volume>326</volume>:<fpage>1005</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">19779148</pub-id>
</mixed-citation></ref><ref id="CIT0227"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kanmert</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Cantlon</surname><given-names>A</given-names></string-name>, <string-name><surname>Muratore</surname><given-names>CR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>C-terminally truncated forms of Tau, but not full-length Tau or its C-terminal fragments, are released from neurons independently of cell death</article-title>. <source>J Neurosci</source><year>2015</year>;<volume>35</volume>:<fpage>10851</fpage>&#x02013;<lpage>10865</lpage>.<pub-id pub-id-type="pmid">26224867</pub-id>
</mixed-citation></ref><ref id="CIT0228"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Karantali</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Kazis</surname><given-names>D</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neurofilament light chain in patients with a concussion or head impacts: a systematic review and meta-analysis</article-title>. <source>Eur J Trauma Emerg Surg</source><year>2022</year>;<volume>48</volume>:<fpage>1555</fpage>&#x02013;<lpage>1567</lpage>.<pub-id pub-id-type="pmid">34003313</pub-id>
</mixed-citation></ref><ref id="CIT0229"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Karch</surname>
<given-names>CM</given-names>
</string-name>, <string-name><surname>Goate</surname><given-names>AM.</given-names></string-name></person-group>
<article-title>Alzheimer&#x02019;s disease risk genes and mechanisms of disease pathogenesis</article-title>. <source>Biol Psychiatry</source><year>2015</year>;<volume>77</volume>:<fpage>43</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24951455</pub-id>
</mixed-citation></ref><ref id="CIT0230"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Karch</surname>
<given-names>CM</given-names>
</string-name>, <string-name><surname>Jeng</surname><given-names>AT</given-names></string-name>, <string-name><surname>Nowotny</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Expression of novel Alzheimer&#x02019;s disease risk genes in control and Alzheimer&#x02019;s disease brains</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>e50976</fpage>.<pub-id pub-id-type="pmid">23226438</pub-id>
</mixed-citation></ref><ref id="CIT0231"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kenigsbuch</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Bost</surname><given-names>P</given-names></string-name>, <string-name><surname>Halevi</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A shared disease-associated oligodendrocyte signature among multiple CNS pathologies</article-title>. <source>Nat Neurosci</source><year>2022</year>;<volume>25</volume>:<fpage>876</fpage>&#x02013;<lpage>886</lpage>.<pub-id pub-id-type="pmid">35760863</pub-id>
</mixed-citation></ref><ref id="CIT0232"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Keren-Shaul</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Spinrad</surname><given-names>A</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A unique microglia type associated with restricting development of Alzheimer&#x02019;s disease</article-title>. <source>Cell</source><year>2017</year>;<volume>169</volume>:<fpage>1276</fpage>&#x02013;<lpage>1290.e17</lpage>.<pub-id pub-id-type="pmid">28602351</pub-id>
</mixed-citation></ref><ref id="CIT0233"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kidd</surname>
<given-names>M.</given-names>
</string-name>
</person-group>
<article-title>Paired helical filaments in electron microscopy of Alzheimer&#x02019;s disease</article-title>. <source>Nature</source><year>1963</year>;<volume>197</volume>:<fpage>192</fpage>&#x02013;<lpage>193</lpage>.</mixed-citation></ref><ref id="CIT0234"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kierdorf</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Erny</surname><given-names>D</given-names></string-name>, <string-name><surname>Goldmann</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways</article-title>. <source>Nat Neurosci</source><year>2013</year>;<volume>16</volume>:<fpage>273</fpage>&#x02013;<lpage>280</lpage>.<pub-id pub-id-type="pmid">23334579</pub-id>
</mixed-citation></ref><ref id="CIT0235"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kimberly</surname>
<given-names>WT</given-names>
</string-name>, <string-name><surname>LaVoie</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ostaszewski</surname><given-names>BL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2003</year>;<volume>100</volume>:<fpage>6382</fpage>&#x02013;<lpage>6387</lpage>.<pub-id pub-id-type="pmid">12740439</pub-id>
</mixed-citation></ref><ref id="CIT0236"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kimura</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Ono</surname><given-names>T</given-names></string-name>, <string-name><surname>Takamatsu</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments</article-title>. <source>Dementia</source><year>1996</year>;<volume>7</volume>:<fpage>177</fpage>&#x02013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">8835879</pub-id>
</mixed-citation></ref><ref id="CIT0237"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kisler</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Nelson</surname><given-names>AR</given-names></string-name>, <string-name><surname>Montagne</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease</article-title>. <source>Nat Rev Neurosci</source><year>2017</year>;<volume>18</volume>:<fpage>419</fpage>&#x02013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">28515434</pub-id>
</mixed-citation></ref><ref id="CIT0238"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Knight</surname>
<given-names>EM</given-names>
</string-name>, <string-name><surname>Martins</surname><given-names>IV</given-names></string-name>, <string-name><surname>Gumusgoz</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>High-fat diet-induced memory impairment in triple-transgenic Alzheimer&#x02019;s disease (3xTgAD) mice is independent of changes in amyloid and tau pathology</article-title>. <source>Neurobiol Aging</source><year>2014</year>;<volume>35</volume>:<fpage>1821</fpage>&#x02013;<lpage>1832</lpage>.<pub-id pub-id-type="pmid">24630364</pub-id>
</mixed-citation></ref><ref id="CIT0239"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</string-name>, <string-name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Lundt</surname><given-names>ES</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum</article-title>. <source>Neurobiol Aging</source><year>2016</year>;<volume>46</volume>:<fpage>32</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">27460147</pub-id>
</mixed-citation></ref><ref id="CIT0240"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</string-name>, <string-name><surname>Amieva</surname><given-names>H</given-names></string-name>, <string-name><surname>Petersen</surname><given-names>RC</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer disease</article-title>. <source>Nat Rev Dis Primers</source><year>2021</year>;<volume>7</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">33986301</pub-id>
</mixed-citation></ref><ref id="CIT0241"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Koffie</surname>
<given-names>RM</given-names>
</string-name>, <string-name><surname>Hashimoto</surname><given-names>T</given-names></string-name>, <string-name><surname>Tai</surname><given-names>HC</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E4 effects in Alzheimer&#x02019;s disease are mediated by synaptotoxic oligomeric amyloid-beta</article-title>. <source>Brain</source><year>2012</year>;<volume>135</volume>:<fpage>2155</fpage>&#x02013;<lpage>2168</lpage>.<pub-id pub-id-type="pmid">22637583</pub-id>
</mixed-citation></ref><ref id="CIT0242"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kok</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Haikonen</surname><given-names>S</given-names></string-name>, <string-name><surname>Luoto</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age</article-title>. <source>Ann Neurol</source><year>2009</year>;<volume>65</volume>:<fpage>650</fpage>&#x02013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">19557866</pub-id>
</mixed-citation></ref><ref id="CIT0243"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kole</surname>
<given-names>AJ</given-names>
</string-name>, <string-name><surname>Annis</surname><given-names>RP</given-names></string-name>, <string-name><surname>Deshmukh</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Mature neurons: equipped for survival</article-title>. <source>Cell Death Dis</source><year>2013</year>;<volume>4</volume>:<fpage>e689</fpage>.<pub-id pub-id-type="pmid">23807218</pub-id>
</mixed-citation></ref><ref id="CIT0244"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kountouras</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Tsolaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Gavalas</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Relationship between Helicobacter pylori infection and Alzheimer disease</article-title>. <source>Neurology</source><year>2006</year>;<volume>66</volume>:<fpage>938</fpage>&#x02013;<lpage>940</lpage>.<pub-id pub-id-type="pmid">16567719</pub-id>
</mixed-citation></ref><ref id="CIT0245"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kraft</surname>
<given-names>AW</given-names>
</string-name>, <string-name><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice</article-title>. <source>FASEB J</source><year>2013</year>;<volume>27</volume>:<fpage>187</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">23038755</pub-id>
</mixed-citation></ref><ref id="CIT0246"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kumari</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Dhapola</surname><given-names>R</given-names></string-name>, <string-name><surname>Reddy</surname><given-names>DH.</given-names></string-name></person-group>
<article-title>Apoptosis in Alzheimer&#x02019;s disease: insight into the signaling pathways and therapeutic avenues</article-title>. <source>Apoptosis</source><year>2023</year>;<volume>28</volume>:<fpage>943</fpage>&#x02013;<lpage>957</lpage>.<pub-id pub-id-type="pmid">37186274</pub-id>
</mixed-citation></ref><ref id="CIT0247"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kyalu Ngoie Zola</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Balty</surname><given-names>C</given-names></string-name>, <string-name><surname>Pyr Dit Ruys</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Specific post-translational modifications of soluble tau protein distinguishes Alzheimer&#x02019;s disease and primary tauopathies</article-title>. <source>Nat Commun</source><year>2023</year>;<volume>14</volume>:<fpage>3706</fpage>.<pub-id pub-id-type="pmid">37349319</pub-id>
</mixed-citation></ref><ref id="CIT0248"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Laing</surname>
<given-names>KK</given-names>
</string-name>, <string-name><surname>Simoes</surname><given-names>S</given-names></string-name>, <string-name><surname>Baena-Caldas</surname><given-names>GP</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebrovascular disease promotes tau pathology in Alzheimer&#x02019;s disease</article-title>. <source>Brain Commun</source><year>2020</year>;<volume>2</volume>:<fpage>fcaa132</fpage>.<pub-id pub-id-type="pmid">33215083</pub-id>
</mixed-citation></ref><ref id="CIT0249"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lambert</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Heath</surname><given-names>S</given-names></string-name>, <string-name><surname>Even</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x02019;s disease</article-title>. <source>Nat Genet</source><year>2009</year>;<volume>41</volume>:<fpage>1094</fpage>&#x02013;<lpage>1099</lpage>.<pub-id pub-id-type="pmid">19734903</pub-id>
</mixed-citation></ref><ref id="CIT0250"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lambert</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Ibrahim-Verbaas</surname><given-names>CA</given-names></string-name>, <string-name><surname>Harold</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x02019;s disease</article-title>. <source>Nat Genet</source><year>2013</year>;<volume>45</volume>:<fpage>1452</fpage>&#x02013;<lpage>1458</lpage>.<pub-id pub-id-type="pmid">24162737</pub-id>
</mixed-citation></ref><ref id="CIT0251"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>, <string-name><surname>Yang</surname><given-names>DS</given-names></string-name>, <string-name><surname>Goulbourne</surname><given-names>CN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Faulty autolysosome acidification in Alzheimer&#x02019;s disease mouse models induces autophagic build-up of Abeta in neurons, yielding senile plaques</article-title>. <source>Nat Neurosci</source><year>2022</year>;<volume>25</volume>:<fpage>688</fpage>&#x02013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">35654956</pub-id>
</mixed-citation></ref><ref id="CIT0252"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Le Guen</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Belloy</surname><given-names>ME</given-names></string-name>, <string-name><surname>Grenier-Boley</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2022</year>;<volume>79</volume>:<fpage>652</fpage>&#x02013;<lpage>663</lpage>.<pub-id pub-id-type="pmid">35639372</pub-id>
</mixed-citation></ref><ref id="CIT0253"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lei</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Ayton</surname><given-names>S</given-names></string-name>, <string-name><surname>Finkelstein</surname><given-names>DI</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export</article-title>. <source>Nat Med</source><year>2012</year>;<volume>18</volume>:<fpage>291</fpage>&#x02013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">22286308</pub-id>
</mixed-citation></ref><ref id="CIT0254"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leng</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Edison</surname><given-names>P.</given-names></string-name></person-group>
<article-title>Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here</article-title>? <source>Nat Rev Neurol</source><year>2021</year>;<volume>17</volume>:<fpage>157</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">33318676</pub-id>
</mixed-citation></ref><ref id="CIT0255"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leng</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Knutson</surname><given-names>K</given-names></string-name>, <string-name><surname>Carnethon</surname><given-names>MR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association between sleep quantity and quality in early adulthood with cognitive function in midlife</article-title>. <source>Neurology</source><year>2024</year>;<volume>102</volume>:<fpage>e208056</fpage>.<pub-id pub-id-type="pmid">38170947</pub-id>
</mixed-citation></ref><ref id="CIT0256"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leuzy</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Mattsson-Carlgren</surname><given-names>N</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer&#x02019;s disease in the context of a structured 5-phase development framework</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2021</year>;<volume>48</volume>:<fpage>2121</fpage>&#x02013;<lpage>2139</lpage>.<pub-id pub-id-type="pmid">33674895</pub-id>
</mixed-citation></ref><ref id="CIT0257"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leverenz</surname>
<given-names>JB</given-names>
</string-name>, <string-name><surname>Raskind</surname><given-names>MA.</given-names></string-name></person-group>
<article-title>Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis</article-title>. <source>Exp Neurol</source><year>1998</year>;<volume>150</volume>:<fpage>296</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">9527899</pub-id>
</mixed-citation></ref><ref id="CIT0258"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Levy-Lahad</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Wasco</surname><given-names>W</given-names></string-name>, <string-name><surname>Poorkaj</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Candidate gene for the chromosome 1 familial Alzheimer&#x02019;s disease locus</article-title>. <source>Science</source><year>1995</year>;<volume>269</volume>:<fpage>973</fpage>&#x02013;<lpage>977</lpage>.<pub-id pub-id-type="pmid">7638622</pub-id>
</mixed-citation></ref><ref id="CIT0259"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lewczuk</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Matzen</surname><given-names>A</given-names></string-name>, <string-name><surname>Blennow</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer&#x02019;s disease</article-title>. <source>J Alzheimers Dis</source><year>2017</year>;<volume>55</volume>:<fpage>813</fpage>&#x02013;<lpage>822</lpage>.<pub-id pub-id-type="pmid">27792012</pub-id>
</mixed-citation></ref><ref id="CIT0260"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leyns</surname>
<given-names>CEG</given-names>
</string-name>, <string-name><surname>Ulrich</surname><given-names>JD</given-names></string-name>, <string-name><surname>Finn</surname><given-names>MB</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2017</year>;<volume>114</volume>:<fpage>11524</fpage>&#x02013;<lpage>11529</lpage>.<pub-id pub-id-type="pmid">29073081</pub-id>
</mixed-citation></ref><ref id="CIT0261"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name><surname>Bollinger</surname><given-names>JG</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Validation of plasma amyloid-beta 42/40 for detecting Alzheimer disease amyloid plaques</article-title>. <source>Neurology</source><year>2022</year>;<volume>98</volume>:<fpage>e688</fpage>&#x02013;<lpage>e699</lpage>.<pub-id pub-id-type="pmid">34906975</pub-id>
</mixed-citation></ref><ref id="CIT0262"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liddelow</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Guttenplan</surname><given-names>KA</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>LE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title>. <source>Nature</source><year>2017</year>;<volume>541</volume>:<fpage>481</fpage>&#x02013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">28099414</pub-id>
</mixed-citation></ref><ref id="CIT0263"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Likeman</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Anderson</surname><given-names>VM</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>JM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias</article-title>. <source>Arch Neurol</source><year>2005</year>;<volume>62</volume>:<fpage>1410</fpage>&#x02013;<lpage>1415</lpage>.<pub-id pub-id-type="pmid">16157748</pub-id>
</mixed-citation></ref><ref id="CIT0264"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lim</surname>
<given-names>YY</given-names>
</string-name>, <string-name><surname>Mormino</surname><given-names>EC</given-names></string-name></person-group>; <collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab>. <article-title><italic toggle="yes">APOE</italic> genotype and early beta-amyloid accumulation in older adults without dementia</article-title>. <source>Neurology</source><year>2017</year>;<volume>89</volume>:<fpage>1028</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">28794245</pub-id>
</mixed-citation></ref><ref id="CIT0265"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lin</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Koelsch</surname><given-names>G</given-names></string-name>, <string-name><surname>Wu</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2000</year>;<volume>97</volume>:<fpage>1456</fpage>&#x02013;<lpage>1460</lpage>.<pub-id pub-id-type="pmid">10677483</pub-id>
</mixed-citation></ref><ref id="CIT0266"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Linard</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Letenneur</surname><given-names>L</given-names></string-name>, <string-name><surname>Garrigue</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source><year>2020</year>;<volume>16</volume>:<fpage>200</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">31914220</pub-id>
</mixed-citation></ref><ref id="CIT0267"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Litvinchuk</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Wan</surname><given-names>YW</given-names></string-name>, <string-name><surname>Swartzlander</surname><given-names>DB</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Complement C3aR inactivation attenuates Tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer&#x02019;s disease</article-title>. <source>Neuron</source><year>2018</year>;<volume>100</volume>:<fpage>1337</fpage>&#x02013;<lpage>1353.e5</lpage>.<pub-id pub-id-type="pmid">30415998</pub-id>
</mixed-citation></ref><ref id="CIT0268"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Zaidi</surname><given-names>T</given-names></string-name>, <string-name><surname>Iqbal</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Role of glycosylation in hyperphosphorylation of tau in Alzheimer&#x02019;s disease</article-title>. <source>FEBS Lett</source><year>2002</year>;<volume>512</volume>:<fpage>101</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">11852060</pub-id>
</mixed-citation></ref><ref id="CIT0269"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name><surname>Tanimukai</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source><year>2009</year>;<volume>132</volume>:<fpage>1820</fpage>&#x02013;<lpage>1832</lpage>.<pub-id pub-id-type="pmid">19451179</pub-id>
</mixed-citation></ref><ref id="CIT0270"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hao</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TLR2 is a primary receptor for Alzheimer&#x02019;s amyloid beta peptide to trigger neuroinflammatory activation</article-title>. <source>J Immunol</source><year>2012</year>;<volume>188</volume>:<fpage>1098</fpage>&#x02013;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">22198949</pub-id>
</mixed-citation></ref><ref id="CIT0271"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>CC</given-names>
</string-name>, <string-name><surname>Zhao</surname><given-names>N</given-names></string-name>, <string-name><surname>Fu</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>ApoE4 accelerates early seeding of amyloid pathology</article-title>. <source>Neuron</source><year>2017</year>;<volume>96</volume>:<fpage>1024</fpage>&#x02013;<lpage>1032.e3</lpage>.<pub-id pub-id-type="pmid">29216449</pub-id>
</mixed-citation></ref><ref id="CIT0272"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>CC</given-names>
</string-name>, <string-name><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name><surname>Fu</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Peripheral apoE4 enhances Alzheimer&#x02019;s pathology and impairs cognition by compromising cerebrovascular function</article-title>. <source>Nat Neurosci</source><year>2022</year>;<volume>25</volume>:<fpage>1020</fpage>&#x02013;<lpage>1033</lpage>.<pub-id pub-id-type="pmid">35915180</pub-id>
</mixed-citation></ref><ref id="CIT0273"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>CC</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer&#x02019;s disease</article-title>. <source>Nat Immunol</source><year>2023a</year>;<volume>24</volume>:<fpage>1854</fpage>&#x02013;<lpage>1866</lpage>.<pub-id pub-id-type="pmid">37857825</pub-id>
</mixed-citation></ref><ref id="CIT0274"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Xing</surname><given-names>S</given-names></string-name>, <string-name><surname>Wei</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Excessive dietary salt intake exacerbates cognitive impairment progression and increases dementia risk in older adults</article-title>. <source>J Am Med Dir Assoc</source><year>2023b</year>;<volume>24</volume>:<fpage>125</fpage>&#x02013;<lpage>129.e4</lpage>.<pub-id pub-id-type="pmid">36351463</pub-id>
</mixed-citation></ref><ref id="CIT0275"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Livingston</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Sommerlad</surname><given-names>A</given-names></string-name>, <string-name><surname>Orgeta</surname><given-names>V</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dementia prevention, intervention, and care</article-title>. <source>Lancet</source><year>2017</year>;<volume>390</volume>:<fpage>2673</fpage>&#x02013;<lpage>2734</lpage>.<pub-id pub-id-type="pmid">28735855</pub-id>
</mixed-citation></ref><ref id="CIT0276"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Livingston</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name><surname>Sommerlad</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dementia prevention, intervention, and care: 2020 report of the Lancet Commission</article-title>. <source>Lancet</source><year>2020</year>;<volume>396</volume>:<fpage>413</fpage>&#x02013;<lpage>446</lpage>.<pub-id pub-id-type="pmid">32738937</pub-id>
</mixed-citation></ref><ref id="CIT0277"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lodato</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Rodin</surname><given-names>RE</given-names></string-name>, <string-name><surname>Bohrson</surname><given-names>CL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Aging and neurodegeneration are associated with increased mutations in single human neurons</article-title>. <source>Science</source><year>2018</year>;<volume>359</volume>:<fpage>555</fpage>&#x02013;<lpage>559</lpage>.<pub-id pub-id-type="pmid">29217584</pub-id>
</mixed-citation></ref><ref id="CIT0278"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Long</surname>
<given-names>JM</given-names>
</string-name>, <string-name><surname>Holtzman</surname><given-names>DM.</given-names></string-name></person-group>
<article-title>Alzheimer disease: an update on pathobiology and treatment strategies</article-title>. <source>Cell</source><year>2019</year>;<volume>179</volume>:<fpage>312</fpage>&#x02013;<lpage>339</lpage>.<pub-id pub-id-type="pmid">31564456</pub-id>
</mixed-citation></ref><ref id="CIT0279"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lopatko Lindman</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Weidung</surname><given-names>B</given-names></string-name>, <string-name><surname>Olsson</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A genetic signature including apolipoprotein Eepsilon4 potentiates the risk of herpes simplex-associated Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement (N Y)</source><year>2019</year>;<volume>5</volume>:<fpage>697</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">31921962</pub-id>
</mixed-citation></ref><ref id="CIT0280"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lopera</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Marino</surname><given-names>C</given-names></string-name>, <string-name><surname>Chandrahas</surname><given-names>AS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Resilience to autosomal dominant Alzheimer&#x02019;s disease in a Reelin-COLBOS heterozygous man</article-title>. <source>Nat Med</source><year>2023</year>;<volume>29</volume>:<fpage>1243</fpage>&#x02013;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">37188781</pub-id>
</mixed-citation></ref><ref id="CIT0281"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Losev</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Paul</surname><given-names>A</given-names></string-name>, <string-name><surname>Frenkel-Pinter</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity</article-title>. <source>Sci Rep</source><year>2019</year>;<volume>9</volume>:<fpage>2254</fpage>.<pub-id pub-id-type="pmid">30783169</pub-id>
</mixed-citation></ref><ref id="CIT0282"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lott</surname>
<given-names>IT</given-names>
</string-name>, <string-name><surname>Head</surname><given-names>E.</given-names></string-name></person-group>
<article-title>Dementia in Down syndrome: unique insights for Alzheimer disease research</article-title>. <source>Nat Rev Neurol</source><year>2019</year>;<volume>15</volume>:<fpage>135</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">30733618</pub-id>
</mixed-citation></ref><ref id="CIT0283"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lu</surname>
<given-names>DC</given-names>
</string-name>, <string-name><surname>Soriano</surname><given-names>S</given-names></string-name>, <string-name><surname>Bredesen</surname><given-names>DE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity</article-title>. <source>J Neurochem</source><year>2003</year>;<volume>87</volume>:<fpage>733</fpage>&#x02013;<lpage>741</lpage>.<pub-id pub-id-type="pmid">14535955</pub-id>
</mixed-citation></ref><ref id="CIT0284"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lucassen</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Chung</surname><given-names>WC</given-names></string-name>, <string-name><surname>Kamphorst</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>DNA damage distribution in the human brain as shown by <italic toggle="yes">in situ</italic> end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology</article-title>. <source>J Neuropathol Exp Neurol</source><year>1997</year>;<volume>56</volume>:<fpage>887</fpage>&#x02013;<lpage>900</lpage>.<pub-id pub-id-type="pmid">9258259</pub-id>
</mixed-citation></ref><ref id="CIT0285"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lucey</surname>
<given-names>BP</given-names>
</string-name>, <string-name><surname>Hicks</surname><given-names>TJ</given-names></string-name>, <string-name><surname>McLeland</surname><given-names>JS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Effect of sleep on overnight cerebrospinal fluid amyloid beta kinetics</article-title>. <source>Ann Neurol</source><year>2018</year>;<volume>83</volume>:<fpage>197</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">29220873</pub-id>
</mixed-citation></ref><ref id="CIT0286"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Luchsinger</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Tang</surname><given-names>MX</given-names></string-name>, <string-name><surname>Shea</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Caloric intake and the risk of Alzheimer disease</article-title>. <source>Arch Neurol</source><year>2002</year>;<volume>59</volume>:<fpage>1258</fpage>&#x02013;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">12164721</pub-id>
</mixed-citation></ref><ref id="CIT0287"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Luna-Munoz</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Chavez-Macias</surname><given-names>L</given-names></string-name>, <string-name><surname>Garcia-Sierra</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer&#x02019;s disease</article-title>. <source>J Alzheimers Dis</source><year>2007</year>;<volume>12</volume>:<fpage>365</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">18198423</pub-id>
</mixed-citation></ref><ref id="CIT0288"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Luo</surname>
<given-names>HB</given-names>
</string-name>, <string-name><surname>Xia</surname><given-names>YY</given-names></string-name>, <string-name><surname>Shu</surname><given-names>XJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2014</year>;<volume>111</volume>:<fpage>16586</fpage>&#x02013;<lpage>16591</lpage>.<pub-id pub-id-type="pmid">25378699</pub-id>
</mixed-citation></ref><ref id="CIT0289"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Luo</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Thomassen</surname><given-names>JQ</given-names></string-name>, <string-name><surname>Bellenguez</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Genetic associations between modifiable risk factors and Alzheimer disease</article-title>. <source>JAMA Netw Open</source><year>2023</year>;<volume>6</volume>:<fpage>e2313734</fpage>.<pub-id pub-id-type="pmid">37195665</pub-id>
</mixed-citation></ref><ref id="CIT0290"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mahmoudi</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Sadaghiyani</surname><given-names>S</given-names></string-name>, <string-name><surname>Lin</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Diagnosis of Alzheimer&#x02019;s disease and related dementia among people with multiple sclerosis: Large cohort study, USA</article-title>. <source>Mult Scler Relat Disord</source><year>2022</year>;<volume>57</volume>:<fpage>103351</fpage>.<pub-id pub-id-type="pmid">35158460</pub-id>
</mixed-citation></ref><ref id="CIT0291"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Majumdar</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Capetillo-Zarate</surname><given-names>E</given-names></string-name>, <string-name><surname>Cruz</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Degradation of Alzheimer&#x02019;s amyloid fibrils by microglia requires delivery of ClC-7 to lysosomes</article-title>. <source>Mol Biol Cell</source><year>2011</year>;<volume>22</volume>:<fpage>1664</fpage>&#x02013;<lpage>1676</lpage>.<pub-id pub-id-type="pmid">21441306</pub-id>
</mixed-citation></ref><ref id="CIT0292"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Malaguarnera</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Bella</surname><given-names>R</given-names></string-name>, <string-name><surname>Alagona</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Helicobacter pylori and Alzheimer&#x02019;s disease: a possible link</article-title>. <source>Eur J Intern Med</source><year>2004</year>;<volume>15</volume>:<fpage>381</fpage>&#x02013;<lpage>386</lpage>.<pub-id pub-id-type="pmid">15522573</pub-id>
</mixed-citation></ref><ref id="CIT0293"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marschallinger</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Iram</surname><given-names>T</given-names></string-name>, <string-name><surname>Zardeneta</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain</article-title>. <source>Nat Neurosci</source><year>2020</year>;<volume>23</volume>:<fpage>194</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">31959936</pub-id>
</mixed-citation></ref><ref id="CIT0294"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Martini-Stoica</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Cole</surname><given-names>AL</given-names></string-name>, <string-name><surname>Swartzlander</surname><given-names>DB</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading</article-title>. <source>J Exp Med</source><year>2018</year>;<volume>215</volume>:<fpage>2355</fpage>&#x02013;<lpage>2377</lpage>.<pub-id pub-id-type="pmid">30108137</pub-id>
</mixed-citation></ref><ref id="CIT0295"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Martorell</surname>
<given-names>AJ</given-names>
</string-name>, <string-name><surname>Paulson</surname><given-names>AL</given-names></string-name>, <string-name><surname>Suk</surname><given-names>HJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Multi-sensory gamma stimulation ameliorates Alzheimer&#x02019;s-associated pathology and improves cognition</article-title>. <source>Cell</source><year>2019</year>;<volume>177</volume>:<fpage>256</fpage>&#x02013;<lpage>271.e22</lpage>.<pub-id pub-id-type="pmid">30879788</pub-id>
</mixed-citation></ref><ref id="CIT0296"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Masters</surname>
<given-names>CL</given-names>
</string-name>, <string-name><surname>Simms</surname><given-names>G</given-names></string-name>, <string-name><surname>Weinman</surname><given-names>NA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid plaque core protein in Alzheimer disease and Down syndrome</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1985</year>;<volume>82</volume>:<fpage>4245</fpage>&#x02013;<lpage>4249</lpage>.<pub-id pub-id-type="pmid">3159021</pub-id>
</mixed-citation></ref><ref id="CIT0297"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mastorakos</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Mihelson</surname><given-names>N</given-names></string-name>, <string-name><surname>Luby</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Temporally distinct myeloid cell responses mediate damage and repair after cerebrovascular injury</article-title>. <source>Nat Neurosci</source><year>2021</year>;<volume>24</volume>:<fpage>245</fpage>&#x02013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">33462481</pub-id>
</mixed-citation></ref><ref id="CIT0298"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mathys</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Davila-Velderrain</surname><given-names>J</given-names></string-name>, <string-name><surname>Peng</surname><given-names>Z</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Single-cell transcriptomic analysis of Alzheimer&#x02019;s disease</article-title>. <source>Nature</source><year>2019</year>;<volume>570</volume>:<fpage>332</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">31042697</pub-id>
</mixed-citation></ref><ref id="CIT0299"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mathys</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name><surname>Boix</surname><given-names>CA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer&#x02019;s disease pathology</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>4365</fpage>&#x02013;<lpage>4385.e27</lpage>.<pub-id pub-id-type="pmid">37774677</pub-id>
</mixed-citation></ref><ref id="CIT0300"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mattsson</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Andreasson</surname><given-names>U</given-names></string-name>, <string-name><surname>Zetterberg</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2017</year>;<volume>74</volume>:<fpage>557</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">28346578</pub-id>
</mixed-citation></ref><ref id="CIT0301"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mattsson</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Groot</surname><given-names>C</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>WJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source><year>2018</year>;<volume>14</volume>:<fpage>913</fpage>&#x02013;<lpage>924</lpage>.<pub-id pub-id-type="pmid">29601787</pub-id>
</mixed-citation></ref><ref id="CIT0302"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mattsson</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Cullen</surname><given-names>NC</given-names></string-name>, <string-name><surname>Andreasson</surname><given-names>U</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association between longitudinal plasma neurofilament light and neurodegeneration in patients With Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2019</year>;<volume>76</volume>:<fpage>791</fpage>&#x02013;<lpage>799</lpage>.<pub-id pub-id-type="pmid">31009028</pub-id>
</mixed-citation></ref><ref id="CIT0303"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McDowell</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Xi</surname><given-names>G</given-names></string-name>, <string-name><surname>Lindsay</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Mapping the connections between education and dementia</article-title>. <source>J Clin Exp Neuropsychol</source><year>2007</year>;<volume>29</volume>:<fpage>127</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">17365248</pub-id>
</mixed-citation></ref><ref id="CIT0304"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</string-name>, <string-name><surname>Itagaki</surname><given-names>S</given-names></string-name>, <string-name><surname>Tago</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR</article-title>. <source>Neurosci Lett</source><year>1987</year>;<volume>79</volume>:<fpage>195</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">3670729</pub-id>
</mixed-citation></ref><ref id="CIT0305"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McHutchison</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Cvoro</surname><given-names>V</given-names></string-name>, <string-name><surname>Makin</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Functional, cognitive and physical outcomes 3 years after minor lacunar or cortical ischaemic stroke</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2019</year>;<volume>90</volume>:<fpage>436</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">30554134</pub-id>
</mixed-citation></ref><ref id="CIT0306"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McKee</surname>
<given-names>AC</given-names>
</string-name>, <string-name><surname>Cantu</surname><given-names>RC</given-names></string-name>, <string-name><surname>Nowinski</surname><given-names>CJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury</article-title>. <source>J Neuropathol Exp Neurol</source><year>2009</year>;<volume>68</volume>:<fpage>709</fpage>&#x02013;<lpage>735</lpage>.<pub-id pub-id-type="pmid">19535999</pub-id>
</mixed-citation></ref><ref id="CIT0307"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McKhann</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name><surname>Chertkow</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The diagnosis of dementia due to Alzheimer&#x02019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source><year>2011</year>;<volume>7</volume>:<fpage>263</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">21514250</pub-id>
</mixed-citation></ref><ref id="CIT0308"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Messier</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Awad</surname><given-names>N</given-names></string-name>, <string-name><surname>Gagnon</surname><given-names>M.</given-names></string-name></person-group>
<article-title>The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia</article-title>. <source>Neurol Res</source><year>2004</year>;<volume>26</volume>:<fpage>567</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">15265276</pub-id>
</mixed-citation></ref><ref id="CIT0309"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Meyer-Luehmann</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Coomaraswamy</surname><given-names>J</given-names></string-name>, <string-name><surname>Bolmont</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host</article-title>. <source>Science</source><year>2006</year>;<volume>313</volume>:<fpage>1781</fpage>&#x02013;<lpage>1784</lpage>.<pub-id pub-id-type="pmid">16990547</pub-id>
</mixed-citation></ref><ref id="CIT0310"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Middeldorp</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Lehallier</surname><given-names>B</given-names></string-name>, <string-name><surname>Villeda</surname><given-names>SA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Preclinical assessment of young blood plasma for Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2016</year>;<volume>73</volume>:<fpage>1325</fpage>&#x02013;<lpage>1333</lpage>.<pub-id pub-id-type="pmid">27598869</pub-id>
</mixed-citation></ref><ref id="CIT0311"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Miklossy</surname>
<given-names>J.</given-names>
</string-name>
</person-group>
<article-title>Bacterial amyloid and DNA are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile plaques</article-title>. <source>J Alzheimers Dis</source><year>2016</year>;<volume>53</volume>:<fpage>1459</fpage>&#x02013;<lpage>1473</lpage>.<pub-id pub-id-type="pmid">27314530</pub-id>
</mixed-citation></ref><ref id="CIT0312"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Miklossy</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Qing</surname><given-names>H</given-names></string-name>, <string-name><surname>Radenovic</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes</article-title>. <source>Neurobiol Aging</source><year>2010</year>;<volume>31</volume>:<fpage>1503</fpage>&#x02013;<lpage>1515</lpage>.<pub-id pub-id-type="pmid">18950899</pub-id>
</mixed-citation></ref><ref id="CIT0313"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Miller</surname>
<given-names>MB</given-names>
</string-name>, <string-name><surname>Huang</surname><given-names>AY</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Somatic genomic changes in single Alzheimer&#x02019;s disease neurons</article-title>. <source>Nature</source><year>2022</year>;<volume>604</volume>:<fpage>714</fpage>&#x02013;<lpage>722</lpage>.<pub-id pub-id-type="pmid">35444284</pub-id>
</mixed-citation></ref><ref id="CIT0314"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Millet</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ledo</surname><given-names>JH</given-names></string-name>, <string-name><surname>Tavazoie</surname><given-names>SF.</given-names></string-name></person-group>
<article-title>An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer&#x02019;s brains</article-title>. <source>Immunity</source><year>2024</year>;<volume>57</volume>:<fpage>153</fpage>&#x02013;<lpage>170.e6</lpage>.<pub-id pub-id-type="pmid">38159571</pub-id>
</mixed-citation></ref><ref id="CIT0315"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Min</surname>
<given-names>SW</given-names>
</string-name>, <string-name><surname>Cho</surname><given-names>SH</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Acetylation of tau inhibits its degradation and contributes to tauopathy</article-title>. <source>Neuron</source><year>2010</year>;<volume>67</volume>:<fpage>953</fpage>&#x02013;<lpage>966</lpage>.<pub-id pub-id-type="pmid">20869593</pub-id>
</mixed-citation></ref><ref id="CIT0316"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mody</surname>
<given-names>PH</given-names>
</string-name>, <string-name><surname>Marvin</surname><given-names>KN</given-names></string-name>, <string-name><surname>Hynds</surname><given-names>DL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cytomegalovirus infection induces Alzheimer&#x02019;s disease-associated alterations in tau</article-title>. <source>J Neurovirol</source><year>2023</year>;<volume>29</volume>:<fpage>400</fpage>&#x02013;<lpage>415</lpage>.<pub-id pub-id-type="pmid">37436577</pub-id>
</mixed-citation></ref><ref id="CIT0317"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mori</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Kondo</surname><given-names>J</given-names></string-name>, <string-name><surname>Ihara</surname><given-names>Y.</given-names></string-name></person-group>
<article-title>Ubiquitin is a component of paired helical filaments in Alzheimer&#x02019;s disease</article-title>. <source>Science</source><year>1987</year>;<volume>235</volume>:<fpage>1641</fpage>&#x02013;<lpage>1644</lpage>.<pub-id pub-id-type="pmid">3029875</pub-id>
</mixed-citation></ref><ref id="CIT0318"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morio</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Fardet</surname><given-names>A</given-names></string-name>, <string-name><surname>Legrand</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Involvement of dietary saturated fats, from all sources or of dairy origin only, in insulin resistance and type 2 diabetes</article-title>. <source>Nutr Rev</source><year>2016</year>;<volume>74</volume>:<fpage>33</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">26545916</pub-id>
</mixed-citation></ref><ref id="CIT0319"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morris</surname>
<given-names>MC</given-names>
</string-name>, <string-name><surname>Evans</surname><given-names>DA</given-names></string-name>, <string-name><surname>Bienias</surname><given-names>JL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dietary fats and the risk of incident Alzheimer disease</article-title>. <source>Arch Neurol</source><year>2003</year>;<volume>60</volume>:<fpage>194</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">12580703</pub-id>
</mixed-citation></ref><ref id="CIT0320"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morris</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Roe</surname><given-names>CM</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging</article-title>. <source>Ann Neurol</source><year>2010</year>;<volume>67</volume>:<fpage>122</fpage>&#x02013;<lpage>131</lpage>.<pub-id pub-id-type="pmid">20186853</pub-id>
</mixed-citation></ref><ref id="CIT0321"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morris</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Knudsen</surname><given-names>GM</given-names></string-name>, <string-name><surname>Maeda</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice</article-title>. <source>Nat Neurosci</source><year>2015</year>;<volume>18</volume>:<fpage>1183</fpage>&#x02013;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">26192747</pub-id>
</mixed-citation></ref><ref id="CIT0322"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Moscoso</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Grothe</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ashton</surname><given-names>NJ</given-names></string-name></person-group>
<etal>et al</etal>
<collab>Alzheimer&#x02019;s Disease Neuroimaging Initiative</collab>. <article-title>Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2021</year>;<volume>78</volume>:<fpage>396</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">33427873</pub-id>
</mixed-citation></ref><ref id="CIT0323"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mothes</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Portal</surname><given-names>B</given-names></string-name>, <string-name><surname>Konstantinidis</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Astrocytic uptake of neuronal corpses promotes cell-to-cell spreading of tau pathology</article-title>. <source>Acta Neuropathol Commun</source><year>2023</year>;<volume>11</volume>:<fpage>97</fpage>.<pub-id pub-id-type="pmid">37330529</pub-id>
</mixed-citation></ref><ref id="CIT0324"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mulcahy</surname>
<given-names>LA</given-names>
</string-name>, <string-name><surname>Pink</surname><given-names>RC</given-names></string-name>, <string-name><surname>Carter</surname><given-names>DR.</given-names></string-name></person-group>
<article-title>Routes and mechanisms of extracellular vesicle uptake</article-title>. <source>J Extracell Vesicles</source><year>2014</year>;<volume>3</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="CIT0325"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mummery</surname>
<given-names>CJ</given-names>
</string-name>, <string-name><surname>Borjesson-Hanson</surname><given-names>A</given-names></string-name>, <string-name><surname>Blackburn</surname><given-names>DJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer&#x02019;s disease: a phase 1b, randomized, placebo-controlled trial</article-title>. <source>Nat Med</source><year>2023</year>;<volume>29</volume>:<fpage>1437</fpage>&#x02013;<lpage>1447</lpage>.<pub-id pub-id-type="pmid">37095250</pub-id>
</mixed-citation></ref><ref id="CIT0326"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Murdock</surname>
<given-names>MH</given-names>
</string-name>, <string-name><surname>Yang</surname><given-names>CY</given-names></string-name>, <string-name><surname>Sun</surname><given-names>N</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Multisensory gamma stimulation promotes glymphatic clearance of amyloid</article-title>. <source>Nature</source><year>2024</year>;<volume>627</volume>:<fpage>149</fpage>&#x02013;<lpage>156</lpage>.<pub-id pub-id-type="pmid">38418876</pub-id>
</mixed-citation></ref><ref id="CIT0327"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Musiek</surname>
<given-names>ES</given-names>
</string-name>, <string-name><surname>Ju</surname><given-names>YS.</given-names></string-name></person-group>
<article-title>Targeting sleep and circadian function in the prevention of Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2022</year>;<volume>79</volume>:<fpage>835</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="pmid">35816332</pub-id>
</mixed-citation></ref><ref id="CIT0328"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Musiek</surname>
<given-names>ES</given-names>
</string-name>, <string-name><surname>Bhimasani</surname><given-names>M</given-names></string-name>, <string-name><surname>Zangrilli</surname><given-names>MA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2018</year>;<volume>75</volume>:<fpage>582</fpage>&#x02013;<lpage>590</lpage>.<pub-id pub-id-type="pmid">29379963</pub-id>
</mixed-citation></ref><ref id="CIT0329"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nacharaju</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Ko</surname><given-names>L</given-names></string-name>, <string-name><surname>Yen</surname><given-names>SH.</given-names></string-name></person-group>
<article-title>Characterization of <italic toggle="yes">in vitro</italic> glycation sites of tau</article-title>. <source>J Neurochem</source><year>1997</year>;<volume>69</volume>:<fpage>1709</fpage>&#x02013;<lpage>1719</lpage>.<pub-id pub-id-type="pmid">9326300</pub-id>
</mixed-citation></ref><ref id="CIT0330"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Naj</surname>
<given-names>AC</given-names>
</string-name>, <string-name><surname>Jun</surname><given-names>G</given-names></string-name>, <string-name><surname>Beecham</surname><given-names>GW</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x02019;s disease</article-title>. <source>Nat Genet</source><year>2011</year>;<volume>43</volume>:<fpage>436</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">21460841</pub-id>
</mixed-citation></ref><ref id="CIT0331"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Narayan</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Orte</surname><given-names>A</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>RW</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1-40) peptide</article-title>. <source>Nat Struct Mol Biol</source><year>2011</year>;<volume>19</volume>:<fpage>79</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">22179788</pub-id>
</mixed-citation></ref><ref id="CIT0332"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nath</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Agholme</surname><given-names>L</given-names></string-name>, <string-name><surname>Kurudenkandy</surname><given-names>FR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid</article-title>. <source>J Neurosci</source><year>2012</year>;<volume>32</volume>:<fpage>8767</fpage>&#x02013;<lpage>8777</lpage>.<pub-id pub-id-type="pmid">22745479</pub-id>
</mixed-citation></ref><ref id="CIT0333"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nelson</surname>
<given-names>PT</given-names>
</string-name>, <string-name><surname>Alafuzoff</surname><given-names>I</given-names></string-name>, <string-name><surname>Bigio</surname><given-names>EH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature</article-title>. <source>J Neuropathol Exp Neurol</source><year>2012</year>;<volume>71</volume>:<fpage>362</fpage>&#x02013;<lpage>381</lpage>.<pub-id pub-id-type="pmid">22487856</pub-id>
</mixed-citation></ref><ref id="CIT0334"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nelson</surname>
<given-names>MR</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>P</given-names></string-name>, <string-name><surname>Agrawal</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation</article-title>. <source>Nat Neurosci</source><year>2023</year>;<volume>26</volume>:<fpage>2104</fpage>&#x02013;<lpage>2121</lpage>.<pub-id pub-id-type="pmid">37957317</pub-id>
</mixed-citation></ref><ref id="CIT0335"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nemetz</surname>
<given-names>PN</given-names>
</string-name>, <string-name><surname>Leibson</surname><given-names>C</given-names></string-name>, <string-name><surname>Naessens</surname><given-names>JM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Traumatic brain injury and time to onset of Alzheimer&#x02019;s disease: a population-based study</article-title>. <source>Am J Epidemiol</source><year>1999</year>;<volume>149</volume>:<fpage>32</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">9883791</pub-id>
</mixed-citation></ref><ref id="CIT0336"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Neu</surname>
<given-names>SC</given-names>
</string-name>, <string-name><surname>Pa</surname><given-names>J</given-names></string-name>, <string-name><surname>Kukull</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis</article-title>. <source>JAMA Neurol</source><year>2017</year>;<volume>74</volume>:<fpage>1178</fpage>&#x02013;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">28846757</pub-id>
</mixed-citation></ref><ref id="CIT0337"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nielsen</surname>
<given-names>HM</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>K</given-names></string-name>, <string-name><surname>Lee</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Peripheral apoE isoform levels in cognitively normal APOE epsilon3/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism</article-title>. <source>Alzheimers Res Ther</source><year>2017</year>;<volume>9</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">28137305</pub-id>
</mixed-citation></ref><ref id="CIT0338"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nixon</surname>
<given-names>RA.</given-names>
</string-name>
</person-group>
<article-title>Autophagy, amyloidogenesis and Alzheimer disease</article-title>. <source>J Cell Sci</source><year>2007</year>;<volume>120</volume>:<fpage>4081</fpage>&#x02013;<lpage>4091</lpage>.<pub-id pub-id-type="pmid">18032783</pub-id>
</mixed-citation></ref><ref id="CIT0339"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Norton</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Matthews</surname><given-names>FE</given-names></string-name>, <string-name><surname>Barnes</surname><given-names>DE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Potential for primary prevention of Alzheimer&#x02019;s disease: an analysis of population-based data</article-title>. <source>Lancet Neurol</source><year>2014</year>;<volume>13</volume>:<fpage>788</fpage>&#x02013;<lpage>794</lpage>.<pub-id pub-id-type="pmid">25030513</pub-id>
</mixed-citation></ref><ref id="CIT0340"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nyamayaro</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Chibanda</surname><given-names>D</given-names></string-name>, <string-name><surname>Robbins</surname><given-names>RN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Assessment of neurocognitive deficits in people living with HIV in Sub Saharan Africa: a systematic review</article-title>. <source>Clin Neuropsychol</source><year>2019</year>;<volume>33</volume>:<fpage>1</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="CIT0341"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Oeckl</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Anderl-Straub</surname><given-names>S</given-names></string-name>, <string-name><surname>Von Arnim</surname><given-names>CAF</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Serum GFAP differentiates Alzheimer&#x02019;s disease from frontotemporal dementia and predicts MCI-to-dementia conversion</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2022</year>;<volume>93</volume>:<fpage>659</fpage>&#x02013;<lpage>667</lpage>.</mixed-citation></ref><ref id="CIT0342"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Olive</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Ibanez</surname><given-names>L</given-names></string-name>, <string-name><surname>Farias</surname><given-names>FHG</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Examination of the effect of rare variants in TREM2, ABI3, and PLCG2 in LOAD through multiple phenotypes</article-title>. <source>J Alzheimers Dis</source><year>2020</year>;<volume>77</volume>:<fpage>1469</fpage>&#x02013;<lpage>1482</lpage>.<pub-id pub-id-type="pmid">32894242</pub-id>
</mixed-citation></ref><ref id="CIT0343"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Olivera</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Lejbman</surname><given-names>N</given-names></string-name>, <string-name><surname>Jeromin</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Peripheral total Tau in military personnel who sustain traumatic brain injuries during deployment</article-title>. <source>JAMA Neurol</source><year>2015</year>;<volume>72</volume>:<fpage>1109</fpage>&#x02013;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">26237304</pub-id>
</mixed-citation></ref><ref id="CIT0344"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ossenkoppele</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Schonhaut</surname><given-names>DR</given-names></string-name>, <string-name><surname>Scholl</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source><year>2016</year>;<volume>139</volume>:<fpage>1551</fpage>&#x02013;<lpage>1567</lpage>.<pub-id pub-id-type="pmid">26962052</pub-id>
</mixed-citation></ref><ref id="CIT0345"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ossenkoppele</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name><surname>Smith</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Discriminative accuracy of [18F]flortaucipir Positron emission tomography for Alzheimer disease vs other neurodegenerative disorders</article-title>. <source>JAMA</source><year>2018</year>;<volume>320</volume>:<fpage>1151</fpage>&#x02013;<lpage>1162</lpage>.<pub-id pub-id-type="pmid">30326496</pub-id>
</mixed-citation></ref><ref id="CIT0346"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ost</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Nylen</surname><given-names>K</given-names></string-name>, <string-name><surname>Csajbok</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury</article-title>. <source>Neurology</source><year>2006</year>;<volume>67</volume>:<fpage>1600</fpage>&#x02013;<lpage>1604</lpage>.<pub-id pub-id-type="pmid">17101890</pub-id>
</mixed-citation></ref><ref id="CIT0347"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Palmqvist</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name><surname>Quiroz</surname><given-names>YT</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders</article-title>. <source>JAMA</source><year>2020</year>;<volume>324</volume>:<fpage>772</fpage>&#x02013;<lpage>781</lpage>.<pub-id pub-id-type="pmid">32722745</pub-id>
</mixed-citation></ref><ref id="CIT0348"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pan</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>JM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A new dawn of preventing dementia by preventing cerebrovascular diseases</article-title>. <source>BMJ</source><year>2020</year>;<volume>371</volume>:<fpage>m3692</fpage>.<pub-id pub-id-type="pmid">33037035</pub-id>
</mixed-citation></ref><ref id="CIT0349"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pandey</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Shen</surname><given-names>K</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Disease-associated oligodendrocyte responses across neurodegenerative diseases</article-title>. <source>Cell Rep</source><year>2022</year>;<volume>40</volume>:<fpage>111189</fpage>.<pub-id pub-id-type="pmid">36001972</pub-id>
</mixed-citation></ref><ref id="CIT0350"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Parhizkar</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Arzberger</surname><given-names>T</given-names></string-name>, <string-name><surname>Brendel</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE</article-title>. <source>Nat Neurosci</source><year>2019</year>;<volume>22</volume>:<fpage>191</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">30617257</pub-id>
</mixed-citation></ref><ref id="CIT0351"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Park</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Shaked</surname><given-names>GM</given-names></string-name>, <string-name><surname>Bredesen</surname><given-names>DE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein</article-title>. <source>Biochem Biophys Res Commun</source><year>2009</year>;<volume>388</volume>:<fpage>450</fpage>&#x02013;<lpage>455</lpage>.<pub-id pub-id-type="pmid">19679105</pub-id>
</mixed-citation></ref><ref id="CIT0352"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Park</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Cho</surname><given-names>B</given-names></string-name>, <string-name><surname>Kim</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Single-cell RNA-sequencing identifies disease-associated oligodendrocytes in male APP NL-G-F and 5XFAD mice</article-title>. <source>Nat Commun</source><year>2023</year>;<volume>14</volume>:<fpage>802</fpage>.<pub-id pub-id-type="pmid">36781874</pub-id>
</mixed-citation></ref><ref id="CIT0353"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Parra Bravo</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Giani</surname><given-names>AM</given-names></string-name>, <string-name><surname>Perez</surname><given-names>JM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Human iPSC 4R tauopathy model uncovers modifiers of tau propagation</article-title>. <source>Cell</source><year>2024</year>;<volume>187</volume>:<fpage>2446</fpage>&#x02013;<lpage>2464</lpage>.<pub-id pub-id-type="pmid">38582079</pub-id>
</mixed-citation></ref><ref id="CIT0354"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Paudel</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Jeong</surname><given-names>SY</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>CP</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Death Induced by Survival gene Elimination (DISE) correlates with neurotoxicity in Alzheimer&#x02019;s disease and aging</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>264</fpage>.<pub-id pub-id-type="pmid">38238311</pub-id>
</mixed-citation></ref><ref id="CIT0355"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Peacock</surname>
<given-names>ML</given-names>
</string-name>, <string-name><surname>Warren</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Roses</surname><given-names>AD</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer&#x02019;s disease</article-title>. <source>Neurology</source><year>1993</year>;<volume>43</volume>:<fpage>1254</fpage>&#x02013;<lpage>1256</lpage>.<pub-id pub-id-type="pmid">8170579</pub-id>
</mixed-citation></ref><ref id="CIT0356"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pendlebury</surname>
<given-names>ST</given-names>
</string-name>, <string-name><surname>Rothwell</surname><given-names>PM</given-names></string-name>, <string-name><surname>Oxford Vascular</surname><given-names>S.</given-names></string-name></person-group>
<article-title>Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study</article-title>. <source>Lancet Neurol</source><year>2019</year>;<volume>18</volume>:<fpage>248</fpage>&#x02013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">30784556</pub-id>
</mixed-citation></ref><ref id="CIT0357"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Peng</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Malhotra</surname><given-names>S</given-names></string-name>, <string-name><surname>Torchia</surname><given-names>JA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1</article-title>. <source>Sci Signal</source><year>2010</year>;<volume>3</volume>:<fpage>ra38</fpage>.<pub-id pub-id-type="pmid">20484116</pub-id>
</mixed-citation></ref><ref id="CIT0358"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Penninkilampi</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Casey</surname><given-names>AN</given-names></string-name>, <string-name><surname>Singh</surname><given-names>MF</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The association between social engagement, loneliness, and risk of dementia: a systematic review and meta-analysis</article-title>. <source>J Alzheimers Dis</source><year>2018</year>;<volume>66</volume>:<fpage>1619</fpage>&#x02013;<lpage>1633</lpage>.<pub-id pub-id-type="pmid">30452410</pub-id>
</mixed-citation></ref><ref id="CIT0359"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Perry</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Friedman</surname><given-names>R</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1987</year>;<volume>84</volume>:<fpage>3033</fpage>&#x02013;<lpage>3036</lpage>.<pub-id pub-id-type="pmid">3033674</pub-id>
</mixed-citation></ref><ref id="CIT0360"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Perry</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Nunomura</surname><given-names>A</given-names></string-name>, <string-name><surname>Lucassen</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apoptosis and Alzheimer&#x02019;s disease</article-title>. <source>Science</source><year>1998</year>;<volume>282</volume>:<fpage>1268</fpage>&#x02013;<lpage>1269</lpage>.<pub-id pub-id-type="pmid">9867630</pub-id>
</mixed-citation></ref><ref id="CIT0361"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Dickson</surname><given-names>D</given-names></string-name>, <string-name><surname>Kehoe</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation</article-title>. <source>Hum Mol Genet</source><year>2004</year>;<volume>13</volume>:<fpage>703</fpage>&#x02013;<lpage>714</lpage>.<pub-id pub-id-type="pmid">14962978</pub-id>
</mixed-citation></ref><ref id="CIT0362"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Plescher</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Seifert</surname><given-names>G</given-names></string-name>, <string-name><surname>Hansen</surname><given-names>JN</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer&#x02019;s disease mouse model</article-title>. <source>Glia</source><year>2018</year>;<volume>66</volume>:<fpage>1464</fpage>&#x02013;<lpage>1480</lpage>.<pub-id pub-id-type="pmid">29493017</pub-id>
</mixed-citation></ref><ref id="CIT0363"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Poduslo</surname>
<given-names>JF</given-names>
</string-name>, <string-name><surname>Curran</surname><given-names>GL</given-names></string-name>, <string-name><surname>Berg</surname><given-names>CT.</given-names></string-name></person-group>
<article-title>Macromolecular permeability across the blood-nerve and blood-brain barriers</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1994</year>;<volume>91</volume>:<fpage>5705</fpage>&#x02013;<lpage>5709</lpage>.<pub-id pub-id-type="pmid">8202551</pub-id>
</mixed-citation></ref><ref id="CIT0364"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Polvikoski</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Sulkava</surname><given-names>R</given-names></string-name>, <string-name><surname>Haltia</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein</article-title>. <source>N Engl J Med</source><year>1995</year>;<volume>333</volume>:<fpage>1242</fpage>&#x02013;<lpage>1247</lpage>.<pub-id pub-id-type="pmid">7566000</pub-id>
</mixed-citation></ref><ref id="CIT0365"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Povellato</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Tuxworth</surname><given-names>RI</given-names></string-name>, <string-name><surname>Hanger</surname><given-names>DP</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Modification of the Drosophila model of <italic toggle="yes">in vivo</italic> Tau toxicity reveals protective phosphorylation by GSK3beta</article-title>. <source>Biol Open</source><year>2014</year>;<volume>3</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">24429107</pub-id>
</mixed-citation></ref><ref id="CIT0366"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Prifti</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Tsakiri</surname><given-names>EN</given-names></string-name>, <string-name><surname>Vourkou</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The two cysteines of Tau protein are functionally distinct and contribute differentially to its pathogenicity <italic toggle="yes">in vivo</italic></article-title>. <source>J Neurosci</source><year>2021</year>;<volume>41</volume>:<fpage>797</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">33334867</pub-id>
</mixed-citation></ref><ref id="CIT0367"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Profenno</surname>
<given-names>LA</given-names>
</string-name>, <string-name><surname>Porsteinsson</surname><given-names>AP</given-names></string-name>, <string-name><surname>Faraone</surname><given-names>SV.</given-names></string-name></person-group>
<article-title>Meta-analysis of Alzheimer&#x02019;s disease risk with obesity, diabetes, and related disorders</article-title>. <source>Biol Psychiatry</source><year>2010</year>;<volume>67</volume>:<fpage>505</fpage>&#x02013;<lpage>512</lpage>.<pub-id pub-id-type="pmid">19358976</pub-id>
</mixed-citation></ref><ref id="CIT0368"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Purro</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Farrow</surname><given-names>MA</given-names></string-name>, <string-name><surname>Linehan</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Transmission of amyloid-beta protein pathology from cadaveric pituitary growth hormone</article-title>. <source>Nature</source><year>2018</year>;<volume>564</volume>:<fpage>415</fpage>&#x02013;<lpage>419</lpage>.<pub-id pub-id-type="pmid">30546139</pub-id>
</mixed-citation></ref><ref id="CIT0369"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Qiu</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Winblad</surname><given-names>B</given-names></string-name>, <string-name><surname>Marengoni</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study</article-title>. <source>Arch Intern Med</source><year>2006</year>;<volume>166</volume>:<fpage>1003</fpage>&#x02013;<lpage>1008</lpage>.<pub-id pub-id-type="pmid">16682574</pub-id>
</mixed-citation></ref><ref id="CIT0370"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rabin</surname>
<given-names>JS</given-names>
</string-name>, <string-name><surname>Nichols</surname><given-names>E</given-names></string-name>, <string-name><surname>La Joie</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline</article-title>. <source>Brain</source><year>2022</year>;<volume>145</volume>:<fpage>2823</fpage>&#x02013;<lpage>2833</lpage>.<pub-id pub-id-type="pmid">35759327</pub-id>
</mixed-citation></ref><ref id="CIT0371"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rachmian</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Medina</surname><given-names>S</given-names></string-name>, <string-name><surname>Cherqui</surname><given-names>U</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Identification of senescent, TREM2-expressing microglia in aging and Alzheimer&#x02019;s disease model mouse brain</article-title>. <source>Nat Neurosci</source><year>2024</year>.</mixed-citation></ref><ref id="CIT0372"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rannikmae</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Kalaria</surname><given-names>RN</given-names></string-name>, <string-name><surname>Greenberg</surname><given-names>SM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2014</year>;<volume>85</volume>:<fpage>300</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">24163429</pub-id>
</mixed-citation></ref><ref id="CIT0373"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rehm</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Hasan</surname><given-names>OSM</given-names></string-name>, <string-name><surname>Black</surname><given-names>SE</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alcohol use and dementia: a systematic scoping review</article-title>. <source>Alzheimers Res Ther</source><year>2019</year>;<volume>11</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">30611304</pub-id>
</mixed-citation></ref><ref id="CIT0374"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reiman</surname>
<given-names>EM</given-names>
</string-name>, <string-name><surname>Quiroz</surname><given-names>YT</given-names></string-name>, <string-name><surname>Fleisher</surname><given-names>AS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x02019;s disease in the presenilin 1 E280A kindred: a case-control study</article-title>. <source>Lancet Neurol</source><year>2012</year>;<volume>11</volume>:<fpage>1048</fpage>&#x02013;<lpage>1056</lpage>.<pub-id pub-id-type="pmid">23137948</pub-id>
</mixed-citation></ref><ref id="CIT0375"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rezai</surname>
<given-names>AR</given-names>
</string-name>, <string-name><surname>D&#x02019;Haese</surname><given-names>PF</given-names></string-name>, <string-name><surname>Finomore</surname><given-names>V</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Ultrasound blood-brain barrier opening and Aducanumab in Alzheimer&#x02019;s disease</article-title>. <source>N Engl J Med</source><year>2024</year>;<volume>390</volume>:<fpage>55</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">38169490</pub-id>
</mixed-citation></ref><ref id="CIT0376"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rhodius-Meester</surname>
<given-names>HFM</given-names>
</string-name>, <string-name><surname>van Maurik</surname><given-names>IS</given-names></string-name>, <string-name><surname>Koikkalainen</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy</article-title>. <source>PLoS One</source><year>2020</year>;<volume>15</volume>:<fpage>e0226784</fpage>.<pub-id pub-id-type="pmid">31940390</pub-id>
</mixed-citation></ref><ref id="CIT0377"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ring</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Weyer</surname><given-names>SW</given-names></string-name>, <string-name><surname>Kilian</surname><given-names>SB</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice</article-title>. <source>J Neurosci</source><year>2007</year>;<volume>27</volume>:<fpage>7817</fpage>&#x02013;<lpage>7826</lpage>.<pub-id pub-id-type="pmid">17634375</pub-id>
</mixed-citation></ref><ref id="CIT0378"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ringman</surname>
<given-names>JM</given-names>
</string-name>, <string-name><surname>O&#x02019;Neill</surname><given-names>J</given-names></string-name>, <string-name><surname>Geschwind</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer&#x02019;s disease mutations</article-title>. <source>Brain</source><year>2007</year>;<volume>130</volume>:<fpage>1767</fpage>&#x02013;<lpage>1776</lpage>.<pub-id pub-id-type="pmid">17522104</pub-id>
</mixed-citation></ref><ref id="CIT0379"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rissman</surname>
<given-names>RA</given-names>
</string-name>, <string-name><surname>Poon</surname><given-names>WW</given-names></string-name>, <string-name><surname>Blurton-Jones</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology</article-title>. <source>J Clin Invest</source><year>2004</year>;<volume>114</volume>:<fpage>121</fpage>&#x02013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">15232619</pub-id>
</mixed-citation></ref><ref id="CIT0380"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rivera</surname>
<given-names>EJ</given-names>
</string-name>, <string-name><surname>Goldin</surname><given-names>A</given-names></string-name>, <string-name><surname>Fulmer</surname><given-names>N</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer&#x02019;s disease: link to brain reductions in acetylcholine</article-title>. <source>J Alzheimers Dis</source><year>2005</year>;<volume>8</volume>:<fpage>247</fpage>&#x02013;<lpage>268</lpage>.<pub-id pub-id-type="pmid">16340083</pub-id>
</mixed-citation></ref><ref id="CIT0381"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roberts</surname>
<given-names>GW</given-names>
</string-name>, <string-name><surname>Gentleman</surname><given-names>SM</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>beta A4 amyloid protein deposition in brain after head trauma</article-title>. <source>Lancet</source><year>1991</year>;<volume>338</volume>:<fpage>1422</fpage>&#x02013;<lpage>1423</lpage>.<pub-id pub-id-type="pmid">1683421</pub-id>
</mixed-citation></ref><ref id="CIT0382"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roberts</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Sevastou</surname><given-names>I</given-names></string-name>, <string-name><surname>Imaizumi</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol Commun</source><year>2020</year>;<volume>8</volume>:<fpage>13</fpage>.<pub-id pub-id-type="pmid">32019610</pub-id>
</mixed-citation></ref><ref id="CIT0383"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rohan de Silva</surname>
<given-names>HA</given-names>
</string-name>, <string-name><surname>Jen</surname><given-names>A</given-names></string-name>, <string-name><surname>Wickenden</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes</article-title>. <source>Brain Res Mol Brain Res</source><year>1997</year>;<volume>47</volume>:<fpage>147</fpage>&#x02013;<lpage>156</lpage>.<pub-id pub-id-type="pmid">9221912</pub-id>
</mixed-citation></ref><ref id="CIT0384"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roher</surname>
<given-names>AE</given-names>
</string-name>, <string-name><surname>Lowenson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1993</year>;<volume>90</volume>:<fpage>10836</fpage>&#x02013;<lpage>10840</lpage>.<pub-id pub-id-type="pmid">8248178</pub-id>
</mixed-citation></ref><ref id="CIT0385"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roussos</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Katsel</surname><given-names>P</given-names></string-name>, <string-name><surname>Fam</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer&#x02019;s dementia</article-title>. <source>Alzheimers Dement</source><year>2015</year>;<volume>11</volume>:<fpage>1163</fpage>&#x02013;<lpage>1170</lpage>.<pub-id pub-id-type="pmid">25499537</pub-id>
</mixed-citation></ref><ref id="CIT0386"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rusanen</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Kivipelto</surname><given-names>M</given-names></string-name>, <string-name><surname>Quesenberry</surname><given-names>CP</given-names><suffix>Jr</suffix></string-name></person-group>
<etal>et al</etal>
<article-title>Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia</article-title>. <source>Arch Intern Med</source><year>2011</year>;<volume>171</volume>:<fpage>333</fpage>&#x02013;<lpage>339</lpage>.<pub-id pub-id-type="pmid">20975015</pub-id>
</mixed-citation></ref><ref id="CIT0387"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ryan</surname>
<given-names>CM</given-names>
</string-name>, <string-name><surname>Geckle</surname><given-names>MO.</given-names></string-name></person-group>
<article-title>Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes</article-title>. <source>Diabetes Care</source><year>2000</year>;<volume>23</volume>:<fpage>1486</fpage>&#x02013;<lpage>1493</lpage>.<pub-id pub-id-type="pmid">11023141</pub-id>
</mixed-citation></ref><ref id="CIT0388"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ryman</surname>
<given-names>DC</given-names>
</string-name>, <string-name><surname>Acosta-Baena</surname><given-names>N</given-names></string-name>, <string-name><surname>Aisen</surname><given-names>PS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis</article-title>. <source>Neurology</source><year>2014</year>;<volume>83</volume>:<fpage>253</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">24928124</pub-id>
</mixed-citation></ref><ref id="CIT0389"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saab</surname>
<given-names>AS</given-names>
</string-name>, <string-name><surname>Tzvetavona</surname><given-names>ID</given-names></string-name>, <string-name><surname>Trevisiol</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism</article-title>. <source>Neuron</source><year>2016</year>;<volume>91</volume>:<fpage>119</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">27292539</pub-id>
</mixed-citation></ref><ref id="CIT0390"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sabia</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Fayosse</surname><given-names>A</given-names></string-name>, <string-name><surname>Dumurgier</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of sleep duration in middle and old age with incidence of dementia</article-title>. <source>Nat Commun</source><year>2021</year>;<volume>12</volume>:<fpage>2289</fpage>.<pub-id pub-id-type="pmid">33879784</pub-id>
</mixed-citation></ref><ref id="CIT0391"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sadick</surname>
<given-names>JS</given-names>
</string-name>, <string-name><surname>O&#x02019;Dea</surname><given-names>MR</given-names></string-name>, <string-name><surname>Hasel</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer&#x02019;s disease</article-title>. <source>Neuron</source><year>2022</year>;<volume>110</volume>:<fpage>1788</fpage>&#x02013;<lpage>1805.e10</lpage>.<pub-id pub-id-type="pmid">35381189</pub-id>
</mixed-citation></ref><ref id="CIT0392"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saeed</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Lopez</surname><given-names>O</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cardiovascular disease and Alzheimer&#x02019;s disease: the heart-brain axis</article-title>. <source>J Am Heart Assoc</source><year>2023</year>;<volume>12</volume>:<fpage>e030780</fpage>.<pub-id pub-id-type="pmid">37929715</pub-id>
</mixed-citation></ref><ref id="CIT0393"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Salloway</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Chalkias</surname><given-names>S</given-names></string-name>, <string-name><surname>Barkhof</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease</article-title>. <source>JAMA Neurol</source><year>2022</year>;<volume>79</volume>:<fpage>13</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">34807243</pub-id>
</mixed-citation></ref><ref id="CIT0394"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saman</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>W</given-names></string-name>, <string-name><surname>Raya</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease</article-title>. <source>J Biol Chem</source><year>2012</year>;<volume>287</volume>:<fpage>3842</fpage>&#x02013;<lpage>3849</lpage>.<pub-id pub-id-type="pmid">22057275</pub-id>
</mixed-citation></ref><ref id="CIT0396"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Samieri</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Perier</surname><given-names>MC</given-names></string-name>, <string-name><surname>Gaye</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of cardiovascular health level in older age with cognitive decline and incident dementia</article-title>. <source>JAMA</source><year>2018</year>;<volume>320</volume>:<fpage>657</fpage>&#x02013;<lpage>664</lpage>.<pub-id pub-id-type="pmid">30140876</pub-id>
</mixed-citation></ref><ref id="CIT0397"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sando</surname>
<given-names>SB</given-names>
</string-name>, <string-name><surname>Melquist</surname><given-names>S</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Risk-reducing effect of education in Alzheimer&#x02019;s disease</article-title>. <source>Int J Geriatr Psychiatry</source><year>2008</year>;<volume>23</volume>:<fpage>1156</fpage>&#x02013;<lpage>1162</lpage>.<pub-id pub-id-type="pmid">18484674</pub-id>
</mixed-citation></ref><ref id="CIT0398"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saresella</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>La Rosa</surname><given-names>F</given-names></string-name>, <string-name><surname>Piancone</surname><given-names>F</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer&#x02019;s disease</article-title>. <source>Mol Neurodegener</source><year>2016</year>;<volume>11</volume>:<fpage>23</fpage>.<pub-id pub-id-type="pmid">26939933</pub-id>
</mixed-citation></ref><ref id="CIT0399"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sartori</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Mendes</surname><given-names>T</given-names></string-name>, <string-name><surname>Desai</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr(348) phosphorylation</article-title>. <source>Acta Neuropathol</source><year>2019</year>;<volume>138</volume>:<fpage>631</fpage>&#x02013;<lpage>652</lpage>.<pub-id pub-id-type="pmid">31065832</pub-id>
</mixed-citation></ref><ref id="CIT0400"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sastre</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Steiner</surname><given-names>H</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch</article-title>. <source>EMBO Rep</source><year>2001</year>;<volume>2</volume>:<fpage>835</fpage>&#x02013;<lpage>841</lpage>.<pub-id pub-id-type="pmid">11520861</pub-id>
</mixed-citation></ref><ref id="CIT0401"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Savastano</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Flores</surname><given-names>D</given-names></string-name>, <string-name><surname>Kadavath</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Disease-associated Tau phosphorylation hinders tubulin assembly within Tau condensates</article-title>. <source>Angew Chem Int Ed Engl</source><year>2021</year>;<volume>60</volume>:<fpage>726</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">33017094</pub-id>
</mixed-citation></ref><ref id="CIT0402"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sayed</surname>
<given-names>FA</given-names>
</string-name>, <string-name><surname>Telpoukhovskaia</surname><given-names>M</given-names></string-name>, <string-name><surname>Kodama</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2018</year>;<volume>115</volume>:<fpage>10172</fpage>&#x02013;<lpage>10177</lpage>.<pub-id pub-id-type="pmid">30232263</pub-id>
</mixed-citation></ref><ref id="CIT0403"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Scheltens</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>De Strooper</surname><given-names>B</given-names></string-name>, <string-name><surname>Kivipelto</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>:<fpage>1577</fpage>&#x02013;<lpage>1590</lpage>.<pub-id pub-id-type="pmid">33667416</pub-id>
</mixed-citation></ref><ref id="CIT0404"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schlepckow</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Kleinberger</surname><given-names>G</given-names></string-name>, <string-name><surname>Fukumori</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function</article-title>. <source>EMBO Mol Med</source><year>2017</year>;<volume>9</volume>:<fpage>1356</fpage>&#x02013;<lpage>1365</lpage>.<pub-id pub-id-type="pmid">28855300</pub-id>
</mixed-citation></ref><ref id="CIT0405"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schmechel</surname>
<given-names>DE</given-names>
</string-name>, <string-name><surname>Saunders</surname><given-names>AM</given-names></string-name>, <string-name><surname>Strittmatter</surname><given-names>WJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1993</year>;<volume>90</volume>:<fpage>9649</fpage>&#x02013;<lpage>9653</lpage>.<pub-id pub-id-type="pmid">8415756</pub-id>
</mixed-citation></ref><ref id="CIT0406"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name><surname>Bienias</surname><given-names>JL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology</article-title>. <source>Neurology</source><year>2004</year>;<volume>62</volume>:<fpage>1148</fpage>&#x02013;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">15079015</pub-id>
</mixed-citation></ref><ref id="CIT0407"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schneider</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Boyle</surname><given-names>PA</given-names></string-name>, <string-name><surname>Arvanitakis</surname><given-names>Z</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Subcortical infarcts, Alzheimer&#x02019;s disease pathology, and memory function in older persons</article-title>. <source>Ann Neurol</source><year>2007</year>;<volume>62</volume>:<fpage>59</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">17503514</pub-id>
</mixed-citation></ref><ref id="CIT0408"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schrijvers</surname>
<given-names>EM</given-names>
</string-name>, <string-name><surname>Koudstaal</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Hofman</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Plasma clusterin and the risk of Alzheimer disease</article-title>. <source>JAMA</source><year>2011</year>;<volume>305</volume>:<fpage>1322</fpage>&#x02013;<lpage>1326</lpage>.<pub-id pub-id-type="pmid">21467285</pub-id>
</mixed-citation></ref><ref id="CIT0409"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Self</surname>
<given-names>WK</given-names>
</string-name>, <string-name><surname>Holtzman</surname><given-names>DM.</given-names></string-name></person-group>
<article-title>Emerging diagnostics and therapeutics for Alzheimer disease</article-title>. <source>Nat Med</source><year>2023</year>;<volume>29</volume>:<fpage>2187</fpage>&#x02013;<lpage>2199</lpage>.<pub-id pub-id-type="pmid">37667136</pub-id>
</mixed-citation></ref><ref id="CIT0410"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Serrano-Pozo</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Frosch</surname><given-names>MP</given-names></string-name>, <string-name><surname>Masliah</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Neuropathological alterations in Alzheimer disease</article-title>. <source>Cold Spring Harb Perspect Med</source><year>2011</year>;<volume>1</volume>:<fpage>a006189</fpage>.<pub-id pub-id-type="pmid">22229116</pub-id>
</mixed-citation></ref><ref id="CIT0411"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Fitzpatrick</surname><given-names>AL</given-names></string-name>, <string-name><surname>Ikram</surname><given-names>MA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Genome-wide analysis of genetic loci associated with Alzheimer disease</article-title>. <source>JAMA</source><year>2010</year>;<volume>303</volume>:<fpage>1832</fpage>&#x02013;<lpage>1840</lpage>.<pub-id pub-id-type="pmid">20460622</pub-id>
</mixed-citation></ref><ref id="CIT0412"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sha</surname>
<given-names>SJ</given-names>
</string-name>, <string-name><surname>Deutsch</surname><given-names>GK</given-names></string-name>, <string-name><surname>Tian</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer Symptom Amelioration Study: a randomized clinical trial</article-title>. <source>JAMA Neurol</source><year>2019</year>;<volume>76</volume>:<fpage>35</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">30383097</pub-id>
</mixed-citation></ref><ref id="CIT0413"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shafiei</surname>
<given-names>SS</given-names>
</string-name>, <string-name><surname>Guerrero-Munoz</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Castillo-Carranza</surname><given-names>DL.</given-names></string-name></person-group>
<article-title>Tau oligomers: cytotoxicity, propagation, and mitochondrial damage</article-title>. <source>Front Aging Neurosci</source><year>2017</year>;<volume>9</volume>:<fpage>83</fpage>.<pub-id pub-id-type="pmid">28420982</pub-id>
</mixed-citation></ref><ref id="CIT0414"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shahidehpour</surname>
<given-names>RK</given-names>
</string-name>, <string-name><surname>Higdon</surname><given-names>RE</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>NG</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain</article-title>. <source>Neurobiol Aging</source><year>2021</year>;<volume>99</volume>:<fpage>19</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">33422891</pub-id>
</mixed-citation></ref><ref id="CIT0415"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shahim</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Tegner</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>DH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Blood biomarkers for brain injury in concussed professional ice hockey players</article-title>. <source>JAMA Neurol</source><year>2014</year>;<volume>71</volume>:<fpage>684</fpage>&#x02013;<lpage>692</lpage>.<pub-id pub-id-type="pmid">24627036</pub-id>
</mixed-citation></ref><ref id="CIT0416"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sherrington</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Rogaev</surname><given-names>EI</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x02019;s disease</article-title>. <source>Nature</source><year>1995</year>;<volume>375</volume>:<fpage>754</fpage>&#x02013;<lpage>760</lpage>.<pub-id pub-id-type="pmid">7596406</pub-id>
</mixed-citation></ref><ref id="CIT0417"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Yamada</surname><given-names>K</given-names></string-name>, <string-name><surname>Liddelow</surname><given-names>SA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy</article-title>. <source>Nature</source><year>2017</year>;<volume>549</volume>:<fpage>523</fpage>&#x02013;<lpage>527</lpage>.<pub-id pub-id-type="pmid">28959956</pub-id>
</mixed-citation></ref><ref id="CIT0418"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Murzin</surname><given-names>AG</given-names></string-name>, <string-name><surname>Falcon</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cryo-EM structures of tau filaments from Alzheimer&#x02019;s disease with PET ligand APN-1607</article-title>. <source>Acta Neuropathol</source><year>2021a</year>;<volume>141</volume>:<fpage>697</fpage>&#x02013;<lpage>708</lpage>.<pub-id pub-id-type="pmid">33723967</pub-id>
</mixed-citation></ref><ref id="CIT0419"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Structure-based classification of tauopathies</article-title>. <source>Nature</source><year>2021b</year>;<volume>598</volume>:<fpage>359</fpage>&#x02013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">34588692</pub-id>
</mixed-citation></ref><ref id="CIT0420"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shiells</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Schelter</surname><given-names>BO</given-names></string-name>, <string-name><surname>Bentham</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia</article-title>. <source>J Alzheimers Dis</source><year>2020</year>;<volume>75</volume>:<fpage>501</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">32280089</pub-id>
</mixed-citation></ref><ref id="CIT0421"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shinohara</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Murray</surname><given-names>ME</given-names></string-name>, <string-name><surname>Frank</surname><given-names>RD</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol</source><year>2016</year>;<volume>132</volume>:<fpage>225</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">27179972</pub-id>
</mixed-citation></ref><ref id="CIT0422"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shukla</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Skuntz</surname><given-names>S</given-names></string-name>, <string-name><surname>Pant</surname><given-names>HC.</given-names></string-name></person-group>
<article-title>Deregulated Cdk5 activity is involved in inducing Alzheimer&#x02019;s disease</article-title>. <source>Arch Med Res</source><year>2012</year>;<volume>43</volume>:<fpage>655</fpage>&#x02013;<lpage>662</lpage>.<pub-id pub-id-type="pmid">23142263</pub-id>
</mixed-citation></ref><ref id="CIT0423"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sims</surname>
<given-names>JR</given-names>
</string-name>, <string-name><surname>Zimmer</surname><given-names>JA</given-names></string-name>, <string-name><surname>Evans</surname><given-names>CD</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial</article-title>. <source>JAMA</source><year>2023</year>;<volume>330</volume>:<fpage>512</fpage>&#x02013;<lpage>527</lpage>.<pub-id pub-id-type="pmid">37459141</pub-id>
</mixed-citation></ref><ref id="CIT0424"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sinha</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Anderson</surname><given-names>JP</given-names></string-name>, <string-name><surname>Barbour</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Purification and cloning of amyloid precursor protein beta-secretase from human brain</article-title>. <source>Nature</source><year>1999</year>;<volume>402</volume>:<fpage>537</fpage>&#x02013;<lpage>540</lpage>.<pub-id pub-id-type="pmid">10591214</pub-id>
</mixed-citation></ref><ref id="CIT0425"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sisodia</surname>
<given-names>SS</given-names>
</string-name>, <string-name><surname>Koo</surname><given-names>EH</given-names></string-name>, <string-name><surname>Beyreuther</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Evidence that beta-amyloid protein in Alzheimer&#x02019;s disease is not derived by normal processing</article-title>. <source>Science</source><year>1990</year>;<volume>248</volume>:<fpage>492</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">1691865</pub-id>
</mixed-citation></ref><ref id="CIT0426"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Skillback</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Farahmand</surname><given-names>BY</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia</article-title>. <source>Brain</source><year>2015</year>;<volume>138</volume>:<fpage>2716</fpage>&#x02013;<lpage>2731</lpage>.<pub-id pub-id-type="pmid">26133663</pub-id>
</mixed-citation></ref><ref id="CIT0427"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Smith</surname>
<given-names>DH</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>XH</given-names></string-name>, <string-name><surname>Iwata</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid beta accumulation in axons after traumatic brain injury in humans</article-title>. <source>J Neurosurg</source><year>2003</year>;<volume>98</volume>:<fpage>1072</fpage>&#x02013;<lpage>1077</lpage>.<pub-id pub-id-type="pmid">12744368</pub-id>
</mixed-citation></ref><ref id="CIT0428"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sohn</surname>
<given-names>PD</given-names>
</string-name>, <string-name><surname>Tracy</surname><given-names>TE</given-names></string-name>, <string-name><surname>Son</surname><given-names>HI</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment</article-title>. <source>Mol Neurodegener</source><year>2016</year>;<volume>11</volume>:<fpage>47</fpage>.<pub-id pub-id-type="pmid">27356871</pub-id>
</mixed-citation></ref><ref id="CIT0429"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sommerlad</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Kivimaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Larson</surname><given-names>EB</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Social participation and risk of developing dementia</article-title>. <source>Nat Aging</source><year>2023</year>;<volume>3</volume>:<fpage>532</fpage>&#x02013;<lpage>545</lpage>.<pub-id pub-id-type="pmid">37202513</pub-id>
</mixed-citation></ref><ref id="CIT0430"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Song</surname>
<given-names>HL</given-names>
</string-name>, <string-name><surname>Shim</surname><given-names>S</given-names></string-name>, <string-name><surname>Kim</surname><given-names>DH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>beta-Amyloid is transmitted via neuronal connections along axonal membranes</article-title>. <source>Ann Neurol</source><year>2014</year>;<volume>75</volume>:<fpage>88</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">24114864</pub-id>
</mixed-citation></ref><ref id="CIT0431"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Song</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Hooli</surname><given-names>B</given-names></string-name>, <string-name><surname>Mullin</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation</article-title>. <source>Alzheimers Dement</source><year>2017</year>;<volume>13</volume>:<fpage>381</fpage>&#x02013;<lpage>387</lpage>.<pub-id pub-id-type="pmid">27520774</pub-id>
</mixed-citation></ref><ref id="CIT0432"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Song</surname>
<given-names>WM</given-names>
</string-name>, <string-name><surname>Joshita</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism</article-title>. <source>J Exp Med</source><year>2018</year>;<volume>215</volume>:<fpage>745</fpage>&#x02013;<lpage>760</lpage>.<pub-id pub-id-type="pmid">29321225</pub-id>
</mixed-citation></ref><ref id="CIT0433"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sontag</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Luangpirom</surname><given-names>A</given-names></string-name>, <string-name><surname>Hladik</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology</article-title>. <source>J Neuropathol Exp Neurol</source><year>2004</year>;<volume>63</volume>:<fpage>287</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">15099019</pub-id>
</mixed-citation></ref><ref id="CIT0434"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Soula</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Martin-Avila</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Forty-hertz light stimulation does not entrain native gamma oscillations in Alzheimer&#x02019;s disease model mice</article-title>. <source>Nat Neurosci</source><year>2023</year>;<volume>26</volume>:<fpage>570</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">36879142</pub-id>
</mixed-citation></ref><ref id="CIT0435"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Spangenberg</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Severson</surname><given-names>PL</given-names></string-name>, <string-name><surname>Hohsfield</surname><given-names>LA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x02019;s disease model</article-title>. <source>Nat Commun</source><year>2019</year>;<volume>10</volume>:<fpage>3758</fpage>.<pub-id pub-id-type="pmid">31434879</pub-id>
</mixed-citation></ref><ref id="CIT0436"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Spillantini</surname>
<given-names>MG</given-names>
</string-name>, <string-name><surname>Goedert</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Tau protein pathology in neurodegenerative diseases</article-title>. <source>Trends Neurosci</source><year>1998</year>;<volume>21</volume>:<fpage>428</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">9786340</pub-id>
</mixed-citation></ref><ref id="CIT0437"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stadelmann</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Bruck</surname><given-names>W</given-names></string-name>, <string-name><surname>Bancher</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis</article-title>. <source>J Neuropathol Exp Neurol</source><year>1998</year>;<volume>57</volume>:<fpage>456</fpage>&#x02013;<lpage>464</lpage>.<pub-id pub-id-type="pmid">9596416</pub-id>
</mixed-citation></ref><ref id="CIT0438"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Steen</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Terry</surname><given-names>BM</given-names></string-name>, <string-name><surname>Rivera</surname><given-names>EJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer&#x02019;s disease&#x02013;is this type 3 diabetes</article-title>? <source>J Alzheimers Dis</source><year>2005</year>;<volume>7</volume>:<fpage>63</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">15750215</pub-id>
</mixed-citation></ref><ref id="CIT0439"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Streit</surname>
<given-names>WJ</given-names>
</string-name>, <string-name><surname>Braak</surname><given-names>H</given-names></string-name>, <string-name><surname>Xue</surname><given-names>QS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol</source><year>2009</year>;<volume>118</volume>:<fpage>475</fpage>&#x02013;<lpage>485</lpage>.<pub-id pub-id-type="pmid">19513731</pub-id>
</mixed-citation></ref><ref id="CIT0440"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Suarez-Calvet</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Karikari</surname><given-names>TK</given-names></string-name>, <string-name><surname>Ashton</surname><given-names>NJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer&#x02019;s continuum when only subtle changes in Abeta pathology are detected</article-title>. <source>EMBO Mol Med</source><year>2020</year>;<volume>12</volume>:<fpage>e12921</fpage>.<pub-id pub-id-type="pmid">33169916</pub-id>
</mixed-citation></ref><ref id="CIT0441"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Suelves</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Saleki</surname><given-names>S</given-names></string-name>, <string-name><surname>Ibrahim</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-beta accumulation in a mouse model of amyloid pathology</article-title>. <source>Acta Neuropathol Commun</source><year>2023</year>;<volume>11</volume>:<fpage>82</fpage>.<pub-id pub-id-type="pmid">37198698</pub-id>
</mixed-citation></ref><ref id="CIT0442"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sugarman</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name><surname>Blennow</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer&#x02019;s disease</article-title>. <source>Neurobiol Aging</source><year>2020</year>;<volume>94</volume>:<fpage>60</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">32585491</pub-id>
</mixed-citation></ref><ref id="CIT0443"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Suri</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Topiwala</surname><given-names>A</given-names></string-name>, <string-name><surname>Chappell</surname><given-names>MA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of midlife cardiovascular risk profiles with cerebral perfusion at older ages</article-title>. <source>JAMA Netw Open</source><year>2019</year>;<volume>2</volume>:<fpage>e195776</fpage>.<pub-id pub-id-type="pmid">31225888</pub-id>
</mixed-citation></ref><ref id="CIT0444"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sveikata</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Charidimou</surname><given-names>A</given-names></string-name>, <string-name><surname>Viswanathan</surname><given-names>A.</given-names></string-name></person-group>
<article-title>Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab</article-title>. <source>Stroke</source><year>2022</year>;<volume>53</volume>:<fpage>298</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">34905943</pub-id>
</mixed-citation></ref><ref id="CIT0445"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Takasugi</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Tomita</surname><given-names>T</given-names></string-name>, <string-name><surname>Hayashi</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The role of presenilin cofactors in the gamma-secretase complex</article-title>. <source>Nature</source><year>2003</year>;<volume>422</volume>:<fpage>438</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">12660785</pub-id>
</mixed-citation></ref><ref id="CIT0446"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tan</surname>
<given-names>JX</given-names>
</string-name>, <string-name><surname>Finkel</surname><given-names>T.</given-names></string-name></person-group>
<article-title>A phosphoinositide signalling pathway mediates rapid lysosomal repair</article-title>. <source>Nature</source><year>2022</year>;<volume>609</volume>:<fpage>815</fpage>&#x02013;<lpage>821</lpage>.<pub-id pub-id-type="pmid">36071159</pub-id>
</mixed-citation></ref><ref id="CIT0447"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tan</surname>
<given-names>MS</given-names>
</string-name>, <string-name><surname>Tan</surname><given-names>L</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer&#x02019;s disease</article-title>. <source>Cell Death Dis</source><year>2014</year>;<volume>5</volume>:<fpage>e1382</fpage>.<pub-id pub-id-type="pmid">25144717</pub-id>
</mixed-citation></ref><ref id="CIT0448"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tao</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Ang</surname><given-names>TFA</given-names></string-name>, <string-name><surname>DeCarli</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Association of chronic low-grade inflammation with risk of Alzheimer disease in ApoE4 carriers</article-title>. <source>JAMA Netw Open</source><year>2018</year>;<volume>1</volume>:<fpage>e183597</fpage>.<pub-id pub-id-type="pmid">30646251</pub-id>
</mixed-citation></ref><ref id="CIT0449"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tarawneh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Holtzman</surname><given-names>DM.</given-names></string-name></person-group>
<article-title>The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment</article-title>. <source>Cold Spring Harb Perspect Med</source><year>2012</year>;<volume>2</volume>:<fpage>a006148</fpage>.<pub-id pub-id-type="pmid">22553492</pub-id>
</mixed-citation></ref><ref id="CIT0450"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tcw</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Goate</surname><given-names>AM.</given-names></string-name></person-group>
<article-title>Genetics of beta-amyloid precursor protein in Alzheimer&#x02019;s disease</article-title>. <source>Cold Spring Harb Perspect Med</source><year>2017</year>;<volume>7</volume>:<fpage>a024539</fpage>.<pub-id pub-id-type="pmid">28003277</pub-id>
</mixed-citation></ref><ref id="CIT0451"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tell</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Hilgeroth</surname><given-names>A.</given-names></string-name></person-group>
<article-title>Recent developments of protein kinase inhibitors as potential AD therapeutics</article-title>. <source>Front Cell Neurosci</source><year>2013</year>;<volume>7</volume>:<fpage>189</fpage>.<pub-id pub-id-type="pmid">24312003</pub-id>
</mixed-citation></ref><ref id="CIT0452"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Terry</surname>
<given-names>RD.</given-names>
</string-name>
</person-group>
<article-title>The fine structure of neurofibrillary tangles in Alzheimer&#x02019;s disease</article-title>. <source>J Neuropathol Exp Neurol</source><year>1963</year>;<volume>22</volume>:<fpage>629</fpage>&#x02013;<lpage>642</lpage>.<pub-id pub-id-type="pmid">14069842</pub-id>
</mixed-citation></ref><ref id="CIT0453"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Teunissen</surname>
<given-names>CE</given-names>
</string-name>, <string-name><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name><surname>Thijssen</surname><given-names>EH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Blood-based biomarkers for Alzheimer&#x02019;s disease: towards clinical implementation</article-title>. <source>Lancet Neurol</source><year>2022</year>;<volume>21</volume>:<fpage>66</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">34838239</pub-id>
</mixed-citation></ref><ref id="CIT0454"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thal</surname>
<given-names>DR</given-names>
</string-name>, <string-name><surname>Gawor</surname><given-names>K</given-names></string-name>, <string-name><surname>Moonen</surname><given-names>S.</given-names></string-name></person-group>
<article-title>Regulated cell death and its role in Alzheimer&#x02019;s disease and amyotrophic lateral sclerosis</article-title>. <source>Acta Neuropathol</source><year>2024</year>;<volume>147</volume>:<fpage>69</fpage>.<pub-id pub-id-type="pmid">38583129</pub-id>
</mixed-citation></ref><ref id="CIT0455"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Theofilas</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Piergies</surname><given-names>AMH</given-names></string-name>, <string-name><surname>Oh</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Caspase-6-cleaved tau is relevant in Alzheimer&#x02019;s disease and marginal in four-repeat tauopathies: Diagnostic and therapeutic implications</article-title>. <source>Neuropathol Appl Neurobiol</source><year>2022</year>;<volume>48</volume>:<fpage>e12819</fpage>.<pub-id pub-id-type="pmid">35508761</pub-id>
</mixed-citation></ref><ref id="CIT0456"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thomas</surname>
<given-names>SN</given-names>
</string-name>, <string-name><surname>Funk</surname><given-names>KE</given-names></string-name>, <string-name><surname>Wan</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Dual modification of Alzheimer&#x02019;s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach</article-title>. <source>Acta Neuropathol</source><year>2012</year>;<volume>123</volume>:<fpage>105</fpage>&#x02013;<lpage>117</lpage>.<pub-id pub-id-type="pmid">22033876</pub-id>
</mixed-citation></ref><ref id="CIT0457"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thomson</surname>
<given-names>RS</given-names>
</string-name>, <string-name><surname>Auduong</surname><given-names>P</given-names></string-name>, <string-name><surname>Miller</surname><given-names>AT</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Hearing loss as a risk factor for dementia: a systematic review</article-title>. <source>Laryngoscope Investig Otolaryngol</source><year>2017</year>;<volume>2</volume>:<fpage>69</fpage>&#x02013;<lpage>79</lpage>.</mixed-citation></ref><ref id="CIT0458"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thornton</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Sevalle</surname><given-names>J</given-names></string-name>, <string-name><surname>Deery</surname><given-names>MJ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer&#x02019;s disease-associated H157Y variant</article-title>. <source>EMBO Mol Med</source><year>2017</year>;<volume>9</volume>:<fpage>1366</fpage>&#x02013;<lpage>1378</lpage>.<pub-id pub-id-type="pmid">28855301</pub-id>
</mixed-citation></ref><ref id="CIT0459"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tiraboschi</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Hansen</surname><given-names>LA</given-names></string-name>, <string-name><surname>Masliah</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease</article-title>. <source>Neurology</source><year>2004</year>;<volume>62</volume>:<fpage>1977</fpage>&#x02013;<lpage>1983</lpage>.<pub-id pub-id-type="pmid">15184600</pub-id>
</mixed-citation></ref><ref id="CIT0460"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tooyama</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Kimura</surname><given-names>H</given-names></string-name>, <string-name><surname>Akiyama</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer&#x02019;s disease</article-title>. <source>Brain Res</source><year>1990</year>;<volume>523</volume>:<fpage>273</fpage>&#x02013;<lpage>280</lpage>.<pub-id pub-id-type="pmid">2400911</pub-id>
</mixed-citation></ref><ref id="CIT0461"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tracy</surname>
<given-names>TE</given-names>
</string-name>, <string-name><surname>Sohn</surname><given-names>PD</given-names></string-name>, <string-name><surname>Minami</surname><given-names>SS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Acetylated Tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss</article-title>. <source>Neuron</source><year>2016</year>;<volume>90</volume>:<fpage>245</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">27041503</pub-id>
</mixed-citation></ref><ref id="CIT0462"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tuo</surname>
<given-names>QZ</given-names>
</string-name>, <string-name><surname>Lei</surname><given-names>P</given-names></string-name>, <string-name><surname>Jackman</surname><given-names>KA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau-mediated iron export prevents ferroptotic damage after ischemic stroke</article-title>. <source>Mol Psychiatry</source><year>2017</year>;<volume>22</volume>:<fpage>1520</fpage>&#x02013;<lpage>1530</lpage>.<pub-id pub-id-type="pmid">28886009</pub-id>
</mixed-citation></ref><ref id="CIT0463"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Turnquist</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Horikawa</surname><given-names>I</given-names></string-name>, <string-name><surname>Foran</surname><given-names>E</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration</article-title>. <source>Cell Death Differ</source><year>2016</year>;<volume>23</volume>:<fpage>1515</fpage>&#x02013;<lpage>1528</lpage>.<pub-id pub-id-type="pmid">27104929</pub-id>
</mixed-citation></ref><ref id="CIT0464"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tzeng</surname>
<given-names>NS</given-names>
</string-name>, <string-name><surname>Chung</surname><given-names>CH</given-names></string-name>, <string-name><surname>Lin</surname><given-names>FH</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections-a nationwide, population-based cohort study in Taiwan</article-title>. <source>Neurotherapeutics</source><year>2018</year>;<volume>15</volume>:<fpage>417</fpage>&#x02013;<lpage>429</lpage>.<pub-id pub-id-type="pmid">29488144</pub-id>
</mixed-citation></ref><ref id="CIT0465"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vagelatos</surname>
<given-names>NT</given-names>
</string-name>, <string-name><surname>Eslick</surname><given-names>GD.</given-names></string-name></person-group>
<article-title>Type 2 diabetes as a risk factor for Alzheimer&#x02019;s disease: the confounders, interactions, and neuropathology associated with this relationship</article-title>. <source>Epidemiol Rev</source><year>2013</year>;<volume>35</volume>:<fpage>152</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">23314404</pub-id>
</mixed-citation></ref><ref id="CIT0466"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Acker Z</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Perdok</surname><given-names>A</given-names></string-name>, <string-name><surname>Bretou</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The microglial lysosomal system in Alzheimer&#x02019;s disease: guardian against proteinopathy</article-title>. <source>Ageing Res Rev</source><year>2021</year>;<volume>71</volume>:<fpage>101444</fpage>.<pub-id pub-id-type="pmid">34391945</pub-id>
</mixed-citation></ref><ref id="CIT0467"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van der Ende</surname>
<given-names>EL</given-names>
</string-name>, <string-name><surname>Bron</surname><given-names>EE</given-names></string-name>, <string-name><surname>Poos</surname><given-names>JM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia</article-title>. <source>Brain</source><year>2022</year>;<volume>145</volume>:<fpage>1805</fpage>&#x02013;<lpage>1817</lpage>.<pub-id pub-id-type="pmid">34633446</pub-id>
</mixed-citation></ref><ref id="CIT0468"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Dyck</surname>
<given-names>CH</given-names>
</string-name>, <string-name><surname>Swanson</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Aisen</surname><given-names>P</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Lecanemab in early Alzheimer&#x02019;s disease</article-title>. <source>N Engl J Med</source><year>2023</year>;<volume>388</volume>:<fpage>9</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id>
</mixed-citation></ref><ref id="CIT0469"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vassar</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Bennett</surname><given-names>BD</given-names></string-name>, <string-name><surname>Babu-Khan</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Beta-secretase cleavage of Alzheimer&#x02019;s amyloid precursor protein by the transmembrane aspartic protease BACE</article-title>. <source>Science</source><year>1999</year>;<volume>286</volume>:<fpage>735</fpage>&#x02013;<lpage>741</lpage>.<pub-id pub-id-type="pmid">10531052</pub-id>
</mixed-citation></ref><ref id="CIT0470"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Verghese</surname>
<given-names>PB</given-names>
</string-name>, <string-name><surname>Castellano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Garai</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2013</year>;<volume>110</volume>:<fpage>E1807</fpage>&#x02013;<lpage>E1816</lpage>.<pub-id pub-id-type="pmid">23620513</pub-id>
</mixed-citation></ref><ref id="CIT0471"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vershinin</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Carter</surname><given-names>BC</given-names></string-name>, <string-name><surname>Razafsky</surname><given-names>DS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Multiple-motor based transport and its regulation by Tau</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2007</year>;<volume>104</volume>:<fpage>87</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">17190808</pub-id>
</mixed-citation></ref><ref id="CIT0472"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Villain</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Planche</surname><given-names>V</given-names></string-name>, <string-name><surname>Levy</surname><given-names>R.</given-names></string-name></person-group>
<article-title>High-clearance anti-amyloid immunotherapies in Alzheimer&#x02019;s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects</article-title>. <source>Rev Neurol (Paris)</source><year>2022</year>;<volume>178</volume>:<fpage>1011</fpage>&#x02013;<lpage>1030</lpage>.<pub-id pub-id-type="pmid">36184326</pub-id>
</mixed-citation></ref><ref id="CIT0473"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vogelsberg-Ragaglia</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Schuck</surname><given-names>T</given-names></string-name>, <string-name><surname>Trojanowski</surname><given-names>JQ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>PP2A mRNA expression is quantitatively decreased in Alzheimer&#x02019;s disease hippocampus</article-title>. <source>Exp Neurol</source><year>2001</year>;<volume>168</volume>:<fpage>402</fpage>&#x02013;<lpage>412</lpage>.<pub-id pub-id-type="pmid">11259128</pub-id>
</mixed-citation></ref><ref id="CIT0474"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wakabayashi</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Yamaguchi</surname><given-names>K</given-names></string-name>, <string-name><surname>Matsui</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer&#x02019;s disease</article-title>. <source>Mol Neurodegener</source><year>2019</year>;<volume>14</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">30975165</pub-id>
</mixed-citation></ref><ref id="CIT0475"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walker</surname>
<given-names>LC</given-names>
</string-name>, <string-name><surname>Jucker</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Neurodegenerative diseases: expanding the prion concept</article-title>. <source>Annu Rev Neurosci</source><year>2015</year>;<volume>38</volume>:<fpage>87</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">25840008</pub-id>
</mixed-citation></ref><ref id="CIT0476"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walter</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Fluhrer</surname><given-names>R</given-names></string-name>, <string-name><surname>Hartung</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Phosphorylation regulates intracellular trafficking of beta-secretase</article-title>. <source>J Biol Chem</source><year>2001</year>;<volume>276</volume>:<fpage>14634</fpage>&#x02013;<lpage>14641</lpage>.<pub-id pub-id-type="pmid">11278841</pub-id>
</mixed-citation></ref><ref id="CIT0477"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Mandelkow</surname><given-names>E.</given-names></string-name></person-group>
<article-title>Tau in physiology and pathology</article-title>. <source>Nat Rev Neurosci</source><year>2016</year>;<volume>17</volume>:<fpage>5</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">26631930</pub-id>
</mixed-citation></ref><ref id="CIT0478"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>JZ</given-names>
</string-name>, <string-name><surname>Grundke-Iqbal</surname><given-names>I</given-names></string-name>, <string-name><surname>Iqbal</surname><given-names>K.</given-names></string-name></person-group>
<article-title>Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer&#x02019;s disease</article-title>. <source>Nat Med</source><year>1996</year>;<volume>2</volume>:<fpage>871</fpage>&#x02013;<lpage>875</lpage>.<pub-id pub-id-type="pmid">8705855</pub-id>
</mixed-citation></ref><ref id="CIT0479"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Cella</surname><given-names>M</given-names></string-name>, <string-name><surname>Mallinson</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x02019;s disease model</article-title>. <source>Cell</source><year>2015</year>;<volume>160</volume>:<fpage>1061</fpage>&#x02013;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">25728668</pub-id>
</mixed-citation></ref><ref id="CIT0480"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Joberty</surname><given-names>G</given-names></string-name>, <string-name><surname>Buist</surname><given-names>A</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>Acta Neuropathol</source><year>2017a</year>;<volume>133</volume>:<fpage>731</fpage>&#x02013;<lpage>749</lpage>.<pub-id pub-id-type="pmid">28083634</pub-id>
</mixed-citation></ref><ref id="CIT0481"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Balaji</surname><given-names>V</given-names></string-name>, <string-name><surname>Kaniyappan</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The release and trans-synaptic transmission of Tau via exosomes</article-title>. <source>Mol Neurodegener</source><year>2017b</year>;<volume>12</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">28086931</pub-id>
</mixed-citation></ref><ref id="CIT0482"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Mustafa</surname><given-names>M</given-names></string-name>, <string-name><surname>Yuede</surname><given-names>CM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x02019;s disease model</article-title>. <source>J Exp Med</source><year>2020a</year>;<volume>217</volume>:<fpage>1</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">32040157</pub-id>
</mixed-citation></ref><ref id="CIT0483"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis</article-title>. <source>Neurology</source><year>2020b</year>;<volume>95</volume>:<fpage>e2610</fpage>&#x02013;<lpage>e2621</lpage>.<pub-id pub-id-type="pmid">32887786</pub-id>
</mixed-citation></ref><ref id="CIT0484"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Fan</surname><given-names>L</given-names></string-name>, <string-name><surname>Khawaja</surname><given-names>RR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Microglial NF-kappaB drives tau spreading and toxicity in a mouse model of tauopathy</article-title>. <source>Nat Commun</source><year>2022</year>;<volume>13</volume>:<fpage>1969</fpage>.<pub-id pub-id-type="pmid">35413950</pub-id>
</mixed-citation></ref><ref id="CIT0485"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Nambiar</surname><given-names>A</given-names></string-name>, <string-name><surname>Strickland</surname><given-names>MR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE-epsilon4 synergizes with sleep disruption to accelerate Abeta deposition and Abeta-associated tau seeding and spreading</article-title>. <source>J Clin Invest</source><year>2023</year>;<volume>133</volume>:<fpage>1</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="CIT0486"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Martini-Stoica</surname><given-names>H</given-names></string-name>, <string-name><surname>Qi</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TFEB-vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy</article-title>. <source>Nat Neurosci</source><year>2024</year>;<volume>27</volume>:<fpage>48</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">37985800</pub-id>
</mixed-citation></ref><ref id="CIT0487"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wardlaw</surname>
<given-names>JM</given-names>
</string-name>, <string-name><surname>Smith</surname><given-names>C</given-names></string-name>, <string-name><surname>Dichgans</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Small vessel disease: mechanisms and clinical implications</article-title>. <source>Lancet Neurol</source><year>2019</year>;<volume>18</volume>:<fpage>684</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">31097385</pub-id>
</mixed-citation></ref><ref id="CIT0488"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wei</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Hou</surname><given-names>J</given-names></string-name>, <string-name><surname>Su</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The prevalence of frascati-criteria-based HIV-Associated Neurocognitive Disorder (HAND) in HIV-infected adults: a systematic review and meta-analysis</article-title>. <source>Front Neurol</source><year>2020</year>;<volume>11</volume>:<fpage>581346</fpage>.<pub-id pub-id-type="pmid">33335509</pub-id>
</mixed-citation></ref><ref id="CIT0489"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Weiner</surname>
<given-names>MW</given-names>
</string-name>, <string-name><surname>Veitch</surname><given-names>DP</given-names></string-name>, <string-name><surname>Hayes</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer&#x02019;s disease in veterans, using the Alzheimer&#x02019;s Disease Neuroimaging Initiative</article-title>. <source>Alzheimers Dement</source><year>2014</year>;<volume>10</volume>:<fpage>S226</fpage>&#x02013;<lpage>S235</lpage>.<pub-id pub-id-type="pmid">24924673</pub-id>
</mixed-citation></ref><ref id="CIT0490"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Weisgraber</surname>
<given-names>KH</given-names>
</string-name>, <string-name><surname>Innerarity</surname><given-names>TL</given-names></string-name>, <string-name><surname>Mahley</surname><given-names>RW.</given-names></string-name></person-group>
<article-title>Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site</article-title>. <source>J Biol Chem</source><year>1982</year>;<volume>257</volume>:<fpage>2518</fpage>&#x02013;<lpage>2521</lpage>.<pub-id pub-id-type="pmid">6277903</pub-id>
</mixed-citation></ref><ref id="CIT0491"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wendeln</surname>
<given-names>AC</given-names>
</string-name>, <string-name><surname>Degenhardt</surname><given-names>K</given-names></string-name>, <string-name><surname>Kaurani</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Innate immune memory in the brain shapes neurological disease hallmarks</article-title>. <source>Nature</source><year>2018</year>;<volume>556</volume>:<fpage>332</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">29643512</pub-id>
</mixed-citation></ref><ref id="CIT0492"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wesseling</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Mair</surname><given-names>W</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Tau PTM profiles identify patient heterogeneity and stages of Alzheimer&#x02019;s disease</article-title>. <source>Cell</source><year>2020</year>;<volume>183</volume>:<fpage>1699</fpage>&#x02013;<lpage>1713.e13</lpage>.<pub-id pub-id-type="pmid">33188775</pub-id>
</mixed-citation></ref><ref id="CIT0493"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Weston</surname>
<given-names>PSJ</given-names>
</string-name>, <string-name><surname>Poole</surname><given-names>T</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>NS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration</article-title>. <source>Neurology</source><year>2017</year>;<volume>89</volume>:<fpage>2167</fpage>&#x02013;<lpage>2175</lpage>.<pub-id pub-id-type="pmid">29070659</pub-id>
</mixed-citation></ref><ref id="CIT0494"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Willem</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Tahirovic</surname><given-names>S</given-names></string-name>, <string-name><surname>Busche</surname><given-names>MA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>eta-Secretase processing of APP inhibits neuronal activity in the hippocampus</article-title>. <source>Nature</source><year>2015</year>;<volume>526</volume>:<fpage>443</fpage>&#x02013;<lpage>447</lpage>.<pub-id pub-id-type="pmid">26322584</pub-id>
</mixed-citation></ref><ref id="CIT0495"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Winblad</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Amouyel</surname><given-names>P</given-names></string-name>, <string-name><surname>Andrieu</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Defeating Alzheimer&#x02019;s disease and other dementias: a priority for European science and society</article-title>. <source>Lancet Neurol</source><year>2016</year>;<volume>15</volume>:<fpage>455</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">26987701</pub-id>
</mixed-citation></ref><ref id="CIT0496"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</string-name>, <string-name><surname>Dalton</surname><given-names>AJ</given-names></string-name>, <string-name><surname>McLachlan</surname><given-names>C</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease in Down&#x02019;s syndrome: clinicopathologic studies</article-title>. <source>Neurology</source><year>1985</year>;<volume>35</volume>:<fpage>957</fpage>&#x02013;<lpage>961</lpage>.<pub-id pub-id-type="pmid">3159974</pub-id>
</mixed-citation></ref><ref id="CIT0497"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wissfeld</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Nozaki</surname><given-names>I</given-names></string-name>, <string-name><surname>Mathews</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Deletion of Alzheimer&#x02019;s disease-associated CD33 results in an inflammatory human microglia phenotype</article-title>. <source>Glia</source><year>2021</year>;<volume>69</volume>:<fpage>1393</fpage>&#x02013;<lpage>1412</lpage>.<pub-id pub-id-type="pmid">33539598</pub-id>
</mixed-citation></ref><ref id="CIT0498"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wojtas</surname>
<given-names>AM</given-names>
</string-name>, <string-name><surname>Kang</surname><given-names>SS</given-names></string-name>, <string-name><surname>Olley</surname><given-names>BM</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2017</year>;<volume>114</volume>:<fpage>E6962</fpage>&#x02013;<lpage>E6971</lpage>.<pub-id pub-id-type="pmid">28701379</pub-id>
</mixed-citation></ref><ref id="CIT0499"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wu</surname>
<given-names>JW</given-names>
</string-name>, <string-name><surname>Herman</surname><given-names>M</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons</article-title>. <source>J Biol Chem</source><year>2013</year>;<volume>288</volume>:<fpage>1856</fpage>&#x02013;<lpage>1870</lpage>.<pub-id pub-id-type="pmid">23188818</pub-id>
</mixed-citation></ref><ref id="CIT0500"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>J</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Mild traumatic brain injury induces microvascular injury and accelerates Alzheimer-like pathogenesis in mice</article-title>. <source>Acta Neuropathol Commun</source><year>2021</year>;<volume>9</volume>:<fpage>74</fpage>.<pub-id pub-id-type="pmid">33892818</pub-id>
</mixed-citation></ref><ref id="CIT0501"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wu</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Sun</surname><given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Targeting aging and age-related diseases with vaccines</article-title>. <source>Nat Aging</source><year>2024</year>;<volume>4</volume>:<fpage>464</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">38622408</pub-id>
</mixed-citation></ref><ref id="CIT0502"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xie</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Kang</surname><given-names>H</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Q</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Sleep drives metabolite clearance from the adult brain</article-title>. <source>Science</source><year>2013</year>;<volume>342</volume>:<fpage>373</fpage>&#x02013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">24136970</pub-id>
</mixed-citation></ref><ref id="CIT0503"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xie</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>YU</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration</article-title>. <source>Nat Neurosci</source><year>2022</year>;<volume>25</volume>:<fpage>26</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">34916658</pub-id>
</mixed-citation></ref><ref id="CIT0504"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xiong</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>James</surname><given-names>BT</given-names></string-name>, <string-name><surname>Boix</surname><given-names>CA</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Epigenomic dissection of Alzheimer&#x02019;s disease pinpoints causal variants and reveals epigenome erosion</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>4422</fpage>&#x02013;<lpage>4437.e21</lpage>.<pub-id pub-id-type="pmid">37774680</pub-id>
</mixed-citation></ref><ref id="CIT0505"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xu</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Xiao</surname><given-names>N</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits</article-title>. <source>Mol Neurodegener</source><year>2015</year>;<volume>10</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">26526066</pub-id>
</mixed-citation></ref><ref id="CIT0506"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Kanaya</surname><given-names>A</given-names></string-name>, <string-name><surname>Lindquist</surname><given-names>K</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The metabolic syndrome, inflammation, and risk of cognitive decline</article-title>. <source>JAMA</source><year>2004</year>;<volume>292</volume>:<fpage>2237</fpage>&#x02013;<lpage>2242</lpage>.<pub-id pub-id-type="pmid">15536110</pub-id>
</mixed-citation></ref><ref id="CIT0507"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Laffan</surname><given-names>AM</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>SL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women</article-title>. <source>JAMA</source><year>2011</year>;<volume>306</volume>:<fpage>613</fpage>&#x02013;<lpage>619</lpage>.<pub-id pub-id-type="pmid">21828324</pub-id>
</mixed-citation></ref><ref id="CIT0508"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yagishita</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Itoh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Nan</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Reappraisal of the fine structure of Alzheimer&#x02019;s neurofibrillary tangles</article-title>. <source>Acta Neuropathol</source><year>1981</year>;<volume>54</volume>:<fpage>239</fpage>&#x02013;<lpage>246</lpage>.<pub-id pub-id-type="pmid">7257733</pub-id>
</mixed-citation></ref><ref id="CIT0509"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yamada</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Naiki</surname><given-names>H.</given-names></string-name></person-group>
<article-title>Cerebral amyloid angiopathy</article-title>. <source>Prog Mol Biol Transl Sci</source><year>2012</year>;<volume>107</volume>:<fpage>41</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">22482447</pub-id>
</mixed-citation></ref><ref id="CIT0510"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yamazaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Zhao</surname><given-names>N</given-names></string-name>, <string-name><surname>Caulfield</surname><given-names>TR</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies</article-title>. <source>Nat Rev Neurol</source><year>2019</year>;<volume>15</volume>:<fpage>501</fpage>&#x02013;<lpage>518</lpage>.<pub-id pub-id-type="pmid">31367008</pub-id>
</mixed-citation></ref><ref id="CIT0511"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yan</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Bienkowski</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Shuck</surname><given-names>ME</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Membrane-anchored aspartyl protease with Alzheimer&#x02019;s disease beta-secretase activity</article-title>. <source>Nature</source><year>1999</year>;<volume>402</volume>:<fpage>533</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">10591213</pub-id>
</mixed-citation></ref><ref id="CIT0512"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yan</surname>
<given-names>HF</given-names>
</string-name>, <string-name><surname>Zou</surname><given-names>T</given-names></string-name>, <string-name><surname>Tuo</surname><given-names>QZ</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Ferroptosis: mechanisms and links with diseases</article-title>. <source>Signal Transduct Target Ther</source><year>2021</year>;<volume>6</volume>:<fpage>49</fpage>.<pub-id pub-id-type="pmid">33536413</pub-id>
</mixed-citation></ref><ref id="CIT0513"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yan</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Chaput</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women</article-title>. <source>Cell</source><year>2022</year>;<volume>185</volume>:<fpage>3913</fpage>&#x02013;<lpage>3930.e19</lpage>.<pub-id pub-id-type="pmid">36198316</pub-id>
</mixed-citation></ref><ref id="CIT0514"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Mufson</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Herrup</surname><given-names>K.</given-names></string-name></person-group>
<article-title>Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer&#x02019;s disease</article-title>. <source>J Neurosci</source><year>2003</year>;<volume>23</volume>:<fpage>2557</fpage>&#x02013;<lpage>2563</lpage>.<pub-id pub-id-type="pmid">12684440</pub-id>
</mixed-citation></ref><ref id="CIT0515"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yang</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>S</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Large soluble oligomers of amyloid beta-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate</article-title>. <source>J Neurosci</source><year>2017</year>;<volume>37</volume>:<fpage>152</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">28053038</pub-id>
</mixed-citation></ref><ref id="CIT0516"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Arseni</surname><given-names>D</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cryo-EM structures of amyloid-beta 42 filaments from human brains</article-title>. <source>Science</source><year>2022</year>;<volume>375</volume>:<fpage>167</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">35025654</pub-id>
</mixed-citation></ref><ref id="CIT0517"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yarza</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Vela</surname><given-names>S</given-names></string-name>, <string-name><surname>Solas</surname><given-names>M</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for Alzheimer&#x02019;s disease</article-title>. <source>Front Pharmacol</source><year>2015</year>;<volume>6</volume>:<fpage>321</fpage>.<pub-id pub-id-type="pmid">26793112</pub-id>
</mixed-citation></ref><ref id="CIT0518"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ye</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Hamaguchi</surname><given-names>T</given-names></string-name>, <string-name><surname>Fritschi</surname><given-names>SK</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Progression of seed-induced abeta deposition within the limbic connectome</article-title>. <source>Brain Pathol</source><year>2015</year>;<volume>25</volume>:<fpage>743</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">25677332</pub-id>
</mixed-citation></ref><ref id="CIT0519"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yeh</surname>
<given-names>FL</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tom</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia</article-title>. <source>Neuron</source><year>2016</year>;<volume>91</volume>:<fpage>328</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">27477018</pub-id>
</mixed-citation></ref><ref id="CIT0520"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yin</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Rosenzweig</surname><given-names>N</given-names></string-name>, <string-name><surname>Kleemann</surname><given-names>KL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APOE4 impairs the microglial response in Alzheimer&#x02019;s disease by inducing TGFbeta-mediated checkpoints</article-title>. <source>Nat Immunol</source><year>2023</year>;<volume>24</volume>:<fpage>1839</fpage>&#x02013;<lpage>1853</lpage>.<pub-id pub-id-type="pmid">37749326</pub-id>
</mixed-citation></ref><ref id="CIT0521"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yuan</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Condello</surname><given-names>C</given-names></string-name>, <string-name><surname>Keene</surname><given-names>CD</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy</article-title>. <source>Neuron</source><year>2016</year>;<volume>90</volume>:<fpage>724</fpage>&#x02013;<lpage>739</lpage>.<pub-id pub-id-type="pmid">27196974</pub-id>
</mixed-citation></ref><ref id="CIT0522"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>YW</given-names>
</string-name>, <string-name><surname>Thompson</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>APP processing in Alzheimer&#x02019;s disease</article-title>. <source>Mol Brain</source><year>2011</year>;<volume>4</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">21214928</pub-id>
</mixed-citation></ref><ref id="CIT0523"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Song</surname><given-names>M</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer&#x02019;s disease</article-title>. <source>Nat Med</source><year>2014</year>;<volume>20</volume>:<fpage>1254</fpage>&#x02013;<lpage>1262</lpage>.<pub-id pub-id-type="pmid">25326800</pub-id>
</mixed-citation></ref><ref id="CIT0524"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>DW</given-names></string-name>, <string-name><surname>Xu</surname><given-names>SF</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>alpha-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice</article-title>. <source>Redox Biol</source><year>2018</year>;<volume>14</volume>:<fpage>535</fpage>&#x02013;<lpage>548</lpage>.<pub-id pub-id-type="pmid">29126071</pub-id>
</mixed-citation></ref><ref id="CIT0525"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Kishimoto</surname><given-names>Y</given-names></string-name>, <string-name><surname>Grammatikakis</surname><given-names>I</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer&#x02019;s disease model</article-title>. <source>Nat Neurosci</source><year>2019</year>;<volume>22</volume>:<fpage>719</fpage>&#x02013;<lpage>728</lpage>.<pub-id pub-id-type="pmid">30936558</pub-id>
</mixed-citation></ref><ref id="CIT0526"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Tarutani</surname><given-names>A</given-names></string-name>, <string-name><surname>Newell</surname><given-names>KL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Novel tau filament fold in corticobasal degeneration</article-title>. <source>Nature</source><year>2020</year>;<volume>580</volume>:<fpage>283</fpage>&#x02013;<lpage>287</lpage>.<pub-id pub-id-type="pmid">32050258</pub-id>
</mixed-citation></ref><ref id="CIT0527"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>ZY</given-names>
</string-name>, <string-name><surname>Harischandra</surname><given-names>DS</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TRIM11 protects against tauopathies and is down-regulated in Alzheimer&#x02019;s disease</article-title>. <source>Science</source><year>2023</year>;<volume>381</volume>:<fpage>eadd6696</fpage>.<pub-id pub-id-type="pmid">37499037</pub-id>
</mixed-citation></ref><ref id="CIT0528"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhao</surname>
<given-names>QF</given-names>
</string-name>, <string-name><surname>Tan</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>HF</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The prevalence of neuropsychiatric symptoms in Alzheimer&#x02019;s disease: systematic review and meta-analysis</article-title>. <source>J Affect Disord</source><year>2016a</year>;<volume>190</volume>:<fpage>264</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">26540080</pub-id>
</mixed-citation></ref><ref id="CIT0529"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Kotilinek</surname><given-names>LA</given-names></string-name>, <string-name><surname>Smith</surname><given-names>B</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Caspase-2 cleavage of tau reversibly impairs memory</article-title>. <source>Nat Med</source><year>2016b</year>;<volume>22</volume>:<fpage>1268</fpage>&#x02013;<lpage>1276</lpage>.<pub-id pub-id-type="pmid">27723722</pub-id>
</mixed-citation></ref><ref id="CIT0530"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 is a receptor for beta-amyloid that mediates microglial function</article-title>. <source>Neuron</source><year>2018</year>;<volume>97</volume>:<fpage>1023</fpage>&#x02013;<lpage>1031.e7</lpage>.<pub-id pub-id-type="pmid">29518356</pub-id>
</mixed-citation></ref><ref id="CIT0531"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Zheng</surname><given-names>Q</given-names></string-name>, <string-name><surname>Hong</surname><given-names>Y</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>beta(2)-Microglobulin coaggregates with Abeta and contributes to amyloid pathology and cognitive deficits in Alzheimer&#x02019;s disease model mice</article-title>. <source>Nat Neurosci</source><year>2023</year>;<volume>26</volume>:<fpage>1170</fpage>&#x02013;<lpage>1184</lpage>.<pub-id pub-id-type="pmid">37264159</pub-id>
</mixed-citation></ref><ref id="CIT0532"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zheng</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer&#x02019;s brains is mediated by USP25</article-title>. <source>Sci Adv</source><year>2021</year>;<volume>7</volume>:<fpage>eabe1340</fpage>.<pub-id pub-id-type="pmid">33523861</pub-id>
</mixed-citation></ref><ref id="CIT0533"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zheng</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Song</surname><given-names>B</given-names></string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>USP25 inhibition ameliorates Alzheimer&#x02019;s pathology through the regulation of APP processing and Abeta generation</article-title>. <source>J Clin Invest</source><year>2022</year>;<volume>132</volume>:<fpage>e152170</fpage>.<pub-id pub-id-type="pmid">35229730</pub-id>
</mixed-citation></ref><ref id="CIT0534"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhong</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>XF</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>ZL</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response</article-title>. <source>J Biol Chem</source><year>2015</year>;<volume>290</volume>:<fpage>15866</fpage>&#x02013;<lpage>15877</lpage>.<pub-id pub-id-type="pmid">25957402</pub-id>
</mixed-citation></ref><ref id="CIT0535"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhong</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>XF</given-names></string-name>, <string-name><surname>Wang</surname><given-names>T</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Soluble TREM2 induces inflammatory responses and enhances microglial survival</article-title>. <source>J Exp Med</source><year>2017</year>;<volume>214</volume>:<fpage>597</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">28209725</pub-id>
</mixed-citation></ref><ref id="CIT0536"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhong</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2)</article-title>. <source>Mol Neurodegener</source><year>2018</year>;<volume>13</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">29587871</pub-id>
</mixed-citation></ref><ref id="CIT0537"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhong</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhuo</surname><given-names>R</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x02019;s disease model</article-title>. <source>Nat Commun</source><year>2019</year>;<volume>10</volume>:<fpage>1365</fpage>.<pub-id pub-id-type="pmid">30911003</pub-id>
</mixed-citation></ref><ref id="CIT0538"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhong</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Sheng</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration</article-title>. <source>Immunity</source><year>2023</year>;<volume>56</volume>:<fpage>1794</fpage>&#x02013;<lpage>1808.e8</lpage>.<pub-id pub-id-type="pmid">37442133</pub-id>
</mixed-citation></ref><ref id="CIT0539"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Song</surname><given-names>WM</given-names></string-name>, <string-name><surname>Andhey</surname><given-names>PS</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>Human and mouse ingle-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x02019;s disease</article-title>. <source>Nat Med</source><year>2020</year>;<volume>26</volume>:<fpage>131</fpage>&#x02013;<lpage>142</lpage>.<pub-id pub-id-type="pmid">31932797</pub-id>
</mixed-citation></ref><ref id="CIT0540"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zivanovic</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Aracki Trenkic</surname><given-names>A</given-names></string-name>, <string-name><surname>Milosevic</surname><given-names>V</given-names></string-name></person-group>
<etal>et al</etal>
<article-title>The role of magnetic resonance imaging in the diagnosis and prognosis of dementia</article-title>. <source>Biomol Biomed</source><year>2023</year>;<volume>23</volume>:<fpage>209</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">36453893</pub-id>
</mixed-citation></ref></ref-list></back></article>